WO2002009758A2 - Inhibitors of cellular efflux pumps of microbes - Google Patents

Inhibitors of cellular efflux pumps of microbes Download PDF

Info

Publication number
WO2002009758A2
WO2002009758A2 PCT/IN2001/000139 IN0100139W WO0209758A2 WO 2002009758 A2 WO2002009758 A2 WO 2002009758A2 IN 0100139 W IN0100139 W IN 0100139W WO 0209758 A2 WO0209758 A2 WO 0209758A2
Authority
WO
WIPO (PCT)
Prior art keywords
oxo
dihydro
fluoro
salts
amino
Prior art date
Application number
PCT/IN2001/000139
Other languages
French (fr)
Other versions
WO2002009758A3 (en
Inventor
Noel J. De Souza
Mahesh V. Patel
Shrikant V. Gupte
Dilip J. Upadhyay
Milind C. Shukla
Nishith C. Chaturvedi
Satish B. Bhawsar
Sheela C. Nair
Mohammed A. Jafri
Original Assignee
Wockhardt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/640,947 external-priority patent/US6750224B1/en
Priority claimed from US09/850,669 external-priority patent/US6608078B2/en
Priority claimed from PCT/IN2001/000100 external-priority patent/WO2001085728A2/en
Application filed by Wockhardt Limited filed Critical Wockhardt Limited
Priority to CA002417799A priority Critical patent/CA2417799A1/en
Priority to AU2001280091A priority patent/AU2001280091A1/en
Priority to EP01958373A priority patent/EP1305048A2/en
Publication of WO2002009758A2 publication Critical patent/WO2002009758A2/en
Publication of WO2002009758A3 publication Critical patent/WO2002009758A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to compounds with efflux pump inhibitor properties, and which are therefore compounds which inhibit cellular efflux pumps of bacteria or other microbes.
  • efflux pump inhibitors are useful, for example, against antibiotic-resistant microbial pathogens, for treating microbial infections by reducing the export of a co-administered antimicrobial agent or by preventing the export of a compound synthesized by microbes (e.g. bacteria, fungi) to allow or improve their growth.
  • this invention also provides processes for preparation of such efflux pump inhibitors, compositions which include such efflux pump inhibitors, and the use of the compounds and compositions in methods for treatment of microbial infections.
  • Microbes are known to have developed the ability to evolve different mechanisms of self-defense against antimicrobial agents.
  • bacterial and fungal pathogens have developed mechanisms of resistance to antibiotics and antimicrobial agents used to inhibit their growth, or to treat infections by them in humans, animals and tissue cultures.
  • treatment regimens can be adversely affected or, in some cases rendered ineffective.
  • Multidrug efflux as a major cause of intrinsic drug resistance in many microorganisms, or overproduction of intrinsic pumps, or acquisition of pump genes from external sources, all play a prominent role, often resulting in high levels of resistance.
  • MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexXY-OprM, AcrAB-TolC, AcrEF, MarA, SoxS, or/and Tet pump/s are known to be present in Gram negative organisms such as P. aeruginosa and E. coli and are reviewed in recent publications and papers, such as K. K. Y. Wong et al, J. of Bacteriology, 2001, 183:367-374; K.
  • Efflux transporters are also among different mechanisms responsible for the resistance to antibiotics displayed by gram-positive bacteria and mycobacteria, particularly aerobic gram- positive cocci.
  • the multidrug transporter NorA belonging to the major facilitator superfamily (MFS) transporters, contributes to the resistance of Staphylococcus aureus to fluoroquinolone antibiotics.
  • MFS major facilitator superfamily
  • a minireview describes effllux-mediated resistance to fluoroquinolones in Gram- positive bacteria and the mycobacteria (K. Poole, Antimicro. Agents and Chemother., 2000, 44: 2595-2599).
  • MFS transporters also belong the Bmr and QacA/QacB efflux pumps of Gram-positive bacteria, and EmrB of E. coli (H.
  • MFP membrane-fusion protein
  • Mef efflux system mediates large fractions of erythromycin-resistant clinical isolates of S. pneumoniae (N. J. Johnston et al, Antimicrob. Agents and Chemother., 1998, 42:2425; T. Nishijima et al, J. Antimicrob. Chemother., 1999, 43:637).
  • Beta-haemolytic streptococci and pneumococci resistant to erythromycin due to the prsence of Mef A efflux pumps in Streptococcus pyogenes, Mef E pumps in S. pneumoniae, and an M phenotype bearing S. agalactiae possessing Mef A or Mef E pumps are found to be emergent and prevalent in Europe (C. Arpin et al, J. Antimicrob. Chemother., 1999, 44:133-138; E. Giovanetti et al, Antimicrob. Agents and Chemother., 1999, 43:1935-1940).
  • One strategy to target resistance mechanisms of microbial self-defense is to find inhibitors of microbial efflux pumps and, in particular of bacterial and fungal efflux pumps.
  • Patent WO 99/17791 discloses a method for inhibiting the selection or propagation of a bacterial mutant that overexpresses an efflux pump wherein the inhibitor disclosed is the dipeptide amide, L-phenylalanyl-L-arginyl-beta-naphthylamide (MC- 207,110), which is unlike the efflux pump inhibitor compounds of the present invention.
  • US Patent 6,245,746, US Patent 6,114,310 and WO 9937667 all with US priority in US application 09/012,363 discloses methods of using efflux pump inhibitors which increase the susceptibility of microbes, in particular P. aeruginosa strains, to antimicrobial agents and pharmaceutical compositions including such compounds which are unlike the efflux inhibitor compounds of the present invention.
  • US Patent 6,204,729 describes peptidomimetic, secondary amide containing benzoxazole derivatives as efflux pump inhibitors, methods of using such efflux pump inhibitor compounds and pharmaceutical compositions including such compounds which are unlike the efflux inhibitor compounds of the present invention.
  • Patent WO 00/32196 discloses inhibitors of multidrug transport proteins which may be used in combination with existing antibacterial agents and/or antifungal agents, wherein the inhibitor is an indole or a urea or an aromatic amide or a quinoline, all of which inhibitors are unlike the efflux pump inhibitor compounds of the present invention.
  • the inhibitors disclosed in patent WO 00/32196 are specifically inhibitors of bacteria expressing a norA pump, or a fungus expressing a multidrug transport protein.
  • Novel inhibitors of the NorA multidrug transporter of S. aureus having structurally diverse chemical structures were also described by P. N. Markham et al, (Antimicrob. Agents and Chemother., 1999, 43:2404), among which the more active compounds include (a) those containing an indole moiety like the previously known inhibitor, reserpine, (b) biphenyl urea derivatives, (c) a substituted pyrimidinone derivative and (d) compounds INF 240 and INF 277, but they are all unlike the efflux pump inhibitor compounds of the present invention.
  • Another inhibitor of the NorA MDR pump in a pathogenic S. aureus strain is 5'- methoxyhydnocarpin (F. R. Stermitz et al., Proc. New York Acad. of Sci., 2000, 97:1433), which has a structure unlike the efflux pump inhibitor compounds of the present invention.
  • Nocardamin a cyclopeptide, was found to be a general antagonist of a tetracycline efflux pump from S. aureus. It has a structure unlike the efflux pump inhibitor compounds of the present invention.
  • Minocycline and l,l-dimethyl-5-(l-hydroxypropyl)-4,6,7-trimethylindan (Ro 07-3149) inhibit the active tetracycline efflux pump in S. aureus 743 (T.Hirata et al., Biol Pharm Bull, 1998, 21:678). Both the compounds have a structure unlike the efflux pump inhibitor compounds of the present invention.
  • Reserpine is not a usable compound for therapy because of its neurotoxicity at the concentration required for efflux pump inhibition.
  • the inhibitors of single drug and multidrug transporters such as the dipeptide amide, MC- 207,110, are broad in specificity, inhibiting all three RND systems of P. aeruginosa involved in fluoroquinolone efflux, but have not been shown to be effective against pumps of other strains, for instance a NorA pump.
  • the methods employed to demonstrate their efflux pump inhibitory properties are mainly in vitro methods. For demonstration of in vivo activity, recourse has had to be taken to parenteral administration ( cf. T.E.Renau et al, J.Med.Chem.,1999, 42, 4928), rather than oral administration, as it is generally known that oral bioavailability is poor for compounds of a peptidic nature.
  • Potent inhibitors of microbial efflux pumps is thus an important goal for the improved control of infectious diseases, allowing a renaissance for drugs that are no longer effective owing to their efflux (K. Poole, Journal of Pharmacy and Pharmacology, 2001, 53:283-294).
  • the current inventors have synthesised, screened and identified novel inhibitors of cellular efflux pumps of microbes. Distinctive structural features characterise the different sets of efflux pump inhibitors for different microorganisms as will be described in the following description.
  • the present invention describes compounds of the formula I as novel microbial efflux pump inhibitors
  • Rs H, Ci.s alkyl, amino, alkylamino, or acylamino.
  • Re H, C ⁇ -6 alkyl, halo such as F, Cl, Br, or I, amino, or hydroxy;
  • R 7 OH, halo such as F, Cl, Br, or I, or
  • NR 9 R 10 wherein R 9 and Rj 0 are the same or different and represent H, . 6 alkyl or (CH 2 ) n OA, or R 9 is H and R ⁇ 0 is a 4-membered, 5-membered, 6-membered, or 7-membered carbocyclic, mono or bicyclic ring, or mono or bicyclic heterocyclic ring linked to the nitrogen of NR 9 R 10 through an atom of the heterocycle other than the heterocyclic atom, or R 9 and R ⁇ 0 taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocyclic or bicyclic.
  • the carbocycle and the heterocycle are optionally substituted at any position of the carbocyclic or heterocyclic group with COOR 3 CONHR 13 , OA, C ⁇ _ 6 alkyl, C 3 -C 6 cycloalkyl, aralkyl, trifluoroalkyl, substituted C ⁇ alkyl, or N R ⁇ R ⁇ 7 .
  • Substituents of the alkyl group are selected from OA, NR 16 R ⁇ , or a halogen atom.
  • R 16 and R ⁇ are the same or different and represent H or C .
  • R 16 and R 16 and R J7 is C 3 -C 6 cycloalkyl, or substituted C ⁇ _ 6 alkyl, or R 16 and R ⁇ 7 taken together with the nitrogen atom form a heterocycle.
  • R 16 or R i7 is a substituted alkyl group, the substituent is selected from NRi ⁇ R ⁇ , alkanoyl or aminoalkanoyl,
  • R 7 NHOA, NHCOORrange, or NH(CH 2 ) radicalNR 9 Ri 0 ;
  • this R 7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R 7 moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is linked to a phenyl carboxylic acid or ester moiety thereof, the phenyl carboxylic acid or ester being optionally substituted by the usual aromatic substituents, such as C C 3 alkyl linear or branched, aralkyl such as benzyl, amino, alkylamino, alkanoylamino, oc-aminoalkanoylamino, hydroxy, alkoxy, alkanoyloxy, oc-aminoalkanoyloxy, or halogen atoms, such as fluoro, chloro, bromo.
  • A H, C 1 -6 alkyl, glycosyl, aralkyl, C ⁇ . 6 alkanoyl or aminoalkanoyl.
  • the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof.
  • the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine.
  • A may also be C 6 H u O 6 , SO 3 H, or PO 3 H 2 .
  • X CH, C-F, C-Cl, C-CH 3 , C-CF 3 , C-OCH 3 , C-OCHF 2 , C-OCF 3 , N or when X is equal to C it forms together with the nitrogen atom of the adjacent ring an optionally substituted 4-membered ring, 5-membered ring, 6-membered ring, 7-membered ring, containing carbon atoms and optionally one or more Y atoms representing one or more nitrogen, oxygen or sulfur atoms, such ring being further optionally substituted by a C ⁇ _ 6 alkyl group;
  • the absolute stereochemistry can be either R- or S- configuration and any combination of configurations. Even racemic materials and diastereomers fulfil the structural generic descriptions.
  • Another object of the invention is to provide a process for preparing the novel efflux pump inhibitors of the formula I of the invention.
  • a further object of the invention is to provide pharmaceutical compositions comprising the compounds of the invention.
  • a composition contains one or more compounds of formula I or salt, hydrate, polymorph or pseudopolymorph therefore.
  • a composition of this invention may also include another antibiotic or antimicrobial compound.
  • Yet another object of the invention relates to method of treatment of infections using the said compounds of the invention or compositions comprising them.
  • Treatment comprises oral, parenteral administration and/or topical application of an effective amount of the compound of the invention or its compositions, whether single or in combination with an antibiotic or antimicrobial agent or two or more compounds of this invention.
  • Yet a further object of the invention includes a method of suppressing growth of a bacterium or fungus expressing an efflux pump, comprising contacting said bacterium or fungus with an efflux pump inhibitor in the presence of a concentration of antibacterial or antifungal agent below the minimum inhibitory concentration (MIC) of said bacterium or fungus.
  • Yet a further object of the invention includes methods for treating the infections in humans and animals, caused by sensitive and resistant microbial strains using an antimicrobial agent and an efflux pump inhibitor in an amount sufficient to reduce efflux pump activity, wherein said efflux pump inhibitor increases the susceptibility of said microbe to said antimicrobial agent.
  • Yet a further object of the invention includes a method for prophylactic treatment of a human or animal, comprising administering to said human or animal at risk of a microbial infection an efflux pump inhibitor, wherein said efflux pump inhibitor decreases the pathogenicity of a microbe in said human or animal.
  • Yet a further object of the invention includes a method for prophylactic treatment of human or animal, comprising administering to said human or animal at risk of a microbial infection an antimicrobial agent and an efflux pump inhibitor, wherein said efflux pump inhibitor increases the susceptibility of a microbe to said antimicrobial agent.
  • Yet a further object of the invention includes a method of treatment using the efflux pump inhibitor compounds of the invention by administering, systemically or topically, optically pure compounds of the invention or stereochemically pure forms of the invention or their salts, hydrates, polymorphs, or pseudopolymorphs thereof to the affected human or animal, thereby avoiding the toxic effects associated with racemic mixtures of the compounds of the invention.
  • Yet a further object of the invention is to enhance the antimicrobial activity of an antimicrobial agent against a microbe by contacting the microbe with an antimicrobial agent and an efflux pump inhibitor.
  • the present invention describes heterocyclic compounds of the formula I as novel microbial efflux pump inhibitors
  • Rs H, C ⁇ _s alkyl, amino, alkylamino, or acylamino.
  • Re H, C ⁇ _ 6 alkyl, halo such as F, Cl, Br, or I, amino, or hydroxy;
  • R 7 OH, halo such as F, Cl, Br, or I, or
  • NR 9 R 10 wherein R 9 and Rio are the same or different and represent H, . 6 alkyl or (CH 2 ) n OA, or R 9 is H and Rio is a 4-membered, 5-membered, 6-membered, or 7-membered carbocyclic, mono or bicyclic ring, or mono or bicyclic heterocyclic ring linked to the nitrogen of NR 9 R ⁇ 0 through an atom of the heterocycle other than the heterocyclic atom, or R 9 and R w taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocyclic, or bicyclic.
  • the ring is a ring such as 2- azetidinyl
  • R ⁇ 0 is a 5-membered ring
  • the ring is a ring such as 2- (or 3-) pyrrolidinyl, or 2- (or 3-) furyl, or 2-(or 3-) thienyl, or 2-(or 4-)imidazolyl, or oxazolyl or pyrazolyl, or thiazolyl
  • R 10 is a 6-membered ring
  • the ring is a ring such as 2-(or 3-, or 4-) piperidinyl, or 2-(or 3-) piperazinyl, or 2-(or 3-) morpholinyl or 2-(or 4-)pyrimidinyI
  • R 10 is a 7-membered heterocycle it is preferred that the heterocycle is a heterocycle such as azepinyl, ox
  • heterocycle is such as azetidine, pyrrolidine, furan, thiophene, imidazole, oxazole, pyrazole, thiazole, piperidine, piperazine, pyrimidine, azepine, oxazine, thiazine, or bicyclic such as isoquinoline, quinuclidine, amino-3-azabicyclo [3.1.0]hexane.
  • the carbocycle and the heterocycle are optionally substituted at any position of the heterocyclic group with COOR 3 CONHR 13 , OA, C ⁇ . 6 alkyl, aralkyl, trifluoroalkyl, substituted alkyl, or N
  • Substituents of the alkyl group are selected from OA, NR ⁇ 6 R ⁇ , or a halogen atom.
  • R ⁇ 6 and R ⁇ are the same or different and represent H or C ⁇ . 6 alkyl, or where one of R i6 and R ⁇ is hydrogen and the other of Rj 6 and R J7 is C 3 -C 6 cycloalkyl, or substituted alkyl, or R ⁇ 6 and R ⁇ taken together with the nitrogen atom form a heterocycle.
  • R 16 or R J7 is a substituted alkyl group
  • n 0, 1, or 2
  • this R 7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R 7 moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is linked to a phenyl carboxylic acid or ester moiety thereof, optionally substituted by the usual aromatic substituents, such as C 1 -C 3 alkyl linear or branched, aralkyl such as benzyl, amino, alkylamino, alkanoylamino, oc-aminoalkanoylamino, hydroxy, alkoxy, alkanoyloxy, cc-aminoalkanoyloxy, or halogen atoms, such as fluoro, chloro, bromo.
  • A H, C 1 - 5 alkyl, glycosyl, aralkyl, C ⁇ . 6 alkanoyl or aminoalkanoyl.
  • the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof.
  • the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, Iysine, methionine, phenylalanine, proline, serine threonine, trytophan, tyrosine or valine.
  • A may also be C 6 HnO 6 , SO 3 H, or PO 3 H 2 ,
  • R 11 H, C ⁇ exclusively6 alkyl, C3.6 cycloalkyl, or heterocyclic group such as a 4-membered ring, it is preferred that the ring is a ring such 2-azetidinyl, a 5-membered ring such as 2- (or 3-) pyrrolidinyl, or 2- (or 3-) furyl, or 2-(or 3-) thienyl, or 2-(or 4-) imidazolyl, or oxazolyl or pyrazolyl, or thiazolyl, or a 6- membered ring such as 2-(or 3-,or 4-) piperidinyl, or 2-(or 3-) piperazinyl, or 2-(or 3-) morpholinyl, or 2-(or 4-)pyrimidinyl, or a 7-membered heterocycle such as azepinyl, or oxazinyl, or thiazinyl, or a bicyclic heterocycle such as tetrahydroisoquinolin
  • X CH, C-F, C-Cl, C-CH 3 , C-CF 3 , C-OCH 3 , C-OCHF 2 , C-OCF 3 , N or when X is equal to C it forms together with the nitrogen atom of the adjacent ring a 5-membered ring, 6-membered ring, 7-membered ring, optionally containing besides carbon atoms additional Y atoms representing one or more nitrogen , oxygen or sulfur atoms, such ring being further optionally substituted by a
  • Ci.6 alkyl group and their pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.
  • R, and R 4 . are combined together to form an oxo group and Re is hydrogen or fluorine.
  • the absolute stereochemistry can be either R- or S- configuration and any combination of configuration. Even racemic materials and diastereomers fulfil the structural generic descriptions.
  • alkyl refers to a branched or unbranched C C 6 aliphatic hydrocarbon group.
  • aralkyl refers to a C C 6 alkyl group substituted with an aryl group which aryl group is defined below.
  • aryl group is defined below.
  • One example of an aralkyl group is a benzyl group.
  • arylaminoalkyl refers to an aryl group as defined below that is bonded respectively through an NH, oxygen , or S(O) t to an alkyl group as defined above.
  • aryl refers to an aromatic group which has at least one ring having conjugated ⁇ electron system and includes both carbocyclic aryl (e.g., phenyl, naphthyl) and heterocyclic aryl groups (e.g. pyridyl, pyrimidyl, pyrazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl and oxazolyl).
  • the aryl group is preferably 5 to 14 carbons, more preferably 5 to 10 carbons.
  • Aryl moieties includes monocyclic, bicyclic, and tricyclic rings, where each ring has preferably five or six members and are 6 ⁇ (or 6 pi)-annelated ring system or substituted 6 ⁇ annelated ring systems composed of a mix of carbocyclic and heterocyclic units (e.g. benzo, pyrido, pyrimido, pyrazino, thieno, furano, pyrrolo, pyrazolo, imidazolo, thiazolo and oxazolo).
  • 6 ⁇ - annelated ring system refers to a ring which has 6 ⁇ electron and is considered aromatic.
  • the ring may have 6 items in its backbone, such as pyridine, pyrimidine, benzene, or it may have less than 6 items in its backbone, such as pyrrole, pyrazole, furan, thiazole, oxazole or thiophene.
  • the aryl moiety may be optionally monosubstituted or disubstituted independently with lower linear or branched C ⁇ -C 6 alkyl or hydroxyl, alkoxy, alkylthio, halogen, haloalkyl, mercapto, amino, mono linear or branched C ⁇ -C 3 alkylamino, di linear or branched C ⁇ -C 3 alkylamino, phenyl, substituted phenyl or optionally substituted phenylamino wherein the phenyl is substituted by usual aromatic substituents, such as C ⁇ -C 3 alkyl linear or branched, aralkyl such as benzyl, amino, alkylamino, alkanoylamino, oc-aminoalkanoylamino, hydroxy, alkoxy, alkanoyloxy, oc- aminoalkanoyloxy, or halogen atoms, such as fluoro, chloro, or bromo.
  • Alkylamino is for example NHCH 3 , N(CH 3 ) 2 , NHC 2 H S , N(C 2 H S ) 2 , NHC 3 H 7 , N(C 3 H 7 ) 2 and
  • Alkanoyl is for example acetyl, propionyl, ethoxycarbonyl, t-butoxycarbonyl,
  • -Oq is for example pyrrolidinylethyl, piperidinylethyl, morpholinylethyl
  • the preferred acid addition salts are those of hydrochloride, hydrobromide, hydroiodide, sulphate, sulfonate, sulfamate, phosphate and salts of organic acids such as acetate, lactate, succinate, oxalate, maleate, fumarate, malate, tartrate, citrate, ascorbate, gluconate, benzoate, cinnamate, methane sulphonate and p-toluene sulphonate.
  • Preferred alkali addition salts are lithium, sodium, potassium salts, and alkaline earth salts are magnesium, calcium salts, or ammonium, or organic amines such as diethanolamine, N-methylglucamine, guanidine or heterocyclic amines such as choline, piperidine, N-methyl-4-hydroxypiperidine, hydroxyethylpyrrolidine, hydroxyethylpiperidine, morpholine, hydroxyethylmorpholine, piperazine, N-methyl piperazine and the like or basic amino acids such as optically pure or racemic isomers of arginine, lysine, histidine, tryptophan and the like.
  • organic amines such as diethanolamine, N-methylglucamine, guanidine or heterocyclic amines such as choline, piperidine, N-methyl-4-hydroxypiperidine, hydroxyethylpyrrolidine, hydroxyethylpiperidine, morpholine, hydroxyethylmorpho
  • RI C 2 H S , C 3 H 5 , CH(CH 3 )CH 2 CH 2 SC 6 H 5 , C 6 H,(2-CF3), where (2-CF3) means that the CF3 group is attached at the 2 position,
  • (4-F) means that the F atom is attached at the 4 position
  • (2,4-F2) means that there are 2 fluorine atoms, one at the 2 position and the other at the 4 position.
  • X..Y..N C-CH 2 CH 2 CH(CH 3 ), C-OCH 2 CH(CH 3 ), C-OCH 2 CH 2 CH(CH 3 )
  • R 2 COOH, COOC 2 H 5 , COOCH(CH 3 ) 2 , COO(CH 2 ) 3 CH 3 , COOCH 2 C 6 H 5 , COOCH 2 COOC 2 H 5 , COO(CH 2 ) 2 -morpholino,
  • COphe-lys-Ome where phe-Iys-Ome is the methylester of the dipeptide from phenylalanine and lysine.
  • R 5 H, CH 3 , or NH 2;
  • R 7 F, Br, pyrrolidin-3-yl-amino, pyrrolidin-3-alkoxycarbonylamino, piperidin-4-yl-amino, pentaalkylpiperidin-4-yl-alkylamino, [l°c,5cc,6oc]-3-azabicyclo[3.1.0]hex-6-yl-amino, quinucIidinyI-3-yl-amino, 3-aminopyrrolidinyl, 5-aminopyrrolidinyl, aminopyrroUdinyl optionally further mono/poly substituted with C C 6 alkyl, (mono/poly aminoalkanoyl)aminopyrrolidinyl; alkoxycarbonyl (mono/poly aminoalkanoyl) aminopyrroUdinyl; acetamidopyrrolidinyl optionally further mono/poly substituted with C ⁇ -C 6 alkyl, hydroxypyrroli
  • X C-H, C-OCH 3 , C-F, N and when X is linked to N of the adjacent ring, it has the meanings as defined above for X..Y...N
  • Suitable acids are hydrochloric, hydrobromic, hydroiodic, sulphuric, sulfamic, sulfonic, phosphoric, acetic, lactic, succinic, oxalic, maleic, fumaric, malic, tartaric, citric, ascorbic, gluconic, benzoic, cinnamic, methanesulfonic and p-toluenesulfonic acid.
  • the pharmaceuticaUy acceptable cationic salts of compounds I may be prepared by conventional methods from the corresponding acids e.g. by reaction with about one equimolar amount of a base.
  • suitable cationic salts are those of alkaU metals such as Uthium, sodium or potassium, alkaline earth metals such as magnesium or calcium or ammonium or organic amines such diethanolamine, N-methylglucamine, guanidine or heterocycUc amines such as choline, piperidine, N-methyl-4-hydroxypiperidine, hydroxyethylpyrrolidine, hydroxyethylpiperidine, morpholine, hydroxyethylmorphoUne, piperazine, N-methyl piperazine and the like or basic amino acids such as opticaUy pure or racemic isomers of arginine, lysine, histidine, tryptophan and the like.
  • hydrates, pseudopolymorphs and polymorphs are prepared by methods known in the art. DetaUed descriptions of different methods to generate hydrates, solvates, pseudopolymorphs and polymorphs and to characterise them are described in chapters 5 and 6 of the book entitled "Polymorphism in Pharmaceutical SoUds” edited by Harry G Brittain (Marcel Dekker Inc., New York), pp. 183-278, 1999.
  • the foUowing is a Ust of compounds that inhibit the efflux pump of different organisms.
  • the list of compounds and organisms is not inclusive. There are compounds on this list that will inhibit the efflux pump of other organisms.
  • Some specific efflux pump inhibitor compounds of the invention are:
  • a microbe appropriate for the use of an efflux pump inhibitor are pathogenic bacterial species, such as Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherischia coli, Staphylococcus aureus which can be intrinsically resistant to commonly used antibacterial agents. Exposing these bacteria to an efflux pump inhibitor can significantly slow the export of an antibacterial agent from the interior of the ceU or the export of siderophores. For instance, overexpression of the norA multidrug transporter has been reported for strains of S. aureus for fluoroquinolone resistance both in-vitro (Yoshida et.
  • efflux pump inhibitors can decrease the virulence of the microbe, for example, by inhibiting the transport of factors important for pathogenicity.
  • inhibition of an efflux pump in this bacterium inhibits the uptake of iron, which is important for pathogenicity.
  • the mechanism of bacterial iron transport involves molecules called siderophores, which are synthesised and exported by bacterial ceUs via efflux pumps. These siderophores bind tightly to iron scavenged from the host, and are then taken up by the bacteria. In this way, the iron needed for bacterial metaboUsm is obtained, and an infection can be maintained.
  • Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherischia coli, Staphylococcus aureus strains wUl become susceptible to antibiotics that could not be used for treatment of the respective bacterial infections, or become more susceptible to antibiotics which do inhibit the respective bacterial growth.
  • Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherischia coli, Staphylococcus aureus strains will become more susceptible to antibiotics currently used for treatment of the respective bacterial infections.
  • Virulence of Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherischia coli, Staphylococcus aureus wiU be attenuated because the avaUabiUty of an essential siderephore bearing element wuT be hampered.
  • microbes include, for example, bacteria, fungi, yeasts, and protozoa.
  • the bacterium to be inhibited through the use of an efflux pump inhibitor can be from other bacterial groups or species, such bacterial groups of species including but not limited to one of the foUowing:
  • Pseudomonas aeruginosa Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenotrophomonas maltophilia, Burkholderia capacia, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundil, Salmonella tryphimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia, marcescens, Francisella tularensis, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens
  • efflux pump refers to a protein assembly which exports substrate molecules from the cytoplasm or periplasm of a ceU, in an energy dependent fashion.
  • an efflux pump wiU typicaUy be located in the cytoplasmic membrane of the cell (spanning the cytoplasmic membrane). In Gram-negative bacteria the pump may span the periplasmic space and there may also be portion of the efflux pump which spans the outer membrane.
  • Certain efflux pumps wiU include a polypeptide which has at least 50% amino acid sequence similarity with a polypeptide which is part of the P.
  • an "efflux pump inhibitor” is a compound which specifically interferes with the abflity of an efflux pump to export its normal substrate, or other compounds such as an antibiotic.
  • the inhibitor may have intrinsic antimicrobial (e.g. antibacterial) activity of its own, but at least a significant portion of the relevant activity is due to the efflux pump inhibiting activity.
  • compounds which inhibit the export or activity of efflux pumps which have a broad substrate range which includes antibacterial agents.
  • Streptococcus pneumoniae-ty ⁇ >e efflux pump inhibitor refers to an efflux pump inhibitor which inhibits a Streptococcus pneumoniae-type efflux pump.
  • Pseudomonas aeruginosa- type efflux pump inhibitor refers to an efflux pump inhibitor which inhibits a Pseudomonas aeruginosa-type efflux pump.
  • Esscherischia coli-type efflux pump inhibitor refers to an efflux pump inhibitor which inhibits an Escherischia coli -type efflux pump.
  • Staphylococcus aureus-type efflux pump inhibitor refers to an efflux pump inhibitor which inhibits a Staphylococcus aureus -type efflux pump.
  • this invention provides a method for treating a microbial infection, e.g., a bacterial infection, in an animal by administering to an animal suffering from such an infection an efflux pump inhibitor as described above in an amount sufficient to reduce efflux pump activity.
  • a microbial infection e.g., a bacterial infection
  • the inhibitor is one which decreases the pathogenicity of the microbe.
  • a decrease in pathogenicity can be obtained, for example, by interfering with essential bacterial element acquisition by inhibiting the transport of siderophores.
  • the pathogenicity may also be reduced by reducing or eliminating the microbial products which cause tissue-damaging effects to the host. Other methods of reducing pathogenicity are, however, also within this aspect.
  • the host is an animal and may be, for example, chickens and turkeys, and in certain preferred embodiments in a mammal, e.g. a human.
  • the microbial infection may be due to bacteria, which may, for example, be any of the bacterial species indicated above, but specificaUy including Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherischia coli, Staphylococcus aureus.
  • this invention provides a method of treating an animal suffering from a microbial infection by administering to the animal an efflux pump inhibitor in an amount sufficient to reduce efflux pump activity.
  • the efflux pump inhibitor in one which reduces the in vivo viabdity of a microbe involved in the infection.
  • the infected animal can more readUy clear its body of the infection, or the microbes may even be lulled.
  • the animal is a mammal.
  • the microbe may be from one of a variety of pathogenic bacterial species, specificaUy including those Usted above.
  • in vivo viabiUty refers to the abUity of a microbe, e.g., a bacterium, to survive or grow in a host, such as an animal. Therefore, an efflux pump inhibitor which reduces the in vivo viability of a microbe may stop the growth of the microbe and/or kill the microbe. Such efflux pump inhibitors, therefore, are antimicrobial agents.
  • this invention includes a method for prophylactic treatment of an animal, e.g., a mammal.
  • an efflux pump inhibitor which reduces the pathogenicity of a microbe is administered to a mammal at risk of a microbial infection, e.g., a bacterial infection.
  • the invention provides a method for treating a microbial infection in an animal, specifically including in a mammal, by treating an animal suffering from such an infection with an antimicrobial agent and an efflux pump inhibitor which increases the susceptibUity of the microbe for that antimicrobial agent.
  • a microbe involved in the infection can be treated using the antimicrobial agent in smaUer quantities, or can be treated with an antimicrobial agent which is not therapeuticaUy effective when used in the absence of the efflux pump inhibitor.
  • this method of treatment is especially appropriate for the treatment of infections using an antimicrobial agent alone due to a need for high dosage levels (which can cause undesirable side effects), or due to lack of any cUnically effective antimicrobial agents.
  • it is also appropriate for treating infections involving microbes which are susceptible to particular antimicrobial agents as a way to reduce the dosage of those particular agents. This can reduce the risk of side effects, but can also reduce the selection effect for highly resistant microbes resulting from the consistent high level use of a particular antimicrobial agent.
  • the microbe is a bacterium, which may, for example, be from any of the groups or species indicated above. Also in particular embodiments various antibacterial agents can be used.
  • an antibiotic of the above classes can be, for example, one of the foUowing: Beta-Lactam Antibiotics
  • Amikacin arbekacin, butirosin, dibekacin, fortimicins, gentamicin, kanamycin, netilmicin, ribostanycin, sisomicin, spectinomycin, streptomycin, tobramycin, cUndamycin, Uncomycin.
  • the term "susceptibiUty" refers to the sensitivity of the microbe for the presence of the antimicrobial agent So, to increase the susceptibiUty means that the microbe wUl be inhibited by a lower concentration of the antimicrobial agent in the medium surrounding the microbial ceUs. This is equivalent to saying that the microbe is more sensitive to the antimicrobial agent. In most cases the minimum inhibitory concentration (MIC) of that antimicrobial agent wiU have been reduced.
  • MIC minimum inhibitory concentration
  • the term “treating” refers to administering a pharmaceutical composition for prophylactic and/or therapeutic purposes.
  • prophylactic treatment refers to treating an organism such as a human patient, who is not yet infected, but who is susceptible to, or otherwise at risk of, a particular infection.
  • susceptible and risk do not refer to the status of organisms of that type generaUy, but rather refers to a significantly enhanced risk. Such risk may for example be due to a specific exposure to a particular potentially infective agent, to a generaUy weakened physical condition, or immune system deficiency.
  • microbial infection refers to a disease state or some adverse condition ⁇ ), such as the presence of a pathogenic microorganism in a body fluid like blood, urine, cerebrospinal or organ tissue, which are otherwise sterile or free of pathogenic microorganisms.
  • therapeutic treatment refers to administering treatment to a patient already suffering from an infection.
  • treating is the administration to a mammal (either for therapeutic or prophylactic purposes) of therapeutically effective amounts of a potentiator and an antibacterial (or antimicrobial) agent in combination (either simultaneously or seriaUy).
  • a potentiator refers to a compound such as an efflux pump inhibitor which has the abiUty to increase the concentration of existing antibiotics in a microbial cell.
  • a therapeuticaUy effective amount is meant an amount of an efflux pump inhibitor, or amounts individually of an efflux pump inhibitor and an antimicrobial agent, as disclosed for this invention, which have a therapeutic effect, which generaUy refers to the inhibition to some extent of the normal metaboUsm of microbial cells causing or contributing to a microbial infection.
  • the doses of efflux pump inhibitor and antimicrobial agent which are useful in combination as a treatment are therapeuticaUy effective amounts.
  • a therapeuticaUy effective amount means those amounts of efflux pump inhibitor and antimicrobial agent which, when used in combination, produce the desired therapeutic effect as judged by cUnical trial results and/or model animal infection studies.
  • the efflux pump inhibitor and antimicrobial agent are combined in predetermined proportions and thus a therapeutically effective amount would be an amount of the combination.
  • This amount and the amount of the efflux pump inhibitor and antimicrobial agent individually can be routinely determined by one of skill in the art, and wiU vary, depending on several factors, such as the particular microbial strain involved and the particular efflux pump inhibitor and antimicrobial agent used. This amount can further depend upon the patient's height, weight, sex, age and medical history.
  • a therapeuticaUy effective amount is that amount which would be effective if a microbial infection existed.
  • a therapeutic effect reUeves, to some extent, one or more of the symptoms of the infection, and includes curing an infection.
  • “Curing” means that the symptoms of active infections are eliminated, including the elimination of excessive numbers of viable microbes of those involved in the infection. However, certain long-term or permanent effects of the infection may exist even after a cure is obtained (such as extensive tissue damage).
  • microbial infection refers to the invasion of the host mammal by pathogenic microbes. This includes the excessive growth of microbes which are normaUy present in or on the body of a mammal. More generaUy, a microbial infection can be any situation in which the presence of a microbial population(s) is damaging to a host mammal. Thus, a mammal is "suffering" from a microbial infection when excessive numbers of a microbial population are present in or on a mammal's body, or when the effects of the presence of a microbial population (s) is damaging the ceUs or other tissue of a mammal. SpecificaUy, this description applies to a bacterial infection.
  • administering refers to a method of giving a dosage of an antimicrobial pharmaceutical composition to a mammal, where the method is, e.g., topical, oral, intravenous, intraperitoneal, or intramuscular.
  • the preferred method of administration can vary depending on various factors e.g., the components of the pharmaceutical composition, the site of the potential or actual bacterial infection, the microbe involved, and the severity of an actual microbial infection.
  • mammal is used in its usual biological sense. Thus, it specifically includes humans, cattle, horses, dogs, and cats, but also includes many other species.
  • This invention also features a method of enhancing the antimicrobial activity of an antimicrobial agent against a microbe, in which such a microbe is contacted with an efflux pump inhibitor, e.g., a non-tetracycline specific efflux pump inhibitor, to an efflux pump in the cell, and an antibacterial agent.
  • an efflux pump inhibitor e.g., a non-tetracycline specific efflux pump inhibitor
  • the efflux pump inhibitor is a compound as described above.
  • the microbe is a bacterium or a fungus, such as any of those described above;
  • the antibacterial agent can be selected from a number of structural classes of antibiotics including, e.g., beta-lactams, glycopeptides, aminoglycosides, quinolones, tetracycUnes, rifamycins, coumermycins, macroUdes, and chloramphenicol.
  • an antibiotic of the above classes can be as stated above.
  • this invention provides pharmaceutical compositions effective for treatment of an infection of an animal, e.g., a mammal, by a microbe, such as a bacterium or a fungus.
  • the composition includes a pharmaceutically acceptable carrier and an efflux pump inhibitor as described above.
  • efflux pump inhibitors which are themselves effective antimicrobial agents, even in the absence of another antimicrobial agent (i.e., have intrinsic antimicrobial activity).
  • pharmaceutical composition including such efflux pump inhibitors can be used either alone or in conjunction with another antimicrobial agent.
  • the efflux pump inhibitors in pharmaceutical compositions of this aspect are efflux pump inhibitors which enhance the effectiveness of an antimicrobial agent other than the efflux pump inhibitor, so such compositions would generaUy be used in combination with such other antimicrobial agent.
  • the invention also provides pharmaceutical compositions similarly effective for treatment of an infection of a mammal which include an efflux pump inhibitor and an antimicrobial agent.
  • the invention provides antimicrobial formulations which include an antimicrobial agent, an efflux pump inhibitor, and a carrier.
  • the antimicrobial agent is an antibacterial agent.
  • a “carrier” or “excipient” is a compound or material used to facUitate administration of the compound, for example, to increase the solubUity of the compound.
  • SoUd carriers include, e.g., starch, lactose, dicalcium phosphate, sucrose, and kaoUn.
  • Liquid carriers include, e.g., sterUe water, saUne, buffers, non-ionic surfactants, and edible oils such as oil, peanut and sesame oils.
  • various adjuvants such as are commonly used in the art may be included.
  • the invention provides a method of suppressing growth of a microbe, e.g., a bacterium, expressing an efflux pump, e.g., a non-tetracycUne-specific efflux pump.
  • a microbe e.g., a bacterium
  • the method involves containing that bacterium with an efflux pump inhibitor, e.g., a non-tetracycline-specific efflux pump inhibitor, in the presence of a concentration of antibacterial agent below the MIC of the bacterium.
  • an efflux pump inhibitor e.g., a non-tetracycline-specific efflux pump inhibitor
  • This method is useful, for example, to prevent or cure contamination of a ceU culture by a bacterium possessing an efflux pump.
  • the invention provides a method for reducing a population of a microbe, e.g., a bacterial strain, involving contacting the population with an efflux pump inhibitor which inhibits a component of an efflux pump expressed in the microbe in that population, which is essential for the growth of the microbe expressing that efflux pump.
  • an efflux pump inhibitor which inhibits a component of an efflux pump expressed in the microbe in that population, which is essential for the growth of the microbe expressing that efflux pump.
  • that component is cytoplasmic membrane component.
  • efflux pump inhibitors may act in various ways, including, but not limited to, acting directly on the essential component, or acting to inhibit the expression of that component.
  • an "essential component" of an efflux pump is one which is essential to the in vivo survival of the microbe, i.e., the survival in a host.
  • this invention provides a method for enhancing growth of an animal by administering an efflux pump inhibitor to the animal, which inhibits an efflux pump expressed in a bacterial strain in the animal, and which inhibits the growth of the bacterial strain.
  • an efflux pump inhibitor to the animal, which inhibits an efflux pump expressed in a bacterial strain in the animal, and which inhibits the growth of the bacterial strain.
  • Such a growth enhancing effect may result from the reduced energy consumption by the bacteria, which increases the food energy available to the animal.
  • This method is appropriate, for example, for use with cattle, swine, and fowl such as chickens and turkeys.
  • the invention provides novel compounds having efflux pump activity. These compounds have chemical structures as described above. As indicated above, while the present invention is presently exemplified by activity against bacteria, compounds of the present invention also have activity against other microbes, for example against yeasts and/or other fungi. Thus, the above aspects also include embodiments in which described compounds are active or effective against such other microbes.
  • the invention provides a method of making a pharmaceutical composition
  • a method of making a pharmaceutical composition comprising the steps of identifying an efflux pump inhibitor having a chemical structure of the formula I; synthesizing said efflux pump inhibitor and preparing a pharmaceutical composition containing said efflux pump inhibitor.
  • the efflux pump inhibitor may have the chemical structure as described above.
  • the pharmaceutical composition may also contain one or more antimicrobial agents, e.g., as identified above, and one or more carriers, dUuents, and excipients.
  • the efflux inhibitor compound is active against a microbe, e.g., a bacterium, as identified above.
  • Identification of efflux pump inhibitors having structures as described for the present invention was performed using screening methods known to those skilled in the art of biological techniques and are described in detail below.
  • the screening method based on inhibition of microbial growth in the presence of a subinhibitory concentration of an antibacterial agent which is normally effluxed by the test microbe and a concentration of a test compound was used for identifying some of the active compounds disclosed herein.
  • inhibition of growth of the microbe is indicative that export of the antibacterial agent is inhibited by the test compound, and that the test compound is therefore an efflux pump inhibitor.
  • the mode of action of the test compound so identified can then be confirmed as inhibiting active efflux.
  • other screening methods for detecting efflux pump inhibitors can also be used.
  • the inventors have screened a Ubrary of synthetic chemicals and identified several compounds that effectively inhibit the respective efflux pumps of Staphylococcus aureus 1199B NorA*, Streptococcus pneumoniae 3514, Pseudomonas aeruginosa 23587, Escherischia coli 2051. Some of these compounds were found to be also effective against presently unidentified multidrug transporters of other microorganisms.
  • the library of compounds was obtained by synthesis according to methods as described in our copending applications PCT appUcation PCT/IN99/00016, US appUcations 09/566,875, 09/640,947, and 09/850,669 and by methodologies described in a later section below.
  • Inhibitors of the bacterial efflux pumps are generaUy initially characterised in vitro. Those which show effective inhibition of the pump(s) and which show synergistic activity with antibiotics are selected for evaluation in vivo. Efficacy testing wUl be done using standard procedures. Primary efficacy evaluation may be done using the murine septicemia model (M.G. Bergeron, 1978, Scand. J. Infect. Dis. Suppl. 14:189-206; S.D. Davis, 1975, Antimicrob. Agents Chemother. 8:50-53). In this model a supra-lethal dose of bacteria is used to chaUenge the rodents. Treatment is initiated, varying either or both time(s) of treatment and dose of antibiotic. In these experiments both the antibiotic and the efflux pump inhibitor doses are varied. A positive result is indicated by significant increase in protection from the lethal infection by the combination of the potentiator (the efflux pump inhibitor) and the antibiotic versus the antibiotic alone.
  • the efflux pump inhibitor the efflux pump inhibitor
  • mice are infected with an appropriate titer of bacteria in the muscle of the hind thigh.
  • Mice are either neutropenic (cyclophosphamide treated at 125 mg/kg on days -4, -2, and 0) or immunocompetent.
  • the infecting dose is commonly 10 s - 10 6 colony forming units per animal.
  • the proliferation (or death) of the bacteria within the thigh muscle is monitored over time. Effective combinations show greater activity than the antibiotic alone. Activity is defined as reduction in growth rate of the test bacteria in the murine tissue.
  • the particular compound that is an efflux pump inhibitor can be administered to a patient either by itself, or in combination with an antimicrobial, e.g., antibacterial, agent, or in pharmaceutical compositions where it is mixed with a suitable carrier(s) or excipient(s) or diluent(s).
  • a combination of an efflux pump inhibitor with an antimicrobial agent can be of at least two different types. In one, a quantity of an efflux pump inhibitor is combined with a quantity of an antimicrobial agent in a mixture, e.g., in a solution or powder mixture. In such mixtures, the relative quantities of the inhibitor and the antimicrobial agent may be varied as appropriate for the speciflc combination and expected treatment.
  • an inhibitor and an antimicrobial agent can be covalently linked in such manner that the Unked molecules can be cleaved within the ceU.
  • the term "in combination” can also refer to other possibilities, including serial administration of an inhibitor and other antimicrobial agent.
  • an efflux pump inhibitor and/or another antimicrobial agent may be administered in pro-drug forms, i.e. the compound is administered in a form which is modified within the ceU to produce the functional form.
  • a therapeuticaUy effective amount of an agent or agents such as these is administered.
  • a therapeutically effective dose refers to that amount of the compound(s) that results in amelioration of symptoms or a prolongation of survival in a patient, and may include eUmination of a microbial infection.
  • Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in ceU cultures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 50/ ED 50 .
  • Compounds which exhibit large therapeutic indices are preferred.
  • the data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human.
  • the dosage of such compounds Ues preferably within a range of circulating concentrations that include the ED 50 with Uttle or no toxicity.
  • the dosage may vary within this range depending upon the dosage and dosage form employed and the route of administration utiUsed. It is preferable that the therapeutic serum concentration of an efflux pump inhibitor should be in the range of 0.1-100 mcg/ml, more preferably 0.1 - 50 mcg/ml, even more preferably 0.1 - 20 mcg/ml, even more preferably 1.0- 50 mcg./ml or most preferably 1.0 - 20 mcg/ml.
  • the therapeuticaUy effective dose can be estimated initiaUy from ceU culture assays.
  • a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 as determined in cell culture. Such information can be used to more accurately determine useful dosage in humans. Levels in plams may be measured, e.g. by HPLC.
  • the efflux inhibitor in a pharmaceutical composition has a structure as shown by the generic structures described above.
  • the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patients condition. (See e.g. Fingl etal., in The Pharmacological Basis of Therapeutics, 1975, Ch.l, p.l). It should be noted that the attending physician would know how and when to terminate, interrupt or adjust administration due to toxicity, or to organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the cUnical response were not adequate, (precluding toxicity). The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the does and perhaps dose frequency wdl also vary according to the age, body weight and response of the individual patient. A programme comparable to that discussed above may be used in veterinary medicine.
  • Such agents may be formulated and administered systemicaUy or locally.
  • Techniques for formulation and administration may be found in Remington's Pharmaceutical Sciences, 19 th ed., Mack PubUshing Co., Easton, Pa. (1990). Suitable routes may include oral, rectal, transdermal, vaginal, transmucosal, or intestinal administration; parentral deUvery, including intramuscular, subcutaneous, intramedullary, injections, as well as intrathecal, direct intraventricular, intravenous, intraperitonial, intranesal, or intraocular injections just to name a few.
  • compositions are prepared according to conventional procedures used by persons skilled in the art to make stable and effective compositions.
  • an effective amount of the active compound or the active ingredient is any amount, which produces the desired results.
  • the pharmaceutical compositions may contain the active compounds of the invention, their derivatives, salts or hydrates thereof, in a form to be administered alone, but generaUy in a form to be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • Suitable carriers which can be used are, for example, diluents or excipients such as fiUers, extenders, binders, emollients, wetting agents, disintegrants, surface active agents and lubricants which are usually employed to prepare such drugs depending on the type of dosage form.
  • any suitable route of administration may be employed for providing the patient with an effective dosage of the compound of the invention, their derivatives, salts or hydrates thereof.
  • oral, rectal, parenteral (subcutaneous, intramuscular, intravenous), transdermal, topical and Uke forms of administration may be employed.
  • Dosage forms include (solutions, suspensions, etc) tablets, piUs, powders, troches, dispersions, suspensions, emulsions, solutions, capsules, injectable preparations, patches, ointments, creams, lotions, shampoos and the like.
  • compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, or aerosol sprays, each containing a predetermined amount of the active ingredient, as a powder or granules, or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oU liquid emulsion.
  • Such compositions may be prepared by any of the methods of pharmacy, but aU methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with Uquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
  • compositions of the present invention include compositions such as suspensions, solutions, elixirs, aerosols, and solid dosage forms.
  • Carriers as described in general above are commonly used in the case of oral soUd preparations (such as powders, capsules and tablets), with the oral soUd preparations being preferred over the oral liquid preparations.
  • the most preferred oral soUd preparation is tablets.
  • tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed.
  • suitable carriers include excipients such as lactose, white sugar, sodium chloride, glucose solution, urea, starch, calcium carbonate, kaolin, crystalUne ceUulose and sUicic acid, binders such as water, ethanol, propanol, simple syrup, glucose, starch solution, gelatine solution, carboxymethyl cellulose, shellac, methyl ceUulose, potassium phosphate and polyvinyl pyrroUdone, disintegrants such as dried starch, sodium alginate, agar powder, laminaria powder, sodium hydrogen carbonate, calcium carbonate, Tween (fatty acid ester of polyoxyethylenesorbitan), sodium lauryl sulfate, stearic acid monoglyceride, starch, and lactose, disintegration inhibitors such as white sugar, stearic acid glyceryl ester, cacao butter and hydrogenated
  • the tablet if desired, can be coated, and made into sugar-coated tablets, gelatine-coated tablets, enteric-coated tablets, film-coated tablets, or tablets comprising two or more layers. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.
  • a wide variety of conventional carriers known in the art can be used.
  • suitable carriers are excipients such as glucose, lactose, starch, cacao butter, hardened vegetable oils, kaoUn and talc, binders such as gum arabic powder, tragacanth powder, gelatin, and ethanol, and disintegrants such as laminaria and agar.
  • a wide variety of carriers known in the art can be used.
  • suitable carriers include polyethylene glycol, cacao butter, higher alcohols, gelatine, and semi-synthetic glycerides.
  • a second preferred method of administration is parenteraUy for intramuscular, intravenous or subcutaneous administration.
  • a third preferred route of administration is topicaUy, for which creams, ointments, shampoos, lotions, dusting powders and the like are well suited.
  • the compounds of the present invention may also be administered by controlled release means and/or delivery devices such as those described in U S Patent Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123 and 4,008,719; the disclosures of which are hereby incorporated by reference.
  • aU diluents customarUy used in the art can be used.
  • suitable diluents are water, ethyl alcohol, polypropylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol, and sorbitan esters.
  • Sodium chloride, glucose or glycerol may be incorporated into a therapeutic agent.
  • the antimicrobial pharmaceutical composition may further contain ordinary dissolving aids, buffers, pain-aUeviating agents, and preservatives, and optionaUy colouring agents, perfumes, flavours, sweeteners, and other drugs.
  • viscous to semi-soUd or soUd forms comprising a carrier compatible with topical application and having a dynamic viscosity preferably greater than water.
  • Suitable formulations include but are not Umited to solutions, suspensions, emulsions, creams, ointments, powders, Uniments, salves, aerosols, etc., which are, if desired, steriUzed or mixed with auxiUary agents, e.g. preservatives, antioxidants, stabUizers, wetting agents, buffers or salts for influencing osmotic pressure, etc.
  • auxiUary agents e.g. preservatives, antioxidants, stabUizers, wetting agents, buffers or salts for influencing osmotic pressure, etc.
  • sprayable aerosol preparations wherein the active ingredient preferably in combination with a soUd or liquid inert carrier material.
  • the compounds of the present invention may be readily prepared in accordance with the foUowing synthesis schemes, as iUustrated in the specific examples provided.
  • those skilled in the art wUl recognise that other synthetic pathways for forming the compounds of this invention can be utilised, and that the following is provided merely by way of example and is not limiting to the present invention.
  • various protecting and deprotecting strategies wiU be employed which are standard in the art (see e.g., "Protective Groups in Organic Synthesis", by Green and Wuts).
  • protecting and deprotecting strategies wiU be employed which are standard in the art (see e.g., "Protective Groups in Organic Synthesis", by Green and Wuts).
  • Those skilled in the art wuT recognise that the selection of any particular protecting group (e.g. amine, hydroxy and carboxyl protecting groups) wiU depend on the stabUity of the protected moiety with regard to the subsequent reaction conditions and wUl understand the appropriate selection.
  • R,, R4 a , R s , Re, X and Y are as hereinbefore described is treated with an appropriate amine of the formula R 9 R ⁇ 0 NH, where R 9 and R ⁇ 0 have the meanings hereinbefore described in an organic solvent such as acetone, alcohol, acetonitrUe, dimethyl sulphoxide, N,N- dimethylformamide preferably acetonitrile or dimethyl sulphoxide, optionaUy in the presence of a base such as triethylamine, pyridine, l,5-diazabicyclo[4.3.0]non-5-ene (DBN), diazabicyclo[5.4.0]undee-7-ene (DBU) preferably triethylamine at 50°C - 120°C, preferably 70°C - 90°C for 4- 24 hr.
  • a base such as triethylamine, pyridine, l,5-diazabicyclo[4.3.0
  • the product obtained is hydrolysed by aqueous alkali preferably sodium hydroxide or a base preferably triethylamine in solution in a solvent such as ethanol.
  • the compounds I of the invention which are esters at a carboxylic acid group may be prepared by treating the free acid of compounds of formula I in solution in an appropriate solvent, preferably N,N-dimethylformamide, with the corresponding halo compound, preferably chloro or bromo-compound, in the presence of a base, preferably anhydrous potassium carbonate, at an elevated temperature, preferably 50°C for an extended period of time, preferably 6 hours.
  • an appropriate solvent preferably N,N-dimethylformamide
  • halo compound preferably chloro or bromo-compound
  • the compounds of the invention which are esters at a carboxylic acid group may be prepared by treating the free acid of compound of formula I in solution in an appropriate solvent, preferably N,N-dimethylacetamide, with the corresponding hydroxy compound, in the presence of a base, preferably triethylamine, in presence of a catalyst, preferably 4-N,N- dimethylaminopyridine, and in the presence of a dehydrating agent, preferably N,N- dicyclohexylcarbodimide at an elevated temperature, preferably 100°C for an extended period of time, preferably 24 hours.
  • an appropriate solvent preferably N,N-dimethylacetamide
  • a base preferably triethylamine
  • a catalyst preferably 4-N,N- dimethylaminopyridine
  • a dehydrating agent preferably N,N- dicyclohexylcarbodimide at an elevated temperature, preferably 100°C for an extended period of time, preferably 24 hours.
  • the compounds of formula I of the invention which are amides at a carboxylic acid groups may be prepared by coupling the free acid of compound of formula I with ammonia or an appropriate amine or an amino acid appropriately protected at the acid functionality of the amino acids with a protecting group.
  • the -COOH protecting groups for amino acids are known in the art. Examples of suitable -COOH protecting groups for amino acids are methyl, ethyl, t-butyl and benzyl groups.
  • the -COOH protecting group is removed by hydrolysis or by hydrogenation.
  • the coupling of a -COOH group of compound of formula I with the amino group of the amino acid is also known in the art.
  • the reaction may be conducted with or without a solvent at a range of temperatures in the presence of a coupling agent.
  • the compounds of the invention which are amides at an NH2 or an NH group are prepared by coupling the free amino group of a compound of formula I or by coupling the free NH bearing compound of formula I with an appropriate acylating agent such as an acyl anhydride or an acyl chloride in the presence of a condensing agent such as a base e.g. triethylamine or aqueous sodium hydroxide optionaUy in the presence of a solvent such as
  • N,N-dimethyl acetamide at an elevated temperature of 50°C - 100°C for an extended period of time upto 24 hours.
  • a protecting group on the NH2 group or NH group which is desired to remain unreactive For compound that contain two NH2 groups, two NH groups or one NH2 and one NH group, it may be necessary when so desired to use a protecting group on the NH2 group or NH group which is desired to remain unreactive.
  • Protecting groups for NH2 and NH groups are weU known to those skiUed in the art.
  • the compounds of the invention which are esters of a free hydroxy group may be prepared by treating the free hydroxy compound of formula I with an organic acid, an organic dibasic acid or appropriate N-protected amino acid or polypeptide as defined above.
  • Nitrogen protecting groups are known in the art Examples of suitable nitrogen protecting groups are
  • C C 6 acyl C 2 -C 6 alkoxycarbonyl optionally substituted benzyloxycarbonyl, aryloxycarbonyl, sUyl, trityl, tetrahydropyranyl, vinyloxycarbonyl, O-nitrophenylsulfonyl, diphenylphosphinyl, p-toluenesulfonyl, and benzyl.
  • the nitrogen protecting group is removed by methods known in the art such as hydrogenation or hydrolysis.
  • the ester forming reaction may be conducted with or without a solvent at a range of temperatures in the presence of a suitable condensing agent, known to those skilled in the art.
  • the compounds of the invention which are alkyl ethers of a free hydroxy group may be prepared by treating the compound bearing the free hydroxy group with an alkyl halide in an organic solvent in the presence of a base or a condensing agent at temperatures upto the boiUng point of the solvent for a period of time upto 24 hours, by methods known to those skilled in the art.
  • the compounds of the invention which are mono or dialkyl derivatives of a free amino group may be prepared by treating the compound bearing the free amino group with appropritae molar amounts of an alkylhalide in an organic solvent optionally in the presence of a base or a condensing agent at temperatures upto the boding point of the solvent for a period of time upto 24 hours, by methods known to those skilled in the art h) General Method for making aminoacid esters at the 8-(4'-hydroxypiperidine substituent of
  • Trifluoroacetic acid (10 ml) was added to the product obtained in the previous step. After 30 mins at room temperature, the acid was evaporated and the trifluoroacetate salt was precipitated by addition of ether. If need be the product could be purified by high pressure
  • the mixture was acidified, extracted with ethylacetate, washed with brine , dried over sodiumsulphate and evaporated to provide the title compound. If need be the product may be purified by high pressure Uquid chromatography on a C8 or C18 column. OptionaUy, dissolving the acid in water with one equivalent sodiumbicarbonate foUowed by freeze drying provided the sodium salt of the title compound.
  • the pharmaceutically acceptable acid addition salts of compounds I are prepared in a conventional manner by treating a solution or suspension of the free base I with about one chemical equivalent of a pharmaceuticaUy acceptable acid. Conventional concentration and recrystalisation techniques are employed in isolating the salts.
  • IUustrative of suitable acids are hydrochloric, hydrobromic, hydroiodic, sulphuric, sulfamic, sulfonic, phosphoric, acetic, lactic, succinic, oxaUc, maleic, fumaric, malic, tartaric, citric, ascorbic, gluconic, benzoic, cinnamic, methanesulfonic and p-toluenesulfonic acid.
  • the pharmaceutically acceptable cationic salts of compounds of formula I may be prepared by conventional methods from the corresponding acids e.g. by reaction with about one equimolar amount of a base.
  • suitable cationic salts are those of alkaU metals such as lithium, sodium or potassium, alkaline earth metals such as magnesium or calcium or ammonium or organic amines such diethanolamine, N-methylglucamine, guanidine or heterocyclic amines such as choUne, piperidine, N-methyl-4-hydroxypiperidine, hydroxyethylpyrroUdine, hydroxyethylpiperidine, morpholine, hydroxyethylmorphoUne, piperazine, N-methyl piperazine and the Uke or basic amino acids such as optically pure or racemic isomers of arginine, lysine, histidine, tryptophan and the like.
  • Example 1 l-Ethyl-6-fluoro-l, 4-dihvdro -7-fl 2 f , 3', 4'-tetrahvdroisoquinoUn-2-yl)-4-oxo-quinoline-3- carboxylic acid.
  • Example 12 l-Cyclopropyl-6-fluoro-l.4-dihvdro -7- ⁇ 4'-(N-dimethylamino) piperidin-l-yl)-4-oxo-quinoline-3- carboxyUc acid.
  • Example 13 l-Cvclopropyl-6-fluoro-l, 4-dihvdro- -7-(3', 5'-dimethyl piperidin-l-ylV4-oxo-quinoUne-3- carboxylic acid.
  • Example 14 l-Cvclopropyl-6-fluoro-l, 4-dihvdro -7-(4'-hydroxy-3 , , 5 , -dimethylpiperidin-l-ylV4-oxo-quinoUne- 3-carboxyUc acid. It was prepared in a similar manner as described in example 9 where 4-hydroxy-3,5- dimethylpiperidine was used in place of 3-acetamido-5-methyl pyrroUdine. Yield 38 %, m.p 178- 80 °C, C 20 H 23 FN 2 O 4 , m z 375 (M+l).
  • Example 15 l-Cvclopropyl-6-fluoro-l, 4-dihvdro- -7-(3', 4', 5'-trimethyl piperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid.
  • Example 16 l-Cvclopropyl-6-fluoro-l, 4-dihvdro- 7-(3', 5 f -dimethyl-4 , -ethyl piperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid.
  • Example 18 l-Cvclopropyl-6-fluoro-l, 4-dihvdro-5-methyl- 7-(3 f , 3'-dimethylpiperazin -l-vD-4-oxo-quinoUne- 3-carboxylic acid.
  • Example 20 l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(4'-hvdroxy-3 '-isobutylpiperidin-l-vD-4-oxo- quinoUne-3-carboxyUc acid.
  • Example 21 l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(4'-hvdroxy-3', 3 f -dimethvIpiperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid.
  • Example 22 l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro ⁇ -H'-hvdroxy-S', 5 , -dimethylpiperidin-l-yl)-4- oxo-quinoline-3-carboxyUc acid.
  • Example 23 l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(3 , -methylpiperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid. It was prepared in a similar manner as described in example 19 where 3-methyl piperazine was used in place of 4-(N-dimethylamino)-3-methylpiperidine. Yield (48 %), m.p 260-61 °C, C ⁇ 9 H 22 FN 3 0 4 , m/z 375 (M+l).
  • Example 1 l-Cvclopropyl-6-fluoro-l, 4-dihvdro-5-methyl- 7-(4 , -methoxypiperidin -l-yl)-4-oxo-quinoline-3- carboxylic acid.
  • Example 12 l-Ethyl-6, 8-difluoro-l, 4-dihvdro -7-(3'-5'-dimethylpiperazin-l-yl)-4-oxo-quinoline-3-carboxyUc acid.
  • Example 13 l-Cyclopropyl-6-fluoro-l, 4-dihvdro-7- (4'-ethyl-3 , -methylpiperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid.
  • Example 14 l-Cyclopropyl-6-fluoro-l.4-dihvdro- -7-(3 f -5'-dimethyl-4 , -ethylpiperazin-l-ylV4-oxo-quinoUne-3- carboxylic acid.
  • Example 19 l-(2', 4 , -Difluorophenyl)-6-fluoro-l, 4-dihvdro-7- (piperidin-4 , -ylaminoV4-oxo-naphthyridine-3- carboxylic acid. Prepared according to example 49 in the list of compounds for the NorA pump.
  • Example 20 l-Cvclopropyl-6-fluoro-l, 4-dihvdro -7-(4 , -amino-3'-ethylpiperidin-l-yl)-4-oxo-naphthyridine-3- carboxylic acid.
  • Trifluoroacetic acid (10 ml) was added to the derivative obtained, stirred for 30 mins at room temp., the acid was evaporated and the trifluoroacetate salt was precipitated by addition of ether. Purified by RP-HPLC on a C18 column. Dissolved the trifluoroacetate salt in 0.1 N hydrochloride acid and freeze-dried provided the titled salt. Yield 75 %, m.p (hygroscopic) °C, C 23 H 26 FN 3 0 7 , m/z 543 (M+l)
  • the compound was purified by prep-HPLC using water-acetonitrile-0.1% trifluoroacetic acid system to get after freeze drying a white powder as trifluoro acetate salt. Yield 74 %, m.p 80-82 °C, C 30 H 34 F 2 N 4 O 5 , m/z 467.5 (M+l).
  • SoUd separated was filtered, dried and purified on sUica column to furnish titled product. Yield 66 %, m.p 150-52 °C, C 20 H 23 FN 2 O 4 , m/z 375 (M+l).
  • Example 23 l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihvdro-7- ((loc, 5oc, 6oc)-6-amino-N-benzyl-3-azabicvclo [3.1.01 hex-6-yl - 4-oxo-l,8-naphthyridine-3-carboxylic acid.
  • Example 30 ( S ) -f-V9-Fluoro-6.7-dihvdro-8- (3 , . 3 , -dimethyl-4 , -ethylaminopiperidin-l-vn-5-methyl-l-oxo-lH, 5H-benzo fi.i[quinoUzine-2-carboxyUc acid.
  • FIC Fractional Inhibition Concentration
  • the assay involves broth microdilution method performed as recommended by the National Committee for CUnical Laboratory Standards (NCCLS) 1997 (Methods for Dilution of Antimicrobial Susceptibility Tests for Bacteria that Grow AerobicaUy, Fourth edition; Approved
  • test organism used for the assay is Staphylococcus aureus 1199 B NorA + .
  • DMSO dimethyl sulfoxide
  • the checkerboard assay is performed in microtiter plates. Ciprofloxacin is diluted in the X-axis, each column containing a single concentration of ciprofloxacin. The efflux pump inhibitor is diluted in the Y-axis, each row containing an equal concentration of efflux pump inhibitor. The result of these manipulations is that each well of the microtiter plate contains a unique combination of concentrations of the two agents. Bacterial inoculum is added at 5 x 10 s CFU/ml. Microtiter plates are incubated at 35°C for 20 hours. Reading is done by visibly noting turbidity and confirmed using a microtiter plate reader (Molecular Devices). The FIC index is calculated as
  • (A) is the concentration of the experimental efflux pump inhibitor in the weU that is the lowest inhibitory concentration in the Y-axis.
  • (MIC A ) is the MIC of Staphylococcus aureus to experimental efflux pump inhibitor alone.
  • FIC A is the fractional inhibitory concentration of an experimental efflux pump inhibitor.
  • (B) is the concentration of the ciprofloxacin in the weU that is the lowest inhibitory concentration in the X-axis.
  • FIC B is the fractional inhibitory concentration of ciprofloxacin.
  • Pseudomonas aeruginosa 23587 is used.
  • Pseudomonas aeruginosa 23587 is a cUnical isolate containing multiple efflux pumps which can be mexAB, mexCD, mexEF but not Umited to mex classification only.
  • Pseudomonas aeruginosa are grown in tryptic soya broth for 20 hours at 35°C.
  • Two antibiotic assay plates are prepared in Mueller Hinton Agar using above inoculum. The bacterial count in a plate is 1 x 10 6 ceUs/ml.
  • levofloxacin is incorporated at 5 mcg/ml, whUe in the control plate an equivalent amount of water is added.
  • An experimental efflux pump inhibitor is evaluated by adding a series of concentrations of the test compound ranging from 0.025 meg to 200 mcg./well in agar plate. The plates are incubated at 35°C for 20 hours and the zone of inhibition was recorded in mm (table 2). The difference in the diameter of zone of inhibition was calculated by subtracting from the diameter of the zone of inhibition in the levofloxacin containing plate the diameter of the zone of inhibition in the water containing control plate.
  • E.coli 2051 The activity of an efflux pump inhibitor of E.coli 2051 was also assessed using an antibiotic diffusion assay.
  • Exoli 2051 is used.
  • E.coli 2051 is a clinical isolate containing multiple efflux pumps.
  • E.coli 2051 are grown in tryptic soya broth for 20 hours at 35°C.
  • Two antibiotic assay plates are prepared in Mueller Hinton Agar using above inoculum. The bacterial count in a plate is 1 x 10 6 cells/ml. In one of the plates, levofloxacin is incorporated at 15 mcg/ml, whUe in the control plate an equivalent amount of water is added.
  • An experimental efflux pump inhibitor is evaluated by adding a series of concentrations of the test compound ranging from 0.025 meg to 200 mcg./well in agar plate. The plates are incubated at 35°C for 20 hours and the zone of inhibition was recorded in mm (table 3) . The difference in the diameter of zone of inhibition was calculated by subtracting from the zone of inhibition in the levofloxacin containing plate the diameter of the zone of inhibition in the control plate.
  • Streptococcus pneumoniae 3514 (Mef+) is used which was obtained from the Centre for Disease Control (CDC), Atlanta. A simUar 2 plate assay method as described above is used with small modifications. Streptococcus pneumoniae 3514 (Mef+) is grown in Columbia blood agar for 18 hours at 25°C. The growth was suspended in sterile todd hewitt broth and CFU were adjusted using macfarland's standard to 1 x 10 s CFU/ml. 0.5 ml of this is added to the MueUer Hinton agar supplemented with 5% sheep blood, final bacterial count was 10 6 ceUs/ml.
  • Streptococcus pyogenus 26-00 is used which was obtained from the Centre for Disease Control (CDC), Atlanta. A similar 2 plate assay method as described above is used with small modifications. Streptococcus pyogenus 26-00 (Mef+) is grown in Columbia blood agar for 18 hours at 25°C. The growth was suspended in sterUe todd hewitt broth and CFU were adjusted using macfarland's standard to 1 x 10 s CFU/ml. 0.5 ml of this is added to the Mueller Hinton agar supplemented with 5% sheep blood, final bacterial count was 10 6 ceUs/ml.
  • *Z the difference of the diameter of the zone of inhibition in the levofloxacin containing plate minus the diameter of the zone of inhibition in the water containing control plate. * S-isomer; ** R-isomer; Absence of an asterisk indicates that the substance is a racemic compound.
  • Z the difference of the diameter of the zone of inhibition in the levofloxacin containing plate minus the diameter of the zone of inhibition in the water containing control plate.
  • *Z the difference of the diameter of the zone of inhibition in the levofloxacin containing plate minus the diameter of the zone of inhibition in the water containing control plate. * S-isomer; ** R-isomer; Absence of an asterisk indicates that the substance is a racemic compound.
  • *Z the difference of the diameter of the zone of inhibition in the levofloxacin containing plate minus the diameter of the zone of inhibition in the water containing control plate. * S-isomer; ** R-isomer; Absence of an asterisk indicates that the substance is a racemic compound.

Abstract

Compounds are described which are efflux pump inhibitors of cellular efflux pumps of microbes. Also described are methods of preparing such compounds, methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.

Description

INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES
This invention relates to compounds with efflux pump inhibitor properties, and which are therefore compounds which inhibit cellular efflux pumps of bacteria or other microbes. Such efflux pump inhibitors are useful, for example, against antibiotic-resistant microbial pathogens, for treating microbial infections by reducing the export of a co-administered antimicrobial agent or by preventing the export of a compound synthesized by microbes (e.g. bacteria, fungi) to allow or improve their growth. Thus, this invention also provides processes for preparation of such efflux pump inhibitors, compositions which include such efflux pump inhibitors, and the use of the compounds and compositions in methods for treatment of microbial infections.
Background of the Invention
Microbes are known to have developed the ability to evolve different mechanisms of self-defense against antimicrobial agents. In particular, bacterial and fungal pathogens have developed mechanisms of resistance to antibiotics and antimicrobial agents used to inhibit their growth, or to treat infections by them in humans, animals and tissue cultures. As a result, treatment regimens can be adversely affected or, in some cases rendered ineffective.
One of the most frequently employed resistance strategies in both prokaryotes and eukaryotes is the transmembrane-protein-catalyst extrusion of drugs from the cell, with these proteins acting like bilge pumps, reducing the intracellular drug concentration to subtoxic levels. (M. Ines Vorges-Walmsley et al, Trends in Microbiology, 2001, 9:71-79).
Recent developments in the efflux area include the discovery of new monodrug efflux systems, as well as the realisation of the importance of multidrug efflux systems (H. Nikaido and H.I. Zgurskaya, Current Opinion in Infectious Diseases, 1999, 12:529). In gram-negative bacteria, for example, single component efflux pumps extrude their substrates into the periplasmic space as is done by the transposon-encoded tetracycline- and chloramphenicol-specific pumps, TetA and CmlA, respectively, and the MDR pump MdfA encoded in the chromosome of Escherichia coll
Bacterial genomes sequenced to date almost invariably contain genes apparently coding for multidrug efflux pumps. Multidrug efflux as a major cause of intrinsic drug resistance in many microorganisms, or overproduction of intrinsic pumps, or acquisition of pump genes from external sources, all play a prominent role, often resulting in high levels of resistance. Examples of multicomponent efflux pumps, belonging mainly to the resistance-nodulation-division (RND) family members, found mostly in gram-negative bacteria, include the MDR pumps AcrAB-TolC and MexAB-OprM from E. coli and Pseudomonas aeruginosa. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance (A. Lee et al, J. of Bacteriology, 2000, 182:3142). MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexXY-OprM, AcrAB-TolC, AcrEF, MarA, SoxS, or/and Tet pump/s are known to be present in Gram negative organisms such as P. aeruginosa and E. coli and are reviewed in recent publications and papers, such as K. K. Y. Wong et al, J. of Bacteriology, 2001, 183:367-374; K. Poole, Antimicrobial Agents and Chemother., 2000, 44:2233-2241; R Srikumar et al, Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemother., 2000, Abstr. 441:74; Xi n Zhi Li et al, Journal of Antimicrob. Chemother., 2000, 45:433-436; Koronakis etal., Nature, 2000, 405:914- 919; M. Oethinger et al, Antimicrob. Agents and Chemother., 2000, 44:10-13; W.V. Kern, et al, Antimicrob. Agents and Chemother., 2000, 44:814-820; O. Lomovskaya, et al, Antimicrob. Agents and Chemother., 1999, 43:1340-1346. Active efflux has been shown to be the primary or molecular mechanism of a fluoroquinolone resistance in Salmonella enterica Serovar Typhimurium (E Giraud et al, Antimicrob. Agents and Chemother., 2000, 44:1223-1228) and in P. aruginosa isolates from cystic fibrosis patients (S Jalal et al, Antimicrob. Agents and Chemother., 2000, 44:710-712). Efflux mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei, the causative agent of meliodosis has been described in R. A. Moore et al, Antimicrob. Agents and Chemother., 1999, 43:465-470.
Efflux transporters are also among different mechanisms responsible for the resistance to antibiotics displayed by gram-positive bacteria and mycobacteria, particularly aerobic gram- positive cocci. The multidrug transporter NorA, belonging to the major facilitator superfamily (MFS) transporters, contributes to the resistance of Staphylococcus aureus to fluoroquinolone antibiotics. A minireview describes effllux-mediated resistance to fluoroquinolones in Gram- positive bacteria and the mycobacteria (K. Poole, Antimicro. Agents and Chemother., 2000, 44: 2595-2599). To the MFS transporters also belong the Bmr and QacA/QacB efflux pumps of Gram-positive bacteria, and EmrB of E. coli (H. Nikaido, Current Opinion in Microbiology, 1: 516-523). A structure-based mechanism for drug binding by multidrug transporters is recently proposed using the BmrR protein from Bacillus subtilis and the multidrug transporter MdfA from E coli (E. E. Zheleznova et al, Trends in Biological Sciences 2000, 25:39-43), which mechanism is also putatively considered for the QacA/QacB efflux system of S. aureus. New MFS pumps include PmrA (a homolog of NorA) of Streptococcus ptieumoniae . Broskey et al, Journal of Antimicrob. Chemother., 2000, 45:SuppI. SI, 95-99; M.J. Gill etal, Antimicrob. Agents and Chemother., 1999, 43:187-189) and Tap of Mycobacterium fortuitum and M. tuberculosis. Recently, NorM, which pumps out fluoroquinolones and some cationic agents was found to be outside the MFS transporter class. The role of membrane-fusion protein (MFP) structural homologues recently identified in low G + C Gram positive bacteria that lack an outer membrane, as essential transport accessory proteins with transporters of the ATP-Binding Cassette (ABC) superfamily has been described (K T Harley et al, Molecular Microbiol., 2000, 38:516-517).
The Mef efflux system mediates large fractions of erythromycin-resistant clinical isolates of S. pneumoniae (N. J. Johnston et al, Antimicrob. Agents and Chemother., 1998, 42:2425; T. Nishijima et al, J. Antimicrob. Chemother., 1999, 43:637). Beta-haemolytic streptococci and pneumococci resistant to erythromycin due to the prsence of Mef A efflux pumps in Streptococcus pyogenes, Mef E pumps in S. pneumoniae, and an M phenotype bearing S. agalactiae possessing Mef A or Mef E pumps are found to be emergent and prevalent in Europe (C. Arpin et al, J. Antimicrob. Chemother., 1999, 44:133-138; E. Giovanetti et al, Antimicrob. Agents and Chemother., 1999, 43:1935-1940).
Efflux and drug resistance in fungi and protozoa have also been described (T. G. White et al., Clin Microbiol. Rev. 1998, 11:382; D. Sanglard, Drug Resistance Updates 1998, 1:255; B. Papadopoulou et al, Drug Resistance Updates 1998, 1: 266; E. Orozao et al, Drug Resistance Updates, 1999, 2:188).
In summary, the above discussion indicates that cellular factors affecting transport (both active and passive transport) of antibiotics into bacterial cells are important components of antibiotic resistance for many microbial species.
One strategy to target resistance mechanisms of microbial self-defense is to find inhibitors of microbial efflux pumps and, in particular of bacterial and fungal efflux pumps.
There is disclosed in PCT Patent publication WO 96/33285 and US Patent application 5,989,832 with priority in US Application 08/427,088 and PCT/US96/05469, methods for screening for inhibitors of microbial efflux pumps, efflux pump inhibitors, compositions containing such efflux pump inhibitors, and methods for treating microbial infections using those compositions, but unlike the efflux pump inhibitors of the present invention, the efflux pump inhibitors disclosed are dipeptide amides specifically inhibiting a Pseudomonas aeruginosa-t pe efflux pump.
There is disclosed in PCT Patent publication WO/001714, with priority in US Application 09/108,906, compounds which have efflux pump inhibitor activity, methods of using such efflux pump inhibitors and pharmaceutical compositions which include such compounds, but unlike the efflux pump inhibitors of the present invention, the efflux pump inhibitors disclosed are dipeptide amide derivatives demonstrating pump inhibitory activity against P. aeruginosa strains containing singular efflux pumps and multiple efflux pumps. Patent WO 99/17791, with US priority in 60/060,898, discloses a method for inhibiting the selection or propagation of a bacterial mutant that overexpresses an efflux pump wherein the inhibitor disclosed is the dipeptide amide, L-phenylalanyl-L-arginyl-beta-naphthylamide (MC- 207,110), which is unlike the efflux pump inhibitor compounds of the present invention.
US Patent 6,245,746, US Patent 6,114,310 and WO 9937667 all with US priority in US application 09/012,363 discloses methods of using efflux pump inhibitors which increase the susceptibility of microbes, in particular P. aeruginosa strains, to antimicrobial agents and pharmaceutical compositions including such compounds which are unlike the efflux inhibitor compounds of the present invention.
US Patent 6,204,729 describes peptidomimetic, secondary amide containing benzoxazole derivatives as efflux pump inhibitors, methods of using such efflux pump inhibitor compounds and pharmaceutical compositions including such compounds which are unlike the efflux inhibitor compounds of the present invention.
Patent WO 00/32196, with US priority in 60/110,841, discloses inhibitors of multidrug transport proteins which may be used in combination with existing antibacterial agents and/or antifungal agents, wherein the inhibitor is an indole or a urea or an aromatic amide or a quinoline, all of which inhibitors are unlike the efflux pump inhibitor compounds of the present invention. In addition, the inhibitors disclosed in patent WO 00/32196 are specifically inhibitors of bacteria expressing a norA pump, or a fungus expressing a multidrug transport protein.
Novel inhibitors of the NorA multidrug transporter of S. aureus having structurally diverse chemical structures were also described by P. N. Markham et al, (Antimicrob. Agents and Chemother., 1999, 43:2404), among which the more active compounds include (a) those containing an indole moiety like the previously known inhibitor, reserpine, (b) biphenyl urea derivatives, (c) a substituted pyrimidinone derivative and (d) compounds INF 240 and INF 277, but they are all unlike the efflux pump inhibitor compounds of the present invention.
Another inhibitor of the NorA MDR pump in a pathogenic S. aureus strain is 5'- methoxyhydnocarpin (F. R. Stermitz et al., Proc. New York Acad. of Sci., 2000, 97:1433), which has a structure unlike the efflux pump inhibitor compounds of the present invention.
Nocardamin, a cyclopeptide, was found to be a general antagonist of a tetracycline efflux pump from S. aureus. It has a structure unlike the efflux pump inhibitor compounds of the present invention. Minocycline and l,l-dimethyl-5-(l-hydroxypropyl)-4,6,7-trimethylindan (Ro 07-3149) inhibit the active tetracycline efflux pump in S. aureus 743 (T.Hirata et al., Biol Pharm Bull, 1998, 21:678). Both the compounds have a structure unlike the efflux pump inhibitor compounds of the present invention.
(±)-3-(2-chloro, 5-bromophenyl) ethyl-4-fluoropiperidine as an example of 3-arylpiperidines has recently been described as potentiator of existing antibacterial agents against E. coli (A. Thorarensen et al, Bioorg. and Medicinal Chem. Letters, 2001, 11:1903-1096). The 3- arylpiperidine compounds have a structure unlike the efflux pump inhibitor compounds of the present invention.
To our knowledge no drug-like organic molecule has been identified, described or proposed as an inhibitor of a Mef efflux pump.
Deficiencies abound in the efflux pump inhibitors disclosed in the art prior to our present invention.
Reserpine is not a usable compound for therapy because of its neurotoxicity at the concentration required for efflux pump inhibition.
The inhibitors of single drug and multidrug transporters such as the dipeptide amide, MC- 207,110, are broad in specificity, inhibiting all three RND systems of P. aeruginosa involved in fluoroquinolone efflux, but have not been shown to be effective against pumps of other strains, for instance a NorA pump. Moreover, the methods employed to demonstrate their efflux pump inhibitory properties are mainly in vitro methods. For demonstration of in vivo activity, recourse has had to be taken to parenteral administration ( cf. T.E.Renau et al, J.Med.Chem.,1999, 42, 4928), rather than oral administration, as it is generally known that oral bioavailability is poor for compounds of a peptidic nature.
The series of inhibitors described in WO 00/32196 and by Markham et al (vide infra) have been minimally and incompletely profiled in terms of their efficacy, safety and tolerability, which has yet to be demonstrated in in vivo models.
Potent inhibitors of microbial efflux pumps is thus an important goal for the improved control of infectious diseases, allowing a renaissance for drugs that are no longer effective owing to their efflux (K. Poole, Journal of Pharmacy and Pharmacology, 2001, 53:283-294). The current inventors have synthesised, screened and identified novel inhibitors of cellular efflux pumps of microbes. Distinctive structural features characterise the different sets of efflux pump inhibitors for different microorganisms as will be described in the following description.
Summary of the Invention
The present invention describes compounds of the formula I as novel microbial efflux pump inhibitors,
Figure imgf000008_0001
wherein,
Ri = H, Cι.6 alkyl, C3.6 cycloalkyl or optionally substituted aryl, aralkyl, arylaminoalkyl, aryloxyalkyl or arylS(O)talkyl, where t=0,l or 2, or when X is C and the nitrogen atom to which Rt is linked forms an optionally substituted 4-, 5-, 6- or 7-membered ring with X of the adjacent ring, the ring optionally containing one or more hetero atoms selected from nitrogen, oxygen or sulfur atoms, said heteroatom(s) represented by Y, preferably Rt is CH2CH2-, CH2Y-, CH2CH2CH2-,
CH2CH2Y-, CH2CH2CH2CH2- and CH2CH2CH2Y- where Y represents NH, O, or S. If the ring is substituted, the substituent is Cι_6 alkyl group.
R2 = H, CHO, COOR3, or CONHRι3) where Rϊ3 = H or the NHR13 of CONHR13 is the residue of one of the 20 naturally occurring amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine or the optically active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl or tripeptidyl or polypeptidyl residues.
R3 = H, Cι_6 alkyl, C3.6 cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, ary!S(O)taIkyl, where t=0,l or 2,
(CH2)nCH(Rι4)
Figure imgf000008_0002
H, or CH3; and Rls = C2H5 or C(CH3)3
Figure imgf000008_0003
Z=NH or NCH3, and when B=N, Z=CH, O, NH, S or
NCH3; p=0-2; q=0-2, R,= H, ja = H, or R4 and R4., taken together are oxo (=O), or thio (=S). Rs= H, Ci.s alkyl, amino, alkylamino, or acylamino.
Re = H, Cι-6 alkyl, halo such as F, Cl, Br, or I, amino, or hydroxy;
R7 = OH, halo such as F, Cl, Br, or I, or
NR9 R10 wherein R9 and Rj0 are the same or different and represent H, .6 alkyl or (CH2)nOA, or R9 is H and Rι0 is a 4-membered, 5-membered, 6-membered, or 7-membered carbocyclic, mono or bicyclic ring, or mono or bicyclic heterocyclic ring linked to the nitrogen of NR9R10 through an atom of the heterocycle other than the heterocyclic atom, or R9 and Rι0 taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocyclic or bicyclic.
The carbocycle and the heterocycle are optionally substituted at any position of the carbocyclic or heterocyclic group with COOR3 CONHR13, OA, Cι_6 alkyl, C3-C6 cycloalkyl, aralkyl, trifluoroalkyl, substituted C^ alkyl, or N RιβRι7. Substituents of the alkyl group are selected from OA, NR16Rπ, or a halogen atom. R16 and Rπ are the same or different and represent H or C .6 alkyl, or where one of Rι6 and R17 is hydrogen and the other of R16 and RJ7 is C3-C6 cycloalkyl, or substituted Cι_6 alkyl, or R16 and Rι7 taken together with the nitrogen atom form a heterocycle. When R16 or Ri7 is a substituted alkyl group, the substituent is selected from NRiβRπ, alkanoyl or aminoalkanoyl,
or R7 = NHOA, NHCOOR„, or NH(CH2)„NR9Ri0 ;
or
Figure imgf000009_0001
or — N (bH2X — NH — vfhere n=0, 1, or 2
such that this R7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R7 moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is linked to a phenyl carboxylic acid or ester moiety thereof, the phenyl carboxylic acid or ester being optionally substituted by the usual aromatic substituents, such as C C3 alkyl linear or branched, aralkyl such as benzyl, amino, alkylamino, alkanoylamino, oc-aminoalkanoylamino, hydroxy, alkoxy, alkanoyloxy, oc-aminoalkanoyloxy, or halogen atoms, such as fluoro, chloro, bromo.
A = H, C1-6 alkyl, glycosyl, aralkyl, Cι.6 alkanoyl or aminoalkanoyl. The aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof. The amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine.
A may also be C6HuO6, SO3H, or PO3H2.
Rπ - H, Ci_6 alkyl, C3.6 cycloalkyl, or heterocyclic group,
X = CH, C-F, C-Cl, C-CH3, C-CF3, C-OCH3, C-OCHF2, C-OCF3, N or when X is equal to C it forms together with the nitrogen atom of the adjacent ring an optionally substituted 4-membered ring, 5-membered ring, 6-membered ring, 7-membered ring, containing carbon atoms and optionally one or more Y atoms representing one or more nitrogen, oxygen or sulfur atoms, such ring being further optionally substituted by a Cι_6 alkyl group;
and their pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.
Where there are centres of asymmetry, the absolute stereochemistry can be either R- or S- configuration and any combination of configurations. Even racemic materials and diastereomers fulfil the structural generic descriptions.
Another object of the invention is to provide a process for preparing the novel efflux pump inhibitors of the formula I of the invention.
A further object of the invention is to provide pharmaceutical compositions comprising the compounds of the invention. A composition contains one or more compounds of formula I or salt, hydrate, polymorph or pseudopolymorph therefore. In addition to one or more compounds of formula I or a salt, hydrate, polymorph or pseudopolymorph thereof, a composition of this invention may also include another antibiotic or antimicrobial compound.
Yet another object of the invention relates to method of treatment of infections using the said compounds of the invention or compositions comprising them. Treatment comprises oral, parenteral administration and/or topical application of an effective amount of the compound of the invention or its compositions, whether single or in combination with an antibiotic or antimicrobial agent or two or more compounds of this invention.
Yet a further object of the invention includes a method of suppressing growth of a bacterium or fungus expressing an efflux pump, comprising contacting said bacterium or fungus with an efflux pump inhibitor in the presence of a concentration of antibacterial or antifungal agent below the minimum inhibitory concentration (MIC) of said bacterium or fungus. Yet a further object of the invention includes methods for treating the infections in humans and animals, caused by sensitive and resistant microbial strains using an antimicrobial agent and an efflux pump inhibitor in an amount sufficient to reduce efflux pump activity, wherein said efflux pump inhibitor increases the susceptibility of said microbe to said antimicrobial agent.
Yet a further object of the invention includes a method for prophylactic treatment of a human or animal, comprising administering to said human or animal at risk of a microbial infection an efflux pump inhibitor, wherein said efflux pump inhibitor decreases the pathogenicity of a microbe in said human or animal.
Yet a further object of the invention includes a method for prophylactic treatment of human or animal, comprising administering to said human or animal at risk of a microbial infection an antimicrobial agent and an efflux pump inhibitor, wherein said efflux pump inhibitor increases the susceptibility of a microbe to said antimicrobial agent.
Yet a further object of the invention includes a method of treatment using the efflux pump inhibitor compounds of the invention by administering, systemically or topically, optically pure compounds of the invention or stereochemically pure forms of the invention or their salts, hydrates, polymorphs, or pseudopolymorphs thereof to the affected human or animal, thereby avoiding the toxic effects associated with racemic mixtures of the compounds of the invention.
Yet a further object of the invention is to enhance the antimicrobial activity of an antimicrobial agent against a microbe by contacting the microbe with an antimicrobial agent and an efflux pump inhibitor.
Detailed Description of the Invention
The present invention describes heterocyclic compounds of the formula I as novel microbial efflux pump inhibitors
Figure imgf000012_0001
wherein,
Ri = H, Cι_6 alkyl, C3.6 cycloalkyl or optionally substituted aryl, aralkyl, arylaminoalkyl, aryloxyalkyl or arylS(O)talkyl, where t=0,l or 2, or when X is C and the nitrogen atom to which Ri is linked forms an optionally substituted 4-, 5-, 6- or 7-membered ring with X of the adjacent ring, the ring optionally containing one or more hetero atoms selected from nitrogen , oxygen or sulfur atoms, said heteroatom(s) represented by Y, prererably Ri is - CH2CH2-, CH2Y-, CH2CH2CH2-, CH2CH2Y-, CH2CH2CH2CH2- and CH2CH2CH2Y- where Y represents NH, O, or S. If the ring is substituted, the substituent is Cι_6 alkyl group.
R2 = H, CHO, COOR3, or CONHR13, where R13 = H or the NHR13 of CONHRι3 is the residue of one of the 20 naturally occurring amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine or the optically active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl or tripeptidyl or polypeptidyl residues.
R3 = H, Cι_6 alkyl, C3.6 cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(O)talkyl, where t=0,l or 2,
(CH2)„CH(R14) OC(=O)Rιs, (CH2)nCH(R14) C(=O)ORls wherein n = 0-6, R14 = H or CH3; and Rls = C2Hs, or C(CH3)3
Figure imgf000012_0002
11 wherein B=CH or N, and when B=CH, Z=NH or NCH3, and when B=N, Z=CH, O, NH, S or NCH3; p=0-2; q=0-2, 4 = H, ja = H, or R4 and R^ taken together are oxo (=O), or thio (=S). Rs= H, Cι_s alkyl, amino, alkylamino, or acylamino. Re = H, Cι_6 alkyl, halo such as F, Cl, Br, or I, amino, or hydroxy; R7 = OH, halo such as F, Cl, Br, or I, or
NR9 R10 wherein R9 and Rio are the same or different and represent H, .6 alkyl or (CH2)nOA, or R9 is H and Rio is a 4-membered, 5-membered, 6-membered, or 7-membered carbocyclic, mono or bicyclic ring, or mono or bicyclic heterocyclic ring linked to the nitrogen of NR9Rι0 through an atom of the heterocycle other than the heterocyclic atom, or R9 and Rw taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocyclic, or bicyclic.
When R9 is H and Rι0 is a 4-membered ring, it is preferred that the ring is a ring such as 2- azetidinyl, when Rι0 is a 5-membered ring, it is preferred that the ring is a ring such as 2- (or 3-) pyrrolidinyl, or 2- (or 3-) furyl, or 2-(or 3-) thienyl, or 2-(or 4-)imidazolyl, or oxazolyl or pyrazolyl, or thiazolyl, or when R10 is a 6-membered ring, it is preferred that the ring is a ring such as 2-(or 3-, or 4-) piperidinyl, or 2-(or 3-) piperazinyl, or 2-(or 3-) morpholinyl or 2-(or 4-)pyrimidinyI, and when R10 is a 7-membered heterocycle it is preferred that the heterocycle is a heterocycle such as azepinyl, oxazinyl, or thiazinyl, or a bicyclic heterocycle such as tetrahydroisoquinolinyl, quinuclidinyl, or 3-azabicyclol-[3.1.0] hex-yl.
When R9 and ι0 taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocyclic, it is preferred that the heterocycle is such as azetidine, pyrrolidine, furan, thiophene, imidazole, oxazole, pyrazole, thiazole, piperidine, piperazine, pyrimidine, azepine, oxazine, thiazine, or bicyclic such as isoquinoline, quinuclidine, amino-3-azabicyclo [3.1.0]hexane.
The carbocycle and the heterocycle are optionally substituted at any position of the heterocyclic group with COOR3 CONHR13, OA, Cι.6 alkyl, aralkyl, trifluoroalkyl, substituted alkyl, or N
Substituents of the alkyl group are selected from OA, NRι6Rπ, or a halogen atom. Rι6 and Rπ are the same or different and represent H or Cι.6 alkyl, or where one of Ri6 and Rπ is hydrogen and the other of Rj6 and RJ7 is C3-C6 cycloalkyl, or substituted alkyl, or Rι6 and Rπ taken together with the nitrogen atom form a heterocycle. When R16 or RJ7 is a substituted alkyl group, the substituent is selected from NRiβRπ, alkanoyl or aminoalkanoyl or R7 = NHOA, NHCOORn, NH(CH2)nNR9Rιo
where n=l, 2 or 3, Z=CH or N, and when Z=CH, W=NH or
Figure imgf000014_0001
when Z=N, W has no meaning.
or where n=0, 1, or 2
Figure imgf000014_0002
such that this R7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R7 moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is linked to a phenyl carboxylic acid or ester moiety thereof, optionally substituted by the usual aromatic substituents, such as C1-C3 alkyl linear or branched, aralkyl such as benzyl, amino, alkylamino, alkanoylamino, oc-aminoalkanoylamino, hydroxy, alkoxy, alkanoyloxy, cc-aminoalkanoyloxy, or halogen atoms, such as fluoro, chloro, bromo.
A = H, C1-5 alkyl, glycosyl, aralkyl, Cι.6 alkanoyl or aminoalkanoyl. The aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof. The amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, Iysine, methionine, phenylalanine, proline, serine threonine, trytophan, tyrosine or valine.
A may also be C6HnO6, SO3H, or PO3H2,
R11 = H, Cι„6 alkyl, C3.6 cycloalkyl, or heterocyclic group such as a 4-membered ring, it is preferred that the ring is a ring such 2-azetidinyl, a 5-membered ring such as 2- (or 3-) pyrrolidinyl, or 2- (or 3-) furyl, or 2-(or 3-) thienyl, or 2-(or 4-) imidazolyl, or oxazolyl or pyrazolyl, or thiazolyl, or a 6- membered ring such as 2-(or 3-,or 4-) piperidinyl, or 2-(or 3-) piperazinyl, or 2-(or 3-) morpholinyl, or 2-(or 4-)pyrimidinyl, or a 7-membered heterocycle such as azepinyl, or oxazinyl, or thiazinyl, or a bicyclic heterocycle such as tetrahydroisoquinolinyl, or quinuclidinyl, or 3- azabicyclol-[3.1.0]hex-yl
X = CH, C-F, C-Cl, C-CH3, C-CF3, C-OCH3, C-OCHF2, C-OCF3, N or when X is equal to C it forms together with the nitrogen atom of the adjacent ring a 5-membered ring, 6-membered ring, 7-membered ring, optionally containing besides carbon atoms additional Y atoms representing one or more nitrogen , oxygen or sulfur atoms, such ring being further optionally substituted by a
Ci.6 alkyl group; and their pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.
It is preferred that R, and R4., are combined together to form an oxo group and Re is hydrogen or fluorine.
Where there are centres of asymmetry, the absolute stereochemistry can be either R- or S- configuration and any combination of configuration. Even racemic materials and diastereomers fulfil the structural generic descriptions.
The term "alkyl" refers to a branched or unbranched C C6 aliphatic hydrocarbon group.
The term "aralkyl" refers to a C C6 alkyl group substituted with an aryl group which aryl group is defined below. One example of an aralkyl group is a benzyl group.
The terms "arylaminoalkyl", "aryloxyalkyl", and "arylS(O)talkyl refers to an aryl group as defined below that is bonded respectively through an NH, oxygen , or S(O)t to an alkyl group as defined above.
The term "aryl" refers to an aromatic group which has at least one ring having conjugated π electron system and includes both carbocyclic aryl (e.g., phenyl, naphthyl) and heterocyclic aryl groups (e.g. pyridyl, pyrimidyl, pyrazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl and oxazolyl). The aryl group is preferably 5 to 14 carbons, more preferably 5 to 10 carbons. Aryl moieties includes monocyclic, bicyclic, and tricyclic rings, where each ring has preferably five or six members and are 6π (or 6 pi)-annelated ring system or substituted 6π annelated ring systems composed of a mix of carbocyclic and heterocyclic units (e.g. benzo, pyrido, pyrimido, pyrazino, thieno, furano, pyrrolo, pyrazolo, imidazolo, thiazolo and oxazolo). The term "6π- annelated ring system" refers to a ring which has 6π electron and is considered aromatic. The ring may have 6 items in its backbone, such as pyridine, pyrimidine, benzene, or it may have less than 6 items in its backbone, such as pyrrole, pyrazole, furan, thiazole, oxazole or thiophene. The aryl moiety may be optionally monosubstituted or disubstituted independently with lower linear or branched Cι-C6 alkyl or hydroxyl, alkoxy, alkylthio, halogen, haloalkyl, mercapto, amino, mono linear or branched Cι-C3alkylamino, di linear or branched Cι-C3alkylamino, phenyl, substituted phenyl or optionally substituted phenylamino wherein the phenyl is substituted by usual aromatic substituents, such as Cι-C3 alkyl linear or branched, aralkyl such as benzyl, amino, alkylamino, alkanoylamino, oc-aminoalkanoylamino, hydroxy, alkoxy, alkanoyloxy, oc- aminoalkanoyloxy, or halogen atoms, such as fluoro, chloro, or bromo. An example of a bicyclic ring system is for instance pyrazolopyridinyl optionally further substituted e.g. by a phenyl group or a substituted phenyl group.
"Alkylamino" is for example NHCH3, N(CH3)2, NHC2HS, N(C2HS)2, NHC3H7, N(C3H7)2 and
"Acylamino" is for example NHCOCH3, NHCOOC2Hs or NHC(=O)O(CH3)3.
"Alkanoyl" is for example acetyl, propionyl, ethoxycarbonyl, t-butoxycarbonyl,
- (CH2)nCHRi4 OC(=O)Rls is for example acetoxymethyl, pivaloxymethyl, pivaloyloxyethyl, pyrrolidinylethyl, piperidinylethyl, morpholinylethyl.
- (CH2)nCHRi4 C(=O)ORi5 is for example methoxycarbonylmethyl, ethoxycarbonylmethyl.
/ \
-(CH2)p- ■B Z
/
-Oq is for example pyrrolidinylethyl, piperidinylethyl, morpholinylethyl
The preferred acid addition salts are those of hydrochloride, hydrobromide, hydroiodide, sulphate, sulfonate, sulfamate, phosphate and salts of organic acids such as acetate, lactate, succinate, oxalate, maleate, fumarate, malate, tartrate, citrate, ascorbate, gluconate, benzoate, cinnamate, methane sulphonate and p-toluene sulphonate. Preferred alkali addition salts are lithium, sodium, potassium salts, and alkaline earth salts are magnesium, calcium salts, or ammonium, or organic amines such as diethanolamine, N-methylglucamine, guanidine or heterocyclic amines such as choline, piperidine, N-methyl-4-hydroxypiperidine, hydroxyethylpyrrolidine, hydroxyethylpiperidine, morpholine, hydroxyethylmorpholine, piperazine, N-methyl piperazine and the like or basic amino acids such as optically pure or racemic isomers of arginine, lysine, histidine, tryptophan and the like.
A number of compounds of this invention are disclosed in our PCT patent application number PCT/TN99/00016 and in our US patent applications 09/566,875, 09/640,947, 09/850,669 and 60/286,291. The subject matter of PCT application PCT/IN99/00016 and of US applications 09/566,875 09/566,875, 09/640,947, 09/850,669 and 60/286,291 are incorporated herein by reference. A list of preferred compounds of the invention as novel microbial efflux pump inhibitors is provided below:
Figure imgf000017_0001
Formula I
RI = C2HS, C3H5, CH(CH3)CH2CH2SC6H5, C6H,(2-CF3), where (2-CF3) means that the CF3 group is attached at the 2 position,
C6H4(4-CF3) where (4-CF3) means that the CF3 group is attached at the 2 position,
where (4-F) means that the F atom is attached at the 4 position, and
C6H3(2,4-F2) where (2,4-F2) means that there are 2 fluorine atoms, one at the 2 position and the other at the 4 position.
X..Y..N = C-CH2CH2CH(CH3), C-OCH2CH(CH3), C-OCH2CH2CH(CH3)
R2 = COOH, COOC2H5, COOCH(CH3)2, COO(CH2)3CH3, COOCH2C6H5, COOCH2COOC2H5, COO(CH2)2-morpholino,
Figure imgf000017_0002
COphe-lys-Ome, where phe-Iys-Ome is the methylester of the dipeptide from phenylalanine and lysine.
R5 = H, CH3, or NH2;
Re= H, or F
R7 = F, Br, pyrrolidin-3-yl-amino, pyrrolidin-3-alkoxycarbonylamino, piperidin-4-yl-amino, pentaalkylpiperidin-4-yl-alkylamino, [l°c,5cc,6oc]-3-azabicyclo[3.1.0]hex-6-yl-amino, quinucIidinyI-3-yl-amino, 3-aminopyrrolidinyl, 5-aminopyrrolidinyl, aminopyrroUdinyl optionally further mono/poly substituted with C C6 alkyl, (mono/poly aminoalkanoyl)aminopyrrolidinyl; alkoxycarbonyl (mono/poly aminoalkanoyl) aminopyrroUdinyl; acetamidopyrrolidinyl optionally further mono/poly substituted with Cι-C6 alkyl, hydroxypyrrolidinyl, piperidinyl optionally further mono/poly substituted with C C6 alkyl, or halogen; aminopiperidinyl optionally further mono/poly substituted with Cι-C6 alkyl, alkoxycarbonyl; aminopiperidinyl optionally further mono/poly substituted with Cι-C6 alkyl, mono/dialkylaminopiperidinyl optionally further mono/poly substituted with Cι-C6 alkyl, acetamidopiperidin-1-yl, l-phenyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-l-yI, mono/polyalkylpiperidinyl, carboxyamidopiperidinyl optionally further mono/poly substituted with C C6 alkyl, hydroxypiperidinyl optionally further substituted with one or more Cι-C6 alkyl or aminoCi- alkyl, alkoxypiperidinyl; alkanoyloxypiperidinyl, oc- aminoalkanoyloxypiperidinyl, alkoxycarbonyl-°c-aminoalkanoyloxypiperidinyl, alkoxycarbonyl-oc-aminoalkanoyaminopiperidinyl, hydroxypiperidinyl optionally further mono/poly substituted with Cι-C6 alkyl, pyrrolidinyl-4-piperidinyl, 4-(piperidin-4-yl)- aminoalkylpiperidinyl, piperazinyl optionally further mono/poly substituted with Cι-C6 alkyl, mono/polyalkylpiperazinyl; alkanoylpiperazine optionally further mono/poly substituted with Cx-Cβ alkyl, 4-(2-oxazolidinone-l-yl)-alkylpiperazine-l-yl; cyclopropylpiperazinyl; morpholino, mono/polyalkylmorpholino, l,2,3,4-tetrahydroisoquinolin-2-yl,
6-amino-3-azabicyclo[3.1.0]hex-3-yl, 6-alkoxycarbonylamino-3-azabicyclo[3.1.0]hex-3-yl, 3-aralkyl-3-azabicyclo[3.1.0]hex-6-yl amino or l-aryl-4,5,6,7-tetrahydropyrazoIo[4,3-c]pyridin-l-yl
Wherever stereoisomeric forms of the substituted heterocyclic moieties are possible, they are also here included.
X = C-H, C-OCH3, C-F, N and when X is linked to N of the adjacent ring, it has the meanings as defined above for X..Y...N
Compounds within the generic description as contained in formula I can be obtained by synthetic chemistry methods known to those skilled in the chemical arts. The methods described in our PCT appUcation PCT/TN99/00016 and US applications 09/566,875 , 09/640,947, 09/850,669 and 60/286,291 are incorporated herein by reference. The pharmaceuticaUy acceptable acid addition salts of compounds I are prepared in a conventional manner by treating a solution or suspension of the free base I with about one chemical equivalent of a pharmaceuticaUy acceptable acid. Conventional concentration and recrystalUsation techniques are employed in isolating the salts. Illustrative of suitable acids are hydrochloric, hydrobromic, hydroiodic, sulphuric, sulfamic, sulfonic, phosphoric, acetic, lactic, succinic, oxalic, maleic, fumaric, malic, tartaric, citric, ascorbic, gluconic, benzoic, cinnamic, methanesulfonic and p-toluenesulfonic acid.
The pharmaceuticaUy acceptable cationic salts of compounds I may be prepared by conventional methods from the corresponding acids e.g. by reaction with about one equimolar amount of a base. Examples of suitable cationic salts are those of alkaU metals such as Uthium, sodium or potassium, alkaline earth metals such as magnesium or calcium or ammonium or organic amines such diethanolamine, N-methylglucamine, guanidine or heterocycUc amines such as choline, piperidine, N-methyl-4-hydroxypiperidine, hydroxyethylpyrrolidine, hydroxyethylpiperidine, morpholine, hydroxyethylmorphoUne, piperazine, N-methyl piperazine and the like or basic amino acids such as opticaUy pure or racemic isomers of arginine, lysine, histidine, tryptophan and the like.
The hydrates, pseudopolymorphs and polymorphs are prepared by methods known in the art. DetaUed descriptions of different methods to generate hydrates, solvates, pseudopolymorphs and polymorphs and to characterise them are described in chapters 5 and 6 of the book entitled "Polymorphism in Pharmaceutical SoUds" edited by Harry G Brittain (Marcel Dekker Inc., New York), pp. 183-278, 1999.
The foUowing is a Ust of compounds that inhibit the efflux pump of different organisms. The list of compounds and organisms is not inclusive. There are compounds on this list that will inhibit the efflux pump of other organisms.
Some specific efflux pump inhibitor compounds of the invention are:
Some Preferred Compounds of the Invention Displaying Inhibition of the Efflux Pump of Stavhylococcus aureus 1199 B (Nor A "*")
1. l-Ethyl-6-fluoro-l, 4-dihydro -7-(l', 2',3',4'-tetrahydroisoquinolin-2-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
2. l-Ethyl-6,8-fluoro-l, 4-dihydro -7-(4'-acetoxypiperidin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts. 3. l-EthyI-6,8-fluoro-l, 4-dihydro -7-(4'-{2'-(2'-oxazolidin-l-yl) ethyl} piperazin-l-yl)-4- oxo-quinoline-3-carboxyUc acid and its salts.
4. 1- Ethyl-6, 8-difluoro-l, 4-dihydro -7-{(loc,5oc,6oc)-6-amino-3-azabicyclo [3.1.0]-hex-3- yI}-4-oxo-quinoIine-3-carboxyIic acid and its salts. 5. 5-Amino-l- ethyl -6, 8-difluoro-l, 4-dihydro -7-(3'-amino-5'-methyl pyrrolidin-l-yl)-4- oxo-quinoline-3-carboxyUc acid and its salts.
6. 5-Amino-l- ethyl-6, 8-difluoro-l, 4-dihydro -7-(4'-aminopiperidin-l-yl)-4-oxo- quinoline-3-carboxyUc acid and its salts.
7. 5-Amino-l- ethyl -6, 8-difluoro-l, 4-dihydro -7-{4'-(acetamido) piperidin-l-yl}-4-oxo- quinoUne-3-carboxyUc acid and its salts.
8. 5-Amino-l- ethyl-6, 8-difluoro-l, 4-dihydro -7-{(loc,5oc,6oc)-6'-(t-butoxycarbonyl amino)-3-azabicyclo [3.1.0]-hex-3-yl}-4-oxo-quinoUne-3-carboxyUc acid and its salts.
9. l-Cyclopropyl-6-fluoro-l, 4-dihydro-7-(3'-acetamido-5'-methylpyrroIidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts. 10. l-Cyclopropyl-6-fluoro-l, 4-dihydro-7-(3'-amino-5'-methylpyrrolidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
11. l-Cyclopropyl-6-fluoro-l,4-dihydro~7-(4'-acetoxypiperidin-l-yl)-4-oxo-quinoIine-3- carboxylic acid and its salts.
12. l-Cyclopropyl-6-fluoro-l,4-dihydro -7-{4'-(dimethylamino) piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
13. l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(3',5'-dimethylpiperidin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts.
14. l-Cyclopropyl-6-fluoro-l, 4-dihydro -7-(4'-hydroxy-3',5'-dimethylpiperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts. 15. l-Cyclopropyl-6-fluoro-l, 4-dihydro- -7-(3', 4', 5'-trimethyl piperazin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
16. l-Cyclopropyl-6-fluoro-l, 4-dihydro- 7-(3', 5'-dimethyI-4'-ethyl piperazin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
17. l-Cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl- 7-(4'-ethoxypiperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
18. l-Cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl- 7-(3', 3'-dimethylpiperazin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
19. l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-(dimethylamino)-3'-methyl piperidin-l-yl}-4-oxo-quinoUne-3-carboxyUc acid and its salts. 20. l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-3'-isobutyl piperidin-1- yl)-4-oxo-quino!ine-3-carboxyUc acid and its salts. 21. l-CyclopropyI-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-3',3'-dimethylpiperidin- l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts.
22. l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-3',5'-dimethyI piperidin- l-yl)-4-oxo-quinoUne-3-carboxylic acid and its salts. 23. l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(3'-methylpiperazin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
24. 5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(cis-4'-amino-3',5'- dimethylpiperidin-l-yl)-4-oxo-quinoline-3-carboxyUc acid and its salts.
25. l-Cyclopropyl-6,8-difluoro-5-methyl-l,4-dihydro-7-(4'-hydroxy-3'-aminomethyl piperidin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts.
26. 5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(5'amino-2'-methyl-pyrrolidin-l- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts.
27. 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{3'-(L-Ala-L-Ala) amino pyrroUdin-l-yl}-4-oxo-quinoline-3-carboxylic acid and its salts. 28. 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{4'-(di-n-butylamino) piperidin-1- yl)-4-oxo-quinolme-3-carboxyUc acid and its salts.
29. 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{4'-(t-butoxycarbonyl-L-Ala-L- Ala)aminopiperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid and its salts.
30. 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-(4'- propionoxy piperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts.
31. 5-Amino-l-cycIopropyl-6, 8-difluoro-l, 4-dihydro -7-(4'-hydroxy-3',3'-dimethyl- piperidin-l-yl)-4-oxo-quinoUne-3-carboxylic acid and its salts.
32. 5-Amino-l-cyclopropyl-6,8-difluoro-l, 4-dihydro -7-{4'-(l-pyrroUdinyl) piperidin-1- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts. 33. 5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-{4'-[(piperidin-4-yl) aminomethyl]- piperidin-l-yl}-4-oxo-quinoline-3-carboxyUc acid and its salts.
34. 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{(l,2',2', 6',6'-pentamethyl piperidin-4-yl)methylamino}-4-oxo-quinoUne-3-carboxyUc acid and its salts.
35. 5-Amino-l-cyclopropyl-6,8-difluoro-l, 4-dihydro -7-(3',5'-dimethyl morphoUn-l-yl)-4- oxo-quinohne-3-carboxyUc acid and its salts.
36. 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-(4'-cyclopropyl piperazin-l-yl)-4- oxo-quinoUne-3-carboxylic acid and its salts.
37. 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-(3', 5'-dimethyl-4-pivaloyl piperazin-l-yI)-4-oxo-quinoline-3-carboxyIic acid and its salts. 38. Ethyl 6,8-difluoro-7-(4-hydroxypiperidin-l-yl)-l-(l-phenylthio-3(.5)-but-3-yl)-l,4- dihydro-4-oxo-quinoline-3-carboxylate 39. 1- (2'-Trifluoromethylphenyl) -6-fluoro-l, 4-dihydro- -7-(3', 3% 4'-trimethyl piperazin- l-yl)-4-oxo-quinoUne-3-carboxylic acid and its salts.
40. 5-Amino-l- (2'-trifluoromethylphenyl)-6,8-difluoro-l, 4-dihydro -7-(morpholin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts. 41. 5-Amino-l- (2'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihydro -7-(3',5'- dimethylmorpholin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts.
42. 5-Amino-l- (2'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihydro -7-(3',5'-dimethyl piperazinyl-l-yl)-4-oxo-quinoline-3-carboxyUc acid and its salts.
43. 5-Amino-l- (4'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihydro -7-(3'- aminopyrroUdin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts.
44. 1- (4'-Fluorophenyl) -6-fluoro-l,4-dihydro -7-{4'-ethylamino)piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
45. 1- (2',4'-Difluorophenyl) -6-fluoro-l, 4-dihydro-7-(3', 5'-dimethyI piperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts. 46. 5-Amino-l- (2',4'-difluorophenyl) -6, 8-difluoro-l, 4-dihydro -7-(3'-hydroxy-5'- methylpyrrolidin-l-yl)-4-oxo-quinoUne-3-carboxyUc acid and its salts.
47. 5-Amino-l- (2',4'-difluorophenyϊ) -6, 8-difluoro-l, 4-dihydro -7-(3',3'-dimethyl piperazinyl-l-yl)-4-oxo-quinoline-3-carboxyUc acid and its salts.
48. l-Cyclopropyl-6-fluoro-l, 4-dihydro -7-{(3'-aminoethoxycarbonyl)pyrrohdin-3-yl}-4- oxo-1, 8-naphthyridine-3-carboxyUc acid and its salts.
49. l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(pyrroUdin-3-yl-amino)-4-oxo-naphthyridine-3- carboxylic acid and its salts.
50. 1- (2',4'-Difluorophenyl) -6-fluoro-l, 4-dihydro -7-(piperidin-4-yl-amino)-4-oxo-l,8- naphthyridine-3-carboxylic acid and its salts. 51. Ethyl-1- (2',4'-difluorophenyl) -6-fluoro-l, 4-dihydro -7-{[loc,5oc,6oc]-3-N-benzyl-3- azabicyclo[3.1.0]hex-6-yl-amino}-4-oxo-l,8-naphthyridine-3-carboxylate and its salts 52. l-(2,4-difluorophenyl) -6-fluoro-7-(l-phenyl-4,5,6,7-tetrahydropyrazolo
[4,3-c]pyridin-l-yl-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxyUc acid and its salts. 53. (S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-carboxamidopiperidin-l-yI)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid and its salts.
54. (R)-(+)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinolizine-2-carboxylic acid L-arginine salt
55. (S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxy-3',3'-dimethylpiperidin-l-yl)-5-methyl-l- oxo-lH,5H-benzo[i,j]quinoUzine-2-carboxylic acid and its salts. 56. (S)-(-)-N-methylpiperidin-l-yl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5- methyl-l-oxo-lH,5H-benzo[i,j]quinolizine-2-carboxylate.
57. (S)-(-)-Morpholinoethyl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l- oxo-lH,5H-benzo[i,j]quinoIizine-2-carboxy!ate and its salts 58. Ethoxycarbonylmethyl (R)-(+)- 9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5- methyI-l-oxo-lH,5H-benzo [i,j] quinoIizine-2-carboxylate
Some Preferred Bis Compounds of the Invention Displaying Inhibition of the Efflux Pump of Staphylococcus aureus 1199 B (Nor A *) 1. N-l-{7-(l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-quinoUne-3-carboxylic acid)}-N-3- amino-{7-(l-(2,4-difluorophenyI)-6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3- carboxylic acid)}-pyrroUdine.
2. N-l-{7-(l -cyclopropyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid)}-N-3-amino-{7-(l-cyclopropyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid)}-pyrroIidine
3. N-l-{7-(l-cycIopropyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naρhthyridine- 3-carboxylic acid)}-N-3-amino-{7-(l-cyclopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo- quinoUne-3-carboxyUc acid)}-pyrroUdine
4. N-l-{7-(l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxyUc acid)}-N-4-{7-(l-cycIopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoline-3- carboxylic acid)}-piperazine
5. N-l-{7-(l-cyclopropyl-6-fluoro-5-methyl-l,4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N-3-amino-{7-( l-(2,4-difluorophenyI) -6-fluoro- 1, -dihydro-4-oxo-l, 8- naphthyridine-3-carboxyIic acid)}-pyrrolidine 6. N-l- {7-(l-cyclopropyl-6-fluoro-5-methyl-l, 4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N-4-amino {7-(l-cyclopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo- quinoUne-3-carboxyUc acid)}-piperidine
7. N-l- {7-(l-cyclopropyI-6-fluoro-5-methyl-l, 4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N-3-amino{7-(l-cyclopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoline- 3-carboxylic acid)}-pyrrolidine
8. N-l- {7-(l-(2,4-difluorophenyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3- carboxylic acid)}-N-4- {7-(l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-quinoIine-3- carboxylic acid)}-piperazine.
9. N-3-azabycyclo{7-(l-(2,4-difluorophenyl)-6-fluoro-l,4-dihydro-4-oxo-l,8- naphthyridine-3-carboxylic acid)}-[l<κ,5oc,6oc]-N-6-amino-{7-l-(2,4-difluorophenyl)-6- fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxyUc acid)}-[3.1.0] hexane 10. N-l- {7-(l-cyclopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoIone-3- carboxylic acid)}-N-4-amino-{ethyl 2,3,6-trifluorophenyl-4-carboxylate}-piperidine
Some Preferred Compounds of the Invention Displaying Inhibition of the Efflux Pumps of Pseudomonas aerueinosa 23587
1. l-Cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl- 7-(4'-methoxypiperidin -l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
2. 7-Bromo-l-cyclopropyl-6-fluoro-5-methyl-l,4-dihydro-4-oxo-quinoUne-3-carboxyUc acid and its salts.
3. l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-amino-3'-methylpiperidin-l-yl)- 4-oxo-quinoline-3-carboxylic acid and its salts.
4. 5-Amino-l-cycIopropyI-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-amino-3'-methyl piperidin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts. 5. 5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-{3,3-dimethyl-4'- ethylamino piperidin-l-yl}-4-oxo-quinoUne-3-carboxyUc acid and its salts.
6. l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-amino-3'-3'-dimethyl iperidin-l- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts.
7. l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-(dimethylamino)piperidin-l-yl}- 4-oxo-quinoline-3-carboxylic acid and its salts
8. l-CycIopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-4'-methylpiperidin-l-yl)- 4-oxo-quinoline-3-carboxylic acid and its salts.
9. l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(3',3'-dimethyl-4'-hydroxypiperidin- l_yl)_4_oχo-quinoUne-3-carboxyUc acid and its salts. 10. l-Cyclopropyl-6,8-difluoro-5-methyl-l,4-dihydro-7-(3'-aminomethyl-4'- hydroxypiperidin-l-yl)-4-oxo-quinoline-3-carboxyUc acid and its salts.
11. 5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(3'-aminomethyl-4'- hydroxypiperidin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts.
12. l-Ethyl-6,8-difluoro-l,4-dihydro-7-(3'-5'-dimethylpiperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts.
13. l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(4'-ethyl-3'-methylpiperazin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
14. l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(3'-5'-dimethyl-4'-ethylpiperazin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts. 15. l-Ethyl-6, 8-difluoro-l, 4-dihydro -7-{(loc,5oc,6oc)-6'-amino-3'-azabicyclo [3.1.0] hex-3'- yl}-4-oxo-quinoUne-3-carboxylic acid and its salts. 16. 5-Anήno-l-(2',4'-difluorophenyl)-6,8-difluoro-l,4-dihydro-7-(3'-aminopyrroIidin-l-yl)- 4-oxo-quinoϊine-3-carboxylic acid and its salts.
17. 5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-{(3'-amimoethoxycarbonyl pyrroUdin-3-yI}-4-oxo-quinoUne~3-carboxylic acid and its salts. 18. l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(pyrroUdin-3'-ylamino)-4-oxo-naphthyridine-3- carboxylic acid and its salts.
19. l-(2',4'-Difluorophenyl)-6-fluoro-l,4-dihydro-7-(piperidin-4'-ylamino)-4-oxo- naphthyridine-3-carboxyIic acid and its salts.
20. l-CyclopropyI-6-fluoro-l, 4-dihydro -7-(4'-amino-3'-ethylpiperidin-l-yl)-4-oxo- naphthyridine-3-carboxylic acid and its salts.
21. (S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinolizine-2-carboxylic acid 0.2 hydrate.
22. (S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidiπ-l-yl)-5-methyI-l-oxo-lH,5H- benzo[i,j]quinolizine-2-carboxylic acid, choline salt. 23. (S)-(-)-9-FIuoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyI-l-oxo-lH,5H- benzo[i,j]quinolizine-2-carboxylic acid. 1-HydroxyethyIpyrroUdine salt.
24. (S)-(-)-9-FIuoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yιi)-5-methyI-l-oxo-lH,5H- benzo[i,j]quinolizine-2-carboxylic acid, diethanolamine salt.
25. (S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylate, L-histidine salt.
26. (RS)-(±)-9-muoro-6,7-dihydro-8-{4'-(D-phenylaIanyloxy) piperidin-l-yl}-5-methyI-l- oxo-lH,5H-benzo[i,j]quino]izine-2-carboxylic acid hydrochloride.
27. (RS)-(±)-9-Fluoro-6,7-dihydro-8-{4'-(L-α-aspartyIoxy) piperidin-l-yl}-5-methyl-l-oxo- lH,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride. 28. (RS)-(±)-9-Fluoro-6,7-dihydro-8-{4'-(L-leucyIoxy)piperidin-l-yl}-5-methyl-l-oxo- lH,5H-benzo[i,j]quinoIizine-2-carboxylic acid hydrochloride.
29. (S)-(-)-9-FIuoro-6,7-dihydro-8-{4'-(D-leucyloxy)piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinolizine-2-carboxylic acid hydrochloride.
30. (S)-(-)-9-Fluoro-6,7-dihydro-8-{4'-(L-alanyloxy)piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinolizine-2-carboxylic acid hydrochloride.
31. (S)-(- Morpholinoethyl-9-fluoro-6.7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l- oxo-lH,5H-benzo[i,j]quinolizine-2-carboxylate and its salts.
32. (R)-(+)-8,9-difluoro-6,7-dihydro-5-methyI-l-oxo-lH,5H-benzo[i,j]quinolizine-2- [S- phenylalanyl-S-lysine methyl ester]carboxamide. 33. (RS)-(+)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl- l-oxo-lH,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts. 34. (RS)-(±)-9-Fluoro-6,7-dihydro-8-(cis-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l- oxo-lH,5H-benzo[i,j]quinoUzine-2-carboxyϊic acid and its salts.
35. (S)-(-)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyI-l- oxo-lH,5H-benzo[i,j]quinoUzine-2-carboxyIic acid and its salts.
36. 7H-Pyrido[l,2,3-de]-l,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(4'-hydroxy-3'- ethylpiperidin-l'-yl)-7-oxo-6-carboxylic acid and its salts.
37. 10-Fluoro-ll-[(loc,5oc,6oc )-6-amino-3-azabicyclo[3.1.0]hex-3-yI]-3,4-dihydro-4(S)- methyl-8-oxo-2H,8H-pyrido[l,2,3-ef]-l,5-benzoxazepine-7-carboxylic cid. hydrochloride.
Some Preferred Compounds of the Invention Displaying Inhibition of the Efflux Pumps of Escherischia coli 2051
1. 7-Bromo-l-cyclopropyl-6-fluoro-5-methyl-l,4-dihydro-4-oxo-quinoUne-3-carboxyUc acid and its salts.
2. l-CycIopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-amino-3'-methylpiperidin-l-yl)- 4-oxo-quinoUne-3-carboxylic acid and its salts.
3. l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-amino-3'-3'-dimethyl piperidin-l- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts. 4. S-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yI)-5-methyI-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid 0.2 hydrate.
5. S-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxyUc acid, choline salt.
6. S-(-)-9-FIuoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid, 1-hydroxyethylpyrroUdine salt.
7. S-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid, diethanolamine salt.
8. (S)-(-)-9-Fluoro-6.7-dihydro-8-{4'-(D-leucyloxy)piperidin-l-yI}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid hydrochloride. 9. (S)-(-)-MorphoUnoethyl-9-fluoro-6.7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l- oxo-lH,5H-benzo[i,j]quinoUzine-2-carboxylate and its salts
10. (R)-(+)-8,9-difluoro-6,7-dihydro-5-methyl-l-oxo-lH,5H-benzo[i,j]quinolizine-2- [S- phenylalanyl-S-lysine methyl ester] carboxamide.
11. S-(-)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-l-yl}-5-methyl-l- oxo-lH,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts. 12. 10-Fluoro-ll-[(loc,5oc,6oc )-6-amino-3-azabicyclo[3.1.0]hex-3yl]-3,4-dihydro-4(S)- methyl-8-oxo-2H,8H-pyrido[l,2,3-ef|-l,5-benzoxazipin-5-yl-7-carboxyUc acid hydrochloride.
Some Preferred Compounds of the Invention Displaying Inhibition of the Mef Efflux Pump of Streptococcus pneumoniae 3514 and Streptococcus pyogenes 26-00
1. l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-amino-3'-methyl piperidin-l- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts. 2. 5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-(methylamino)-
3',3'-dimethylpiperidin-l-yl}-4-oxo-quinoUne-3-carboxyUc acid and its salts.
3. i-Propyl l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-(4'-amino-3',3'- dimethyl-piperidin-l-yl}-4-oxo-quinoUne-3-carboxylate and its salts.
4. n-Butyl l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-(4'-amino-3',3'-dimethyl- piperidin-l-yl}-4-oxo-quinoUne-3-carboxylate and its salts.
5. Ethoxycarbonylmethyl l-cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'- amino-3',3'-dimethylpiperidin-l-yl)-4-oxo-quinoline-3-carboxylate and its salts.
6. Benzyl l-cycIopropyI-6-fluoro-8-methoxy-l,4-dihydro -7-{4'-(t-butoxycarbonyI amino)-3',3'-dimethylpiperidin-l-yl)-4-oxo-quinoUne-3-carboxylate and its salts. 7. l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-N-(t-butoxycarbonyl-L- alanyl) amino-3',3'-dimethylpiperidin-l-yl}-4-oxo-quinoUne-3-carboxyUc acid hydrochloride. 8. l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-L-alanylamino-3',3'- dimethylpiperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride. 9. l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(3',3'-dimethyl-4'-(t-butoxy- carbonylvalinylamino)piperidin-l-yl}-4-oxo-quinoUne-3-carboxylic acid and its salts. 10. l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-(3',3'-dimethyl-4'-(L)-valyl- aminopiperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride. 11. l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-(L)-aspartylamino-3',3'- dimethyIpiperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride
12. l-Ethyl-6,8-difluoro-l,4-dihydro-7-(4'-ethylaminopiperidin-l'-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
13. 5-Anύno-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(4^amino-3'-methyl piperidin - l-yl)-4-oxo-quinoUne-3-carboxy!ic acid and its salts. 14. 5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(quinuclidinyl-3-yl-amino)-4- oxo-quinoUne-3-carboxyUc acid and its salts.
15. 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro-7- {(loc,5oc,6oc)-6-amino-N- benzyI-3-azabicydo [3.1.0] hex-6-yI}-4-oxo-quinoUne-3-carboxyHc acid and its salts.
16. l-(3'-Fluorophenyl)-6-fluoro -1, 4-dihydro -7-(4'-methylpiperazin-l'-yI)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
17. l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihydro-7- (4'-ethylaminopiperidin-l'-yI)- 4- oxo-quinoUne-3-carboxyUc acid and its salts. 18. l-(2',4'-Difluorophenyl)-6-fluoro-5-methyI-l, 4-dihydro -7-(4'-aminopiperidin-l'- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts.
19. l-(2^4'-Difluorophenyl)-6-fluoro-5-methyl-l,4-dihydro-7-(4'-methyIamino piperidin-l'-yl)-4-oxo-quinoUne-3-carboxylic acid and its salts.
20. l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(3'-aminopyrrolidin-l'-yl)-4-oxo-l,8- naphthyridine-3-carboxylic acid and its salts.
21. l-Cyclopropyl-6-fluoro-l,4-dihydro-7-{(loc,5oc,6oc)-6-amino— N-benzyl-3- azabicyclo [3.1.0] hex-6-yI}-4-oxo-l,8-naphthyridine-3-carboxyUc acid and its salts.
22. l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihydro-7-(3'-aminopyrroUdin-l'-yl)- 4-oxo- l,8-naphthyridine-3-carboxyUc acid and its salts. 23. l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihydro-7-{(loc,5oc,6oc)-6-amino-N-benzyl-3- azabicyclo [3.1.0]hex-6-yl}- 4-oxo-l,8-naphthyridine-3-carboxyUc acid and its salts.
24. l-(2,4-Difluorophenyl)-6-fluoro-l,4-dihydro-7-(3',3'-dimethyl-4'-hydroxy piperdin- l'-yl)-4-oxo-l,8-naphthyridine-3-carboxylic acid and its salts.
25. (RS)-(±)-9-Fluoro-6, 7-dihydro-8-{4'-(L-α-aspartyloxy)piperidin-l-yl}-5-methyl-l- oxo-lH,5H-benzo [i,j] quinoUzine-2-carboxylic acid hydrochloride.
26. 7H-Pyrido [l,2,3-de]-l,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(3'-ethyI 4'- hydroxypiperidin-l'-yl)-7-oxo-6-carboxyUc acid and its salts.
27. 7H-Pyrido[l,2,3-de]-l,4-benzoxazine-9-fluoro-2, 3-dihydro-3-methyl-10- (3'-amino methyl-4'-hydroxypiperidin-l'-yl)-7-oxo-6-carboxylic acid and its salt. 28. l-Cyclopropyl-6, 8-difluoro-5-methyl-l, 4-dihydro -7-(3', 3'-dimethyl-4'-ethylamino piperidin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salt.
29. l-cyclopropyl-6,7,8-trifluoro-5-methyl-l,4-dihydro - 4-oxo-quinoUne-3-carboxylic acid.
30. (S)-(-)-9-Fluoro-6,7-dihydro-8- (3', 3'-dimethyl-4'-ethylaminopiperidin-l-yl)-5- methyl-1-oxo-lH, 5H-benzo[i,j]quinolizine-2-carboxyUc acid and its salts. 31. l-Cyclopropyl-6-fluoro-l, 4-dihydro-7- (3'-aminomethyl-4'-hydroxypiperidin 1-yl)- 4-oxo-quinoline-3-carboxylic acid and its salts.
32. l-Cyclopropyl-6-fluoro-l, 4-dihydro-7- (4'-dimethylamino-3'-methylpiperidin-l- yl)-4-oxo-quinoIine-3-carboxyUc acid and its salts. 33. 5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-cyclopropyl aminopiperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid and its salts 34. l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-(t-butoxycarbonyl (L)-Ala- Ala)amino-3', 3 '-dimethyl piperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride. 35. 5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-ethylamino-3', 5'- dimethylpiperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid and its salts.
36. Ethyl l-(2,4-difluorophenyl) -6-fluoro -1, 4-dihydro-7- (4-amino-3-ethylpiperidin- l-yl)- 4-oxo-l,8-naphthyridine-3-carboxylate
37. l-(2,4-difluorophenyl) -6-fluoro-l, 4-dihydro-7- (4-amino-3, 5-dimethylpiperidin-l- yl)- 4-oxo-l,8-naphthyridine-3-carboxylic acid and its salts.
38. Ethyl l-(2,4-difluorophenyl) -6-fluoro-5-methyl-l, 4-dihydro-7- (4-amino-3, 3- dimethylpiperidin-l-yl)- 4-oxo-l,8-naphthyridine-3-carboxylate
39. (S)-(-)-9-fluoro-6.7-dihydro-8- (4'-hydroxy- 3'-fluoropiperidin-l-yl)-5-methyl-l- oxo-lH, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts. 40. 10-Fluoro-ll- (4-aminopiperidin-l-yl)-3,4-dihydro-4 (S)-methyl-8-oxo-2H, 8H- pyrido[l,2,3-efJ-l,5-benzoxazipin-7-carboxylic acid and its salt.
41. (RS)-(±)-6, 7-dihydro-8- (trans-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l- oxo-lH, 5H-benzo[i,j]quinoUzine-2-carboxyUc acid and its salts.
42. (RS)-(±)-6, 7-dihydro-8- (cis-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l-oxo- IH, 5H-benzo[i,j]quinoUzine-2-carboxyUc acid and its salts.
43. (RS)-(±)-6, 7-dihydro-8- (4'-hydroxy-3', 3'-dimethylpiperidin-l-yl)-5-methyl-l-oxo- 1H, 5H-benzo[i,j]quinoUzine-2-carboxyUc acid and its salts.
Particularly appropriate examples of a microbe appropriate for the use of an efflux pump inhibitor are pathogenic bacterial species, such as Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherischia coli, Staphylococcus aureus which can be intrinsically resistant to commonly used antibacterial agents. Exposing these bacteria to an efflux pump inhibitor can significantly slow the export of an antibacterial agent from the interior of the ceU or the export of siderophores. For instance, overexpression of the norA multidrug transporter has been reported for strains of S. aureus for fluoroquinolone resistance both in-vitro (Yoshida et. al., 1990; Kaatz etal., 1990) and in-vivo (Trucksis etal., 1991). Therefore, if another antibacterial agent is administered in conjunction with the efflux pump inhibitor, the antibacterial agent, which would otherwise be maintained at a very low intraceUular concentration by the export process, can accumulate to a concentration which wiU inhibit the growth of the bacterial cells. This growth inhibition can be due to either bacteriostatic or bactericidal activity, depending on the specific antibacterial agent used. Whde P. aeruginosa is an example of an appropriate bacterium, other bacterial and microbial species including those described above may contain simUar broad substrate pumps, which actively export a variety of antimicrobial agents, and thus can also be appropriate targets.
In addition as suggested above, for some microbial, e.g., bacterial, species, efflux pump inhibitors can decrease the virulence of the microbe, for example, by inhibiting the transport of factors important for pathogenicity. Again using P. aeruginosa as an example, inhibition of an efflux pump in this bacterium inhibits the uptake of iron, which is important for pathogenicity. The mechanism of bacterial iron transport involves molecules called siderophores, which are synthesised and exported by bacterial ceUs via efflux pumps. These siderophores bind tightly to iron scavenged from the host, and are then taken up by the bacteria. In this way, the iron needed for bacterial metaboUsm is obtained, and an infection can be maintained.
Therefore, iUustrating the utility of efflux pump inhibitors, inhibiting the efflux pump of Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherischia coli, Staphylococcus aureus aUows obtaining one or more of the following biological effects:
1. Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherischia coli, Staphylococcus aureus strains wUl become susceptible to antibiotics that could not be used for treatment of the respective bacterial infections, or become more susceptible to antibiotics which do inhibit the respective bacterial growth.
2. Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherischia coli, Staphylococcus aureus strains will become more susceptible to antibiotics currently used for treatment of the respective bacterial infections.
3. Virulence of Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherischia coli, Staphylococcus aureus wiU be attenuated because the avaUabiUty of an essential siderephore bearing element wuT be hampered.
4. The inhibition of the pumps or of one of the components of the pumps may be lethal or prevent growth. Obtaining even one of these effects provides a potential therapeutic treatment for infections by these bacteria. Also, as previously mentioned, similar pumps are found in other microorganisms. Some or aU of the above effects can also be obtained with those microbes, and they are therefore also appropriate targets for detecting or using efflux pump inhibitors. Thus, the term "microbes" include, for example, bacteria, fungi, yeasts, and protozoa.
As indicated, the bacterium to be inhibited through the use of an efflux pump inhibitor can be from other bacterial groups or species, such bacterial groups of species including but not limited to one of the foUowing:
Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenotrophomonas maltophilia, Burkholderia capacia, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundil, Salmonella tryphimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia, marcescens, Francisella tularensis, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Λcinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Branhamella catarrhalis, Helicobacter pylori, Campylobacter fetus,
Campylobacter jejuni, Campylobacter coli, Borrelia burgdorferi, Vibrio cholerae, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningiήdis, Kingella, Morazella, Gardenerella vaginalis, Bacteroides fragilis, Bacteroides distasonis, Bacteroides 3452A homology group, Bacteroides distasonis, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, Bacteroides splanchnicus, Clostridium difficile, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium leprae, Corynebacterium diphtheriae, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis and Staphylococcus saccharolyticus.
The term "efflux pump" refers to a protein assembly which exports substrate molecules from the cytoplasm or periplasm of a ceU, in an energy dependent fashion. Thus an efflux pump wiU typicaUy be located in the cytoplasmic membrane of the cell (spanning the cytoplasmic membrane). In Gram-negative bacteria the pump may span the periplasmic space and there may also be portion of the efflux pump which spans the outer membrane. Certain efflux pumps wiU include a polypeptide which has at least 50% amino acid sequence similarity with a polypeptide which is part of the P. aeruginosa mexA/mexB/oprM efflux pump or the efflux pump overexpressed by P.aeruginosa strain K385, or the efflux pump overexpressed by P. aeruginosa strain PAO40998E. Due to the described sequence similarity of a component polypeptide of the efflux pump, such an efflux pump is termed a P. aeruginosa-type efflux pump.
An "efflux pump inhibitor" is a compound which specifically interferes with the abflity of an efflux pump to export its normal substrate, or other compounds such as an antibiotic. The inhibitor may have intrinsic antimicrobial (e.g. antibacterial) activity of its own, but at least a significant portion of the relevant activity is due to the efflux pump inhibiting activity. Of particular interest in this invention, are compounds which inhibit the export or activity of efflux pumps which have a broad substrate range which includes antibacterial agents. The term Streptococcus pneumoniae-ty\>e efflux pump inhibitor refers to an efflux pump inhibitor which inhibits a Streptococcus pneumoniae-type efflux pump. The term "Pseudomonas aeruginosa- type efflux pump inhibitor" refers to an efflux pump inhibitor which inhibits a Pseudomonas aeruginosa-type efflux pump. The term "Escherischia coli-type efflux pump inhibitor" refers to an efflux pump inhibitor which inhibits an Escherischia coli -type efflux pump. The term "Staphylococcus aureus-type efflux pump inhibitor" refers to an efflux pump inhibitor which inhibits a Staphylococcus aureus -type efflux pump.
In another aspect, this invention provides a method for treating a microbial infection, e.g., a bacterial infection, in an animal by administering to an animal suffering from such an infection an efflux pump inhibitor as described above in an amount sufficient to reduce efflux pump activity.
In a preferred embodiment, the inhibitor is one which decreases the pathogenicity of the microbe. Such a decrease in pathogenicity can be obtained, for example, by interfering with essential bacterial element acquisition by inhibiting the transport of siderophores. The pathogenicity may also be reduced by reducing or eliminating the microbial products which cause tissue-damaging effects to the host. Other methods of reducing pathogenicity are, however, also within this aspect.
The host is an animal and may be, for example, chickens and turkeys, and in certain preferred embodiments in a mammal, e.g. a human.
In certain preferred embodiments, the microbial infection may be due to bacteria, which may, for example, be any of the bacterial species indicated above, but specificaUy including Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherischia coli, Staphylococcus aureus. In a related aspect, this invention provides a method of treating an animal suffering from a microbial infection by administering to the animal an efflux pump inhibitor in an amount sufficient to reduce efflux pump activity. In this aspect, the efflux pump inhibitor in one which reduces the in vivo viabdity of a microbe involved in the infection. By reducing the in vivo viabdity, the infected animal can more readUy clear its body of the infection, or the microbes may even be lulled. In particular embodiments the animal is a mammal. Also in particular embodiments, the microbe may be from one of a variety of pathogenic bacterial species, specificaUy including those Usted above.
The term "in vivo viabiUty" refers to the abUity of a microbe, e.g., a bacterium, to survive or grow in a host, such as an animal. Therefore, an efflux pump inhibitor which reduces the in vivo viability of a microbe may stop the growth of the microbe and/or kill the microbe. Such efflux pump inhibitors, therefore, are antimicrobial agents.
In a further related aspect, this invention includes a method for prophylactic treatment of an animal, e.g., a mammal. In this method, an efflux pump inhibitor which reduces the pathogenicity of a microbe is administered to a mammal at risk of a microbial infection, e.g., a bacterial infection.
In a related aspect, the invention provides a method for treating a microbial infection in an animal, specifically including in a mammal, by treating an animal suffering from such an infection with an antimicrobial agent and an efflux pump inhibitor which increases the susceptibUity of the microbe for that antimicrobial agent. In this way a microbe involved in the infection can be treated using the antimicrobial agent in smaUer quantities, or can be treated with an antimicrobial agent which is not therapeuticaUy effective when used in the absence of the efflux pump inhibitor.
Thus, this method of treatment is especially appropriate for the treatment of infections using an antimicrobial agent alone due to a need for high dosage levels (which can cause undesirable side effects), or due to lack of any cUnically effective antimicrobial agents. However, it is also appropriate for treating infections involving microbes which are susceptible to particular antimicrobial agents as a way to reduce the dosage of those particular agents. This can reduce the risk of side effects, but can also reduce the selection effect for highly resistant microbes resulting from the consistent high level use of a particular antimicrobial agent. In particular embodiment the microbe is a bacterium, which may, for example, be from any of the groups or species indicated above. Also in particular embodiments various antibacterial agents can be used. These include quinolones, tetracycUnes, glycopeptides, aminoglycosides, beta-lactams, rifamycins, coumermycins, macrolides, and chloramphenicol. In particular embodiments an antibiotic of the above classes can be, for example, one of the foUowing: Beta-Lactam Antibiotics
Imipeiiem, meropenem, saneftrinem, biapenem, cefaclor, cefadroxil, cefamandole, cefatrizine, cefazedone, cefazolin, cefixime, cefmenoxime, cefodizime, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotiam, cefpimizole, cefpiramide, cefpodoxime, cefsulodin, ceftazidime, cefteram, ceftezole, ceftibuten, ceftizoxime, ceftriazone, cefurozime, cefuzonam, cephaaceterile, cephalexin, cephaloglycin, cephaloridine, cephalothin, cephapirin, cephradine, cefmetazole, cefoxitin, cefotetan, azthreonam, carumonam, flomoxef, moxalactam, amidinociUin, amoxicilUn, amiciUin, azlocUUn, carbenicUUn, benzylpenicUUn, carfecUUn, cloxacUlin, dicloxaciUin, methicUloin, mezlociUin, nafdUin, oxacttUn, penicillin G, piperaciUin, sulbenicUlin, temociUin, ticarcUUn, cefditoren, SC004, KY-020, cefdinir, ceftibuten, FK-312, S-1090, CP-0467, BK-218, FK-037, DQ- 2556, FK-518, Cefozopran, ME1228, KP-736, CP-6232, Ro 09-1227, OPC-20000, LY206763
Macrolides
azithromycin, clarithromycin, erythromycin, oleandomycin, rokitamycin, rosaramicin, roxithromycin, troleandomycin, teUthromycin and other ketolides.
Quinolones
Amifloxacin, cinoxacin, ciprofloxacin, enoxacin, fleroxacin, flumequine, loMefloxacin, naUdixic acid, norfloxacin, ofloxacin, levofloxacin, oxoUnic acid, pefloxacin, difloxacin, marbofloxacin, rosoxacin, temafloxacin, tosufloxacin, sparfloxacin, cUnafloxacin, trovafloxacin, alatrofloxacin, grepafloxacin, moxifloxacin, gatifloxacin, gemifloxacin, nadifloxacin, PD131628, PD140248, Q-35, AM-1155, NM394, T-3761, rufloxacin, OPC-17116, DU-6859a (identified in Sato, K. et. al., 1992, Antimicrob Agents Chemother. 37:1491-98), DV-7751a (identified in Tanaka, M. et. al., 1992 Antimicrob Agents Chemother 37:2212-18).
TetracycUnes
Chlortetracycline, demeclocyUne, doxycycUne, lymecycline, methacycline, minocycline, oxytetracycline, tetracycline,
Aminoglycosides
Amikacin, arbekacin, butirosin, dibekacin, fortimicins, gentamicin, kanamycin, netilmicin, ribostanycin, sisomicin, spectinomycin, streptomycin, tobramycin, cUndamycin, Uncomycin.
Oxazolidinones
Linezolid, eperezolid
Each of the above compounds have been reported in the Uterature. Other antibiotic compounds which may be identified which are effluxed by particular bacteria can also be utilised with the efflux pump inhibitors of this invention.
In the context of the response of a microbe, such as a bacterium, to an antimicrobial agent, the term "susceptibiUty" refers to the sensitivity of the microbe for the presence of the antimicrobial agent So, to increase the susceptibiUty means that the microbe wUl be inhibited by a lower concentration of the antimicrobial agent in the medium surrounding the microbial ceUs. This is equivalent to saying that the microbe is more sensitive to the antimicrobial agent. In most cases the minimum inhibitory concentration (MIC) of that antimicrobial agent wiU have been reduced.
As used herein, the term "treating" refers to administering a pharmaceutical composition for prophylactic and/or therapeutic purposes. The term "prophylactic treatment" refers to treating an organism such as a human patient, who is not yet infected, but who is susceptible to, or otherwise at risk of, a particular infection. The terms "susceptible" and "risk" do not refer to the status of organisms of that type generaUy, but rather refers to a significantly enhanced risk. Such risk may for example be due to a specific exposure to a particular potentially infective agent, to a generaUy weakened physical condition, or immune system deficiency. Preferably, for humans the enhanced risk is sufficient such that a prudent doctor familiar with the treatment of the potential infection would find prophylactic treatment medicaUy warranted. The term "microbial infection" refers to a disease state or some adverse condition^), such as the presence of a pathogenic microorganism in a body fluid like blood, urine, cerebrospinal or organ tissue, which are otherwise sterile or free of pathogenic microorganisms. The term "therapeutic treatment" refers to administering treatment to a patient already suffering from an infection. Thus, in preferred embodiments, treating is the administration to a mammal (either for therapeutic or prophylactic purposes) of therapeutically effective amounts of a potentiator and an antibacterial (or antimicrobial) agent in combination (either simultaneously or seriaUy). The term "potentiator" refers to a compound such as an efflux pump inhibitor which has the abiUty to increase the concentration of existing antibiotics in a microbial cell.
By "therapeutically effective amount" or "pharmaceuticaUy effective amount" is meant an amount of an efflux pump inhibitor, or amounts individually of an efflux pump inhibitor and an antimicrobial agent, as disclosed for this invention, which have a therapeutic effect, which generaUy refers to the inhibition to some extent of the normal metaboUsm of microbial cells causing or contributing to a microbial infection. The doses of efflux pump inhibitor and antimicrobial agent which are useful in combination as a treatment are therapeuticaUy effective amounts. Thus, as used herein, a therapeuticaUy effective amount means those amounts of efflux pump inhibitor and antimicrobial agent which, when used in combination, produce the desired therapeutic effect as judged by cUnical trial results and/or model animal infection studies. In particular embodiments, the efflux pump inhibitor and antimicrobial agent are combined in predetermined proportions and thus a therapeutically effective amount would be an amount of the combination. This amount and the amount of the efflux pump inhibitor and antimicrobial agent individually can be routinely determined by one of skill in the art, and wiU vary, depending on several factors, such as the particular microbial strain involved and the particular efflux pump inhibitor and antimicrobial agent used. This amount can further depend upon the patient's height, weight, sex, age and medical history. For prophylactic treatments, a therapeuticaUy effective amount is that amount which would be effective if a microbial infection existed.
A therapeutic effect reUeves, to some extent, one or more of the symptoms of the infection, and includes curing an infection. "Curing" means that the symptoms of active infections are eliminated, including the elimination of excessive numbers of viable microbes of those involved in the infection. However, certain long-term or permanent effects of the infection may exist even after a cure is obtained (such as extensive tissue damage).
The term "microbial infection" refers to the invasion of the host mammal by pathogenic microbes. This includes the excessive growth of microbes which are normaUy present in or on the body of a mammal. More generaUy, a microbial infection can be any situation in which the presence of a microbial population(s) is damaging to a host mammal. Thus, a mammal is "suffering" from a microbial infection when excessive numbers of a microbial population are present in or on a mammal's body, or when the effects of the presence of a microbial population (s) is damaging the ceUs or other tissue of a mammal. SpecificaUy, this description applies to a bacterial infection.
The term "administration" or "administering" refers to a method of giving a dosage of an antimicrobial pharmaceutical composition to a mammal, where the method is, e.g., topical, oral, intravenous, intraperitoneal, or intramuscular. The preferred method of administration can vary depending on various factors e.g., the components of the pharmaceutical composition, the site of the potential or actual bacterial infection, the microbe involved, and the severity of an actual microbial infection. The term "mammal" is used in its usual biological sense. Thus, it specifically includes humans, cattle, horses, dogs, and cats, but also includes many other species.
This invention also features a method of enhancing the antimicrobial activity of an antimicrobial agent against a microbe, in which such a microbe is contacted with an efflux pump inhibitor, e.g., a non-tetracycline specific efflux pump inhibitor, to an efflux pump in the cell, and an antibacterial agent. The efflux pump inhibitor is a compound as described above. Thus, this method makes an antimicrobial agent more effective against a ceU which expresses an efflux pump when the ceU is treated with the combination of an antimicrobial agent and efflux pump inhibitor. In particular embodiments the microbe is a bacterium or a fungus, such as any of those described above; the antibacterial agent can be selected from a number of structural classes of antibiotics including, e.g., beta-lactams, glycopeptides, aminoglycosides, quinolones, tetracycUnes, rifamycins, coumermycins, macroUdes, and chloramphenicol. In particular embodiments an antibiotic of the above classes can be as stated above.
In a further aspect this invention provides pharmaceutical compositions effective for treatment of an infection of an animal, e.g., a mammal, by a microbe, such as a bacterium or a fungus. The composition includes a pharmaceutically acceptable carrier and an efflux pump inhibitor as described above. In preferred embodiments, such compositions contain efflux pump inhibitors, which are themselves effective antimicrobial agents, even in the absence of another antimicrobial agent (i.e., have intrinsic antimicrobial activity). Thus, pharmaceutical composition including such efflux pump inhibitors can be used either alone or in conjunction with another antimicrobial agent. Also in preferred embodiments, the efflux pump inhibitors in pharmaceutical compositions of this aspect are efflux pump inhibitors which enhance the effectiveness of an antimicrobial agent other than the efflux pump inhibitor, so such compositions would generaUy be used in combination with such other antimicrobial agent. The invention also provides pharmaceutical compositions similarly effective for treatment of an infection of a mammal which include an efflux pump inhibitor and an antimicrobial agent. SimUarly, the invention provides antimicrobial formulations which include an antimicrobial agent, an efflux pump inhibitor, and a carrier. In preferred embodiments, the antimicrobial agent is an antibacterial agent.
A "carrier" or "excipient" is a compound or material used to facUitate administration of the compound, for example, to increase the solubUity of the compound. SoUd carriers include, e.g., starch, lactose, dicalcium phosphate, sucrose, and kaoUn. Liquid carriers include, e.g., sterUe water, saUne, buffers, non-ionic surfactants, and edible oils such as oil, peanut and sesame oils. In addition, various adjuvants such as are commonly used in the art may be included. These and other such compounds are described in the literature, e.g., in the Merck Index, Merck & Company, Rahway, NJ. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Gilman et al. (Eds.) (1990); Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press.
In yet another aspect, the invention provides a method of suppressing growth of a microbe, e.g., a bacterium, expressing an efflux pump, e.g., a non-tetracycUne-specific efflux pump. As illustrated by the case where the microbe is a bacterium, the method involves containing that bacterium with an efflux pump inhibitor, e.g., a non-tetracycline-specific efflux pump inhibitor, in the presence of a concentration of antibacterial agent below the MIC of the bacterium. This method is useful, for example, to prevent or cure contamination of a ceU culture by a bacterium possessing an efflux pump. However, it applies to any situation where such growth suppression is desirable.
In another related aspect, the invention provides a method for reducing a population of a microbe, e.g., a bacterial strain, involving contacting the population with an efflux pump inhibitor which inhibits a component of an efflux pump expressed in the microbe in that population, which is essential for the growth of the microbe expressing that efflux pump. In particular embodiments, that component is cytoplasmic membrane component. As indicated above, such efflux pump inhibitors may act in various ways, including, but not limited to, acting directly on the essential component, or acting to inhibit the expression of that component.
The term "reducing a population" means that the microbes of that population are being killed. This is distinguished from the action of a static agent, e.g., a bacteriostatic agent, which prevents the bacteria from growing and multiplying but does not kiU the microbes. Accordingly, in the context of this aspect, an "essential component" of an efflux pump is one which is essential to the in vivo survival of the microbe, i.e., the survival in a host.
In yet another aspect, this invention provides a method for enhancing growth of an animal by administering an efflux pump inhibitor to the animal, which inhibits an efflux pump expressed in a bacterial strain in the animal, and which inhibits the growth of the bacterial strain. Such a growth enhancing effect may result from the reduced energy consumption by the bacteria, which increases the food energy available to the animal. This method is appropriate, for example, for use with cattle, swine, and fowl such as chickens and turkeys.
In an additional aspect, the invention provides novel compounds having efflux pump activity. These compounds have chemical structures as described above. As indicated above, while the present invention is presently exemplified by activity against bacteria, compounds of the present invention also have activity against other microbes, for example against yeasts and/or other fungi. Thus, the above aspects also include embodiments in which described compounds are active or effective against such other microbes.
In further aspect, the invention provides a method of making a pharmaceutical composition comprising the steps of identifying an efflux pump inhibitor having a chemical structure of the formula I; synthesizing said efflux pump inhibitor and preparing a pharmaceutical composition containing said efflux pump inhibitor. The efflux pump inhibitor may have the chemical structure as described above. The pharmaceutical composition may also contain one or more antimicrobial agents, e.g., as identified above, and one or more carriers, dUuents, and excipients. Further, in preferred embodiments, the efflux inhibitor compound is active against a microbe, e.g., a bacterium, as identified above.
Identification of Efflux Pump Inhibitors
Identification of efflux pump inhibitors having structures as described for the present invention was performed using screening methods known to those skilled in the art of biological techniques and are described in detail below. In particular, the screening method based on inhibition of microbial growth in the presence of a subinhibitory concentration of an antibacterial agent which is normally effluxed by the test microbe and a concentration of a test compound was used for identifying some of the active compounds disclosed herein. In this method, inhibition of growth of the microbe is indicative that export of the antibacterial agent is inhibited by the test compound, and that the test compound is therefore an efflux pump inhibitor. The mode of action of the test compound so identified can then be confirmed as inhibiting active efflux. However, other screening methods for detecting efflux pump inhibitors can also be used.
Synthesis of Derivatives of Efflux Pump Inhibitors from Screening
The inventors have screened a Ubrary of synthetic chemicals and identified several compounds that effectively inhibit the respective efflux pumps of Staphylococcus aureus 1199B NorA*, Streptococcus pneumoniae 3514, Pseudomonas aeruginosa 23587, Escherischia coli 2051. Some of these compounds were found to be also effective against presently unidentified multidrug transporters of other microorganisms. The library of compounds was obtained by synthesis according to methods as described in our copending applications PCT appUcation PCT/IN99/00016, US appUcations 09/566,875, 09/640,947, and 09/850,669 and by methodologies described in a later section below.
Exemplary compounds of the present invention were synthesised by methods as described in the examples below. Those skilled in the art will understand how to synthesise additional compounds within the scope of this invention based on the described syntheses and the knowledge of those skilled in the art of chemical synthesis.
The foUowing examples illustrate methods of screening, which have led to the identification of efflux pump inhibitors. They, however, do not Umit the scope of methods that can be used for screening or the kinds of efflux pump inhibitors that can be found by such varied methods.
Screening of Efflux Pump Inhibitors - In-vivo
Inhibitors of the bacterial efflux pumps are generaUy initially characterised in vitro. Those which show effective inhibition of the pump(s) and which show synergistic activity with antibiotics are selected for evaluation in vivo. Efficacy testing wUl be done using standard procedures. Primary efficacy evaluation may be done using the murine septicemia model (M.G. Bergeron, 1978, Scand. J. Infect. Dis. Suppl. 14:189-206; S.D. Davis, 1975, Antimicrob. Agents Chemother. 8:50-53). In this model a supra-lethal dose of bacteria is used to chaUenge the rodents. Treatment is initiated, varying either or both time(s) of treatment and dose of antibiotic. In these experiments both the antibiotic and the efflux pump inhibitor doses are varied. A positive result is indicated by significant increase in protection from the lethal infection by the combination of the potentiator (the efflux pump inhibitor) and the antibiotic versus the antibiotic alone.
A second efficacy model which is used is the mouse soft tissue infection model (Vogelman etal. 1988, J. Infect. Dis. 157:287-298). In this model anaesthetised mice are infected with an appropriate titer of bacteria in the muscle of the hind thigh. Mice are either neutropenic (cyclophosphamide treated at 125 mg/kg on days -4, -2, and 0) or immunocompetent. The infecting dose is commonly 10s - 106 colony forming units per animal. Treatment with the combination of the efflux pump inhibitor and/or antibiotics foUows infection, or can occur before infection. The proliferation (or death) of the bacteria within the thigh muscle is monitored over time. Effective combinations show greater activity than the antibiotic alone. Activity is defined as reduction in growth rate of the test bacteria in the murine tissue. Pharmaceutical Compositions and Modes of Administration
The particular compound that is an efflux pump inhibitor can be administered to a patient either by itself, or in combination with an antimicrobial, e.g., antibacterial, agent, or in pharmaceutical compositions where it is mixed with a suitable carrier(s) or excipient(s) or diluent(s). A combination of an efflux pump inhibitor with an antimicrobial agent can be of at least two different types. In one, a quantity of an efflux pump inhibitor is combined with a quantity of an antimicrobial agent in a mixture, e.g., in a solution or powder mixture. In such mixtures, the relative quantities of the inhibitor and the antimicrobial agent may be varied as appropriate for the speciflc combination and expected treatment. In a second type of combination an inhibitor and an antimicrobial agent can be covalently linked in such manner that the Unked molecules can be cleaved within the ceU. However, the term "in combination" can also refer to other possibilities, including serial administration of an inhibitor and other antimicrobial agent. In addition, an efflux pump inhibitor and/or another antimicrobial agent may be administered in pro-drug forms, i.e. the compound is administered in a form which is modified within the ceU to produce the functional form. In treating a patient exhibiting a disorder of interest, a therapeuticaUy effective amount of an agent or agents such as these is administered. A therapeutically effective dose refers to that amount of the compound(s) that results in amelioration of symptoms or a prolongation of survival in a patient, and may include eUmination of a microbial infection.
Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in ceU cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ ED50. Compounds which exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds Ues preferably within a range of circulating concentrations that include the ED50 with Uttle or no toxicity. The dosage may vary within this range depending upon the dosage and dosage form employed and the route of administration utiUsed. It is preferable that the therapeutic serum concentration of an efflux pump inhibitor should be in the range of 0.1-100 mcg/ml, more preferably 0.1 - 50 mcg/ml, even more preferably 0.1 - 20 mcg/ml, even more preferably 1.0- 50 mcg./ml or most preferably 1.0 - 20 mcg/ml.
For any compounds used in the method of the invention, the therapeuticaUy effective dose can be estimated initiaUy from ceU culture assays. For example, a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 as determined in cell culture. Such information can be used to more accurately determine useful dosage in humans. Levels in plams may be measured, e.g. by HPLC.
In particular preferred embodiments, the efflux inhibitor in a pharmaceutical composition has a structure as shown by the generic structures described above.
The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patients condition. (See e.g. Fingl etal., in The Pharmacological Basis of Therapeutics, 1975, Ch.l, p.l). It should be noted that the attending physician would know how and when to terminate, interrupt or adjust administration due to toxicity, or to organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the cUnical response were not adequate, (precluding toxicity). The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the does and perhaps dose frequency wdl also vary according to the age, body weight and response of the individual patient. A programme comparable to that discussed above may be used in veterinary medicine.
Depending on the specific infection being treated, such agents may be formulated and administered systemicaUy or locally. Techniques for formulation and administration may be found in Remington's Pharmaceutical Sciences, 19th ed., Mack PubUshing Co., Easton, Pa. (1990). Suitable routes may include oral, rectal, transdermal, vaginal, transmucosal, or intestinal administration; parentral deUvery, including intramuscular, subcutaneous, intramedullary, injections, as well as intrathecal, direct intraventricular, intravenous, intraperitonial, intranesal, or intraocular injections just to name a few.
The pharmaceutical compositions are prepared according to conventional procedures used by persons skilled in the art to make stable and effective compositions. In the soUd, Uquid, parenteral and topical dosage forms, an effective amount of the active compound or the active ingredient is any amount, which produces the desired results.
For the purpose of this invention the pharmaceutical compositions may contain the active compounds of the invention, their derivatives, salts or hydrates thereof, in a form to be administered alone, but generaUy in a form to be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. Suitable carriers which can be used are, for example, diluents or excipients such as fiUers, extenders, binders, emollients, wetting agents, disintegrants, surface active agents and lubricants which are usually employed to prepare such drugs depending on the type of dosage form.
Any suitable route of administration may be employed for providing the patient with an effective dosage of the compound of the invention, their derivatives, salts or hydrates thereof. For example, oral, rectal, parenteral (subcutaneous, intramuscular, intravenous), transdermal, topical and Uke forms of administration may be employed. Dosage forms include (solutions, suspensions, etc) tablets, piUs, powders, troches, dispersions, suspensions, emulsions, solutions, capsules, injectable preparations, patches, ointments, creams, lotions, shampoos and the like.
Pharmaceutical compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, or aerosol sprays, each containing a predetermined amount of the active ingredient, as a powder or granules, or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oU liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy, but aU methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with Uquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
The compositions of the present invention include compositions such as suspensions, solutions, elixirs, aerosols, and solid dosage forms. Carriers as described in general above are commonly used in the case of oral soUd preparations (such as powders, capsules and tablets), with the oral soUd preparations being preferred over the oral liquid preparations. The most preferred oral soUd preparation is tablets.
Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. Examples of suitable carriers include excipients such as lactose, white sugar, sodium chloride, glucose solution, urea, starch, calcium carbonate, kaolin, crystalUne ceUulose and sUicic acid, binders such as water, ethanol, propanol, simple syrup, glucose, starch solution, gelatine solution, carboxymethyl cellulose, shellac, methyl ceUulose, potassium phosphate and polyvinyl pyrroUdone, disintegrants such as dried starch, sodium alginate, agar powder, laminaria powder, sodium hydrogen carbonate, calcium carbonate, Tween (fatty acid ester of polyoxyethylenesorbitan), sodium lauryl sulfate, stearic acid monoglyceride, starch, and lactose, disintegration inhibitors such as white sugar, stearic acid glyceryl ester, cacao butter and hydrogenated oils, absorption promoters such as quaternary ammonium bases and sodium lauryl sulfate, humectants such as glycerol and starch, absorbents such as starch, lactose, kaolin, bentonite and colloidal silicic acid, and lubricants such as purified talc, stearic acid salts, boric acid powder, polyethylene glycol and soUd polyethylene glycol.
The tablet, if desired, can be coated, and made into sugar-coated tablets, gelatine-coated tablets, enteric-coated tablets, film-coated tablets, or tablets comprising two or more layers. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.
In moulding the pharmaceutical composition into piUs, a wide variety of conventional carriers known in the art can be used. Examples of suitable carriers are excipients such as glucose, lactose, starch, cacao butter, hardened vegetable oils, kaoUn and talc, binders such as gum arabic powder, tragacanth powder, gelatin, and ethanol, and disintegrants such as laminaria and agar.
In molding the pharmaceutical composition into a suppository form, a wide variety of carriers known in the art can be used. Examples of suitable carriers include polyethylene glycol, cacao butter, higher alcohols, gelatine, and semi-synthetic glycerides.
A second preferred method of administration is parenteraUy for intramuscular, intravenous or subcutaneous administration.
A third preferred route of administration is topicaUy, for which creams, ointments, shampoos, lotions, dusting powders and the like are well suited.
In addition to the common dosage forms set out above, the compounds of the present invention may also be administered by controlled release means and/or delivery devices such as those described in U S Patent Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123 and 4,008,719; the disclosures of which are hereby incorporated by reference.
When the pharmaceutical composition is formulated into an injectable preparation, in formulating the pharmaceutical composition into the form of a solution or suspension, aU diluents customarUy used in the art can be used. Examples of suitable diluents are water, ethyl alcohol, polypropylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol, and sorbitan esters. Sodium chloride, glucose or glycerol may be incorporated into a therapeutic agent. The antimicrobial pharmaceutical composition may further contain ordinary dissolving aids, buffers, pain-aUeviating agents, and preservatives, and optionaUy colouring agents, perfumes, flavours, sweeteners, and other drugs.
For topical application, there are employed as non-sprayable forms, viscous to semi-soUd or soUd forms comprising a carrier compatible with topical application and having a dynamic viscosity preferably greater than water. Suitable formulations include but are not Umited to solutions, suspensions, emulsions, creams, ointments, powders, Uniments, salves, aerosols, etc., which are, if desired, steriUzed or mixed with auxiUary agents, e.g. preservatives, antioxidants, stabUizers, wetting agents, buffers or salts for influencing osmotic pressure, etc. For topical application, also suitable are sprayable aerosol preparations wherein the active ingredient preferably in combination with a soUd or liquid inert carrier material.
It will be apparent to those skilled in the art that many modifications, both to materials and methods may be practised without departing from the purpose and scope of this invention.
Preparations of intermediates and of exemplary compounds of the invention
The compounds of the present invention may be readily prepared in accordance with the foUowing synthesis schemes, as iUustrated in the specific examples provided. However, those skilled in the art wUl recognise that other synthetic pathways for forming the compounds of this invention can be utilised, and that the following is provided merely by way of example and is not limiting to the present invention. It wiU be further recognised that various protecting and deprotecting strategies wiU be employed which are standard in the art (see e.g., "Protective Groups in Organic Synthesis", by Green and Wuts). Those skilled in the art wuT recognise that the selection of any particular protecting group (e.g. amine, hydroxy and carboxyl protecting groups) wiU depend on the stabUity of the protected moiety with regard to the subsequent reaction conditions and wUl understand the appropriate selection.
General Procedures for preparing the compounds of the invention.
A 7-halo quinolone of the structure shown below
Figure imgf000045_0001
where halo represents F, Cl, or Br, R2 represents COOH, COOCH3, COOC2H5, R2, R4 and 4a taken together represents a difluoroboron coordination complex shown as -C(=O)OB(F2)...O= or R2, R4 and R,., taken together represents a diacetoxyboron coordination complex shown as - C=O(O)B(OAc)2 and R1? R,, R4a, Rs, Re, X and Y are as hereinbefore described is treated with an appropriate amine of the formula R9Rι0NH, where R9 and Rι0 have the meanings hereinbefore described in an organic solvent such as acetone, alcohol, acetonitrUe, dimethyl sulphoxide, N,N- dimethylformamide preferably acetonitrile or dimethyl sulphoxide, optionaUy in the presence of a base such as triethylamine, pyridine, l,5-diazabicyclo[4.3.0]non-5-ene (DBN), diazabicyclo[5.4.0]undee-7-ene (DBU) preferably triethylamine at 50°C - 120°C, preferably 70°C - 90°C for 4- 24 hr. When R2 represents COOCH3 or COOC2Hs or R2, R, and R,., represent - C(=O)OB(F2)...O= or C=O(O)B(OAc)2 or -C(=O)OB(OAc)2, the product obtained is hydrolysed by aqueous alkali preferably sodium hydroxide or a base preferably triethylamine in solution in a solvent such as ethanol.
a) The compounds I of the invention which are esters at a carboxylic acid group may be prepared by treating the free acid of compounds of formula I in solution in an appropriate solvent, preferably N,N-dimethylformamide, with the corresponding halo compound, preferably chloro or bromo-compound, in the presence of a base, preferably anhydrous potassium carbonate, at an elevated temperature, preferably 50°C for an extended period of time, preferably 6 hours.
b) The compounds of the invention which are esters at a carboxylic acid group may be prepared by treating the free acid of compound of formula I in solution in an appropriate solvent, preferably N,N-dimethylacetamide, with the corresponding hydroxy compound, in the presence of a base, preferably triethylamine, in presence of a catalyst, preferably 4-N,N- dimethylaminopyridine, and in the presence of a dehydrating agent, preferably N,N- dicyclohexylcarbodimide at an elevated temperature, preferably 100°C for an extended period of time, preferably 24 hours.
c) The compounds of formula I of the invention which are amides at a carboxylic acid groups may be prepared by coupling the free acid of compound of formula I with ammonia or an appropriate amine or an amino acid appropriately protected at the acid functionality of the amino acids with a protecting group. The -COOH protecting groups for amino acids are known in the art. Examples of suitable -COOH protecting groups for amino acids are methyl, ethyl, t-butyl and benzyl groups. The -COOH protecting group is removed by hydrolysis or by hydrogenation. The coupling of a -COOH group of compound of formula I with the amino group of the amino acid is also known in the art. The reaction may be conducted with or without a solvent at a range of temperatures in the presence of a coupling agent.
d) The compounds of the invention which are amides at an NH2 or an NH group are prepared by coupling the free amino group of a compound of formula I or by coupling the free NH bearing compound of formula I with an appropriate acylating agent such as an acyl anhydride or an acyl chloride in the presence of a condensing agent such as a base e.g. triethylamine or aqueous sodium hydroxide optionaUy in the presence of a solvent such as
N,N-dimethyl acetamide at an elevated temperature of 50°C - 100°C for an extended period of time upto 24 hours. For compound that contain two NH2 groups, two NH groups or one NH2 and one NH group, it may be necessary when so desired to use a protecting group on the NH2 group or NH group which is desired to remain unreactive. Protecting groups for NH2 and NH groups are weU known to those skiUed in the art.
e) The compounds of the invention which are esters of a free hydroxy group may be prepared by treating the free hydroxy compound of formula I with an organic acid, an organic dibasic acid or appropriate N-protected amino acid or polypeptide as defined above. Nitrogen protecting groups are known in the art Examples of suitable nitrogen protecting groups are
C C6 acyl, C2-C6 alkoxycarbonyl optionally substituted benzyloxycarbonyl, aryloxycarbonyl, sUyl, trityl, tetrahydropyranyl, vinyloxycarbonyl, O-nitrophenylsulfonyl, diphenylphosphinyl, p-toluenesulfonyl, and benzyl. The nitrogen protecting group is removed by methods known in the art such as hydrogenation or hydrolysis. The ester forming reaction may be conducted with or without a solvent at a range of temperatures in the presence of a suitable condensing agent, known to those skilled in the art.
f) The compounds of the invention which are alkyl ethers of a free hydroxy group may be prepared by treating the compound bearing the free hydroxy group with an alkyl halide in an organic solvent in the presence of a base or a condensing agent at temperatures upto the boiUng point of the solvent for a period of time upto 24 hours, by methods known to those skilled in the art.
g) The compounds of the invention which are mono or dialkyl derivatives of a free amino group may be prepared by treating the compound bearing the free amino group with appropritae molar amounts of an alkylhalide in an organic solvent optionally in the presence of a base or a condensing agent at temperatures upto the boding point of the solvent for a period of time upto 24 hours, by methods known to those skilled in the art h) General Method for making aminoacid esters at the 8-(4'-hydroxypiperidine substituent of
RS- R-/S-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j] quinoUzine-2-carboxyIic acid
RS- R-/S-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H-benzo [i,j] quinolizine-2-carboxyUc acid (1mm, 360 mg), and triethylamine ( 1 mm, 0.145 ml) was dissolved in dimethylacetamide ( 15 ml). t-Butyloxycarbonyl aminoacid (1.2 mm) and dimethylaminopyridine (1.2 mm, 150 mg) were added, foUowed by dicyclohexylcarbodUmide under ice cooUng. After 30 minutes at 0°C, the mixture was stirred at room temperature overnight. Dicyclohexylurea was filtered and the mixture was dUuted with ethylacetate, transferred in a separating funnel, washed with 0.5 N hydrochloric acid, 1 N sodiumbicarbonate and brine,dried over sodium sulphhate and evaporated to give t- butoxycarbonylaminoacyloxy derivative of RS-/R-/S-9-fluoro-6,7-dihydro-8- (4'- hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H-benzo[i,j]quinolizine-2-carboxylic acid
Trifluoroacetic acid (10 ml) was added to the product obtained in the previous step. After 30 mins at room temperature, the acid was evaporated and the trifluoroacetate salt was precipitated by addition of ether. If need be the product could be purified by high pressure
Uquid chromatography on a C8 or C18 column. Dissolving the trifluoroacetate salt in 0.1 N hydrochloride acid and freeze drying provided the hydrochloride salt.
i) General Method for making an amide derivative at the 2-carboxyl substituent of RS-/R-/S- 9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid using an alpha amino acid
RS-/R-/S-9-FIuoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxyUc acid (1mm, 360 mg), and triethylamine ( 1 mm, 0.145 ml) were are dissolved in dimethylacetamide ( 15 ml) . Isobutylchloroformate (1mm, 0.13 ml) was added under ice cooUng, After 5 min a solution of aminoacid ester hydrochloride (2 mm) and triethylamine (2 mm, 0.28 ml) in dimethylacetamide (10 ml) was added foUowed by dimethylaminopyridine (1 mm, 125 mg) and the mixture was stirred at room temperature overnight. The mixture was then dUuted with ethyl acetate, transferred in a separating funnel, washed with 0.5 N hydrochloric acid, 1 N sodium bicarbonate and brine, dried over sodiumsulphate and evaporated to give the ester of the respective amide from RS- /R-/S-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo [i, j] quinolizine-2-carboxylic acid. The ester was dissolved in methanol, 1 N sodium hydroxide (1.1 eqivalent) was added. The mixture was acidified, extracted with ethylacetate, washed with brine , dried over sodiumsulphate and evaporated to provide the title compound. If need be the product may be purified by high pressure Uquid chromatography on a C8 or C18 column. OptionaUy, dissolving the acid in water with one equivalent sodiumbicarbonate foUowed by freeze drying provided the sodium salt of the title compound.
j) The pharmaceutically acceptable acid addition salts of compounds I are prepared in a conventional manner by treating a solution or suspension of the free base I with about one chemical equivalent of a pharmaceuticaUy acceptable acid. Conventional concentration and recrystalisation techniques are employed in isolating the salts. IUustrative of suitable acids are hydrochloric, hydrobromic, hydroiodic, sulphuric, sulfamic, sulfonic, phosphoric, acetic, lactic, succinic, oxaUc, maleic, fumaric, malic, tartaric, citric, ascorbic, gluconic, benzoic, cinnamic, methanesulfonic and p-toluenesulfonic acid.
k) The pharmaceutically acceptable cationic salts of compounds of formula I may be prepared by conventional methods from the corresponding acids e.g. by reaction with about one equimolar amount of a base. Examples of suitable cationic salts are those of alkaU metals such as lithium, sodium or potassium, alkaline earth metals such as magnesium or calcium or ammonium or organic amines such diethanolamine, N-methylglucamine, guanidine or heterocyclic amines such as choUne, piperidine, N-methyl-4-hydroxypiperidine, hydroxyethylpyrroUdine, hydroxyethylpiperidine, morpholine, hydroxyethylmorphoUne, piperazine, N-methyl piperazine and the Uke or basic amino acids such as optically pure or racemic isomers of arginine, lysine, histidine, tryptophan and the like.
The foUowing examples describe the methods of synthesis of the compounds of the invention.
Some Preferred Compounds of the Invention Displaying Inhibition of the Efflux Pump of Staphylococcus aureus 1199 B (Nor A >
Example 1 l-Ethyl-6-fluoro-l, 4-dihvdro -7-fl 2f, 3', 4'-tetrahvdroisoquinoUn-2-yl)-4-oxo-quinoline-3- carboxylic acid.
A mixture of l-ethyl-6, 7-difluoro-l, 4-dihydro-4-oxo-quinolone-3-carboxyUc acid (2.5 g, 8.3 mmole), 1,2,3,4-tetrahydroisoquinoline (1.67 g, 16.7 mmole) and triethylamine (0.5 ml) in DMSO (15 ml) was stirred at 140 °C for 24 hr and concentrated in vacuum and the residue thus obtained was triturated with 25ml water. The soUd separated was filtered and dried to furnish the required product. Yield 2.0 g (62 %), m.p. 220 °C . C2ιHι9FN2O3, m z 385 (M+l).
Example 2 l-Ethyl-6,8-fluoro-l.4-dihvdro -7-(4'-acetoxypiperidin-l-yl -4-oxo-quinoline-3-carboxyUc acid.
A mixture of l-ethyl-6, 7-difluoro-l, 4-dihydro-4-oxo-quinolone-3-carboxyUc acid (2.5 g, 8.3 mmole), 1,2,3,4-tetrahydroisoquinoUne (1.67 g, 16.7 mmole) and triethylamine (0.5 ml) in dimethylsulfoxide (15 ml) was stirred at 140 °C for 24 hr and concentrated in vacuum and the residue thus obtained was triturated with 25ml water. The soUd separated was filtered and dried to furnish the required product. Yield 56%,m.p. 220-22 °C . C2ιH19FN2O3, m/z 395 (M+l).
Example 3 l-Ethyl-6,8-fluoro-l, 4-dihvdro -7-(4'-{2'-(2f-oxazolidin-lyl) ethyll piperazin-l-yl)-4-oxo-quinoUne- 3-carboxyUc acid.
A mixture of l-ethyl-6, 7-difluoro-l, 4-dihydro-4-oxo-quinolone-3-carboxyUc acid (2.5 g, 8.3 mmole), 1,2,3,4-tetrahydroisoquinoline (1.67 g, 16.7 mmole) and triethylamine (0.5 ml) in dimethylsulfoxide (15 ml) was stirred at 140 °C for 24 hr and concentrated in vacuum and the residue thus obtained was triturated with 25ml water. The solid separated was filtered and dried to furnish the required product. Yield 42%, m.p. 192-94 °C . C2ιH24F2N4O5, m/z 451 (M+l).
Example 4 l-Ethyl-6, 8-difluoro-l, 4-dihvdro -7-/(l°c 5x, 6oc)-6-amino-3-azabicyclo 13.1.01-hex-3-yl -4-oxo- αuinoUne-3-carboxyUc acid.
The condensation of (loc, 5o , 6oc)-6-t-butoxycarbonylamino-3-azabicyclo [3.1.0]-hexane with 1- ethyl-6, 7, 8-trifluoro-l, 4-dihydro-4-oxo-quinoUne-3-carboxyUc acid was carried in similar manner as described in example 1 which on hydrolysis with cone. HCl furnished titled product. Yield 60 %, m.p 224-26 °C, CπH17F2N3O3, m/z 350 (M+l).
Example 5
5-Amino-l- ethyl -6, 8-difluoro-l, 4-dihvdro -7-(3'-amino-5'-methyl pyrroUdin-l-vD-4-oxo- quinoUne-3-carboxyUc acid. The condensation of 5-amino-l-ethyl -6, 7, 8-trifluoro-l, 4-dihydro- 4-oxo-quinohne-3-carboxylic acid with 3-amino-5-methyl pyrroUdine in a simUar manner as described in example 1 give the titled product. Yield 41 %, m.p 238-40 °C, Cι7H19F2N4O3, m/z 393 (M+l).
Example 6
5-Amino-l- ethyl-6, 8-difluoro-l, 4-dihvdro -7-f4,-aminopiperidin-l-yl)-4-oxo-quinoline-3- carboxylic acid.
It was prepared according to procedure described in example 5 where 4-aminopiperidine was used in place of 3-amino-5-methyl pyrroUdine. Yield 67 %, m.p 204-06 °C, C20H28F2N4O3, m/z 411 (M+l).
Example 7
5-Amino-l- ethyl -6, 8-difluoro-l, 4-dihvdro -7-(4'-(acetamido) piperidin-l-yl|-4-oxo-quinoline-3- carboxylic acid.
It was prepared in a similar manner as described in example 5 where 4-(acetamido) piperidine was used in place of 3-amino-5-methyl pyrroUdine. Yield (45%), m.p 280-82 °C, Ci9H22F2N4O5, m/z 425 (M+l).
Example 8
5-Amino-l- ethyl-6, 8-difluoro-l, 4-dihvdro -7-1(1 oc, 5QC, 6oc)-6'-(N-t-butoxycarbonyl amino -3- azabicvclo [3.1.01-hex-3-yll-4-oxo-quinoUne-3-carboxyUc acid.
It was prepared according to procedure described in example 5 where (loc, 5oc, 6<x)-6-(N-t- butoxycarbonyl amino)-3-azabicyclo [3.1.0]-hexane was used in place of 3-amino-5-methyl pyrroUdine and the t-butoxycarbonyl protecting group in the product was removed using cone. HCL. Yield 92 mg (47 %), m.p 220-22 °C, C22H26F2N4O4, m/z 449 (M+l).
Example 9 l-Cyclopropyl-6-fluoro-l, 4-dihvdro-7- (3'-acetamido-5'-methylpyrrolidin-l-yl)-4-oxo-quinoUne-3- carboxylic acid.
The condensation of l-cyclopropyl-6-fluoro-7-chloro-l, 4-dihydro- 4-oxo-quinoUne-3-carboxyUc acid with 3-acetamido-5-methyl pyrroUdine in a simUar manner as described in example 1 give the titled product. Yield (68%), m.p 270-72 °C, C20H22FN3O4, m/z 388 (M+l). Example 10 l-Cvclopropyl-6-fluoro-1.4-dihvdro-7- (3,-amino-5f-methylpyrroUdin-l-yl)-4-oxo-quinoIine-3- carboxylic acid.
It was prepared in a similar manner as described in example 9 where 3-amino-5-methylpyrroIidin was used in place of 3-acetamido-5-methyl pyrroUdine to furnish the titled product. Yield (41 %), m.p 346 °C, C18H20FN3O3, m/z 346 (M+l).
Example 11 l-Cvclopropyl-6-fluoro-l.4-dihydro- -7-(4'-acetoxypiperidin -l-yl)-4-oxo-quinoIine-3-carboxylic acid.
It was prepared in a similar manner as described in example 9 where 4-acetoxy piperidine was used in place of 3-acetamido-5-methyl pyrroUdine. Yield 50 %, m.p 258-60 °C, C2ιH17F5N4O3, m/z 469 (M+l).
Example 12 l-Cyclopropyl-6-fluoro-l.4-dihvdro -7-{4'-(N-dimethylamino) piperidin-l-yl)-4-oxo-quinoline-3- carboxyUc acid.
It was prepared in a similar manner as described in example 9 where 4-(N-dimethyl aminopiperidine was used in place of 3-acetamido-5-methyl pyrroUdine. Yield 59 %, m.p 284-86 °C, C2iH23FN2Os, m/z 403 (M+l)
Example 13 l-Cvclopropyl-6-fluoro-l, 4-dihvdro- -7-(3', 5'-dimethyl piperidin-l-ylV4-oxo-quinoUne-3- carboxylic acid.
It was prepared in a simUar manner as described in example 9 where 3,5-dimethyl piperidine was used in place of 3-acetamido-5-methyl pyrroUdine. Yield 23 %, m.p 212-14 °C, C20H23FN2O3, m/z 359 (M+l).
Example 14 l-Cvclopropyl-6-fluoro-l, 4-dihvdro -7-(4'-hydroxy-3,, 5,-dimethylpiperidin-l-ylV4-oxo-quinoUne- 3-carboxyUc acid. It was prepared in a similar manner as described in example 9 where 4-hydroxy-3,5- dimethylpiperidine was used in place of 3-acetamido-5-methyl pyrroUdine. Yield 38 %, m.p 178- 80 °C, C20H23FN2O4, m z 375 (M+l).
Example 15 l-Cvclopropyl-6-fluoro-l, 4-dihvdro- -7-(3', 4', 5'-trimethyl piperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid.
It was prepared in a similar manner as described in example 9 where 3,4,5-trimethyl piperazine was used in place of 3-acetamido-5-methyl pyrroUdine. Yield 48 %, m.p 200-02 °C, C20H24FN3O3, m z 373 (M+l).
Example 16 l-Cvclopropyl-6-fluoro-l, 4-dihvdro- 7-(3', 5f-dimethyl-4,-ethyl piperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid.
It was prepared in a similar manner as described in example 9 where (3,5-dimethyl-4-ethyl piperazine was used in place of 3-acetamido-5-methyl pyrroUdine. Yield 79 %, m.p 215-20 °C, C2ιH26FN303, m/z 388 (M+l).
Example 17 l-Cvclopropyl-6-fluoro-l, 4-dihvdro-5-methyl- 7- (4'-ethoxypiperidin-l-yl)-4-oxo-quinoUne-3- carboxylic acid.
The condensation of l-cyclopropyl-6, 7-difluoro-5-methyl-l, 4-dihydro- 4-oxo-quinoline-3- carboxylic acid with 4-ethoxypiperidine in a simUar manner as described in example 1 give the titled product. Yield 40 %, m.p 180-82 °C, C2ιH25FN204, m/z 388 (M+l).
Example 18 l-Cvclopropyl-6-fluoro-l, 4-dihvdro-5-methyl- 7-(3f, 3'-dimethylpiperazin -l-vD-4-oxo-quinoUne- 3-carboxylic acid.
It was prepared in a similar manner as described in example 17 where 3,3-dimethyl piperazine was used in place of 4-ethoxypiperidine. Yield 50 %, m.p 238-42 °C, C20H24FN3O3, m/z 374 (M+l).
Example 19 l-Cvclopropyl-6-fluoro-8-methoxy-l.4-dihvdro -7-{4f-(N-dimethylamino)-3,-methylpiperidin-l- yl}-4-oxo-quinoline-3-carboxylic acid.
A mixture of [l-cyclopropyl-6, 7-difluoro-l, 4-dihydro-8-methoxy-4-oxo-quinoUne-3-carboxylate- O3, O4] difluoroboron chelate (100 mg, 0.29 mmole) and 4-(N-dimethylamino)-3-methylpiperidine (100 mg, 0.7 mmole) in acetonitrUe (5 ml) was stirred at 80 °C for 6hr and cooled. Solvent was removed, borate complex was heated under reflux using triethylamine (0.1 ml) in ethanol (5 ml), solvent was removed and solid obtained was purified on silica column to furnish the required product. Yield 74 %, C22H28FN304, m.p.180-82 °C m/z 417 (M+l).
Example 20 l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(4'-hvdroxy-3 '-isobutylpiperidin-l-vD-4-oxo- quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 19 where 4-hydroxy-3- isobutylpiperidine was used in place of 4-(N-dimethylamino)-3-methylpiperidine. Yield (59%), m.p 190-92 °C, C23H29FN2Os, m/z 433 (M+l).
Example 21 l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(4'-hvdroxy-3', 3f-dimethvIpiperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 19 where 4-hydroxy-3, 3- dimethylpiperidine was used in place of 4-(N-dimethylamino)-3-methylpiperidine. Yield 29 %, m.p 240-42 °C, C21H2SFN204, m/z 405 (M+l).
Example 22 l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro ^-H'-hvdroxy-S', 5,-dimethylpiperidin-l-yl)-4- oxo-quinoline-3-carboxyUc acid.
It was prepared according to procedure described in example 19 where 4-hydroxy-3, 5- dimethylpiperidine was used in place of 4-(N-dimethylamino)-3-methylpiperidine. Yield 27 %, m.p 230-32 °C, C2ιH27FN304, m/z 405 (M+l).
Example 23 l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(3,-methylpiperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid. It was prepared in a similar manner as described in example 19 where 3-methyl piperazine was used in place of 4-(N-dimethylamino)-3-methylpiperidine. Yield (48 %), m.p 260-61 °C, Cι9H22FN304, m/z 375 (M+l).
Example 24
5-Amino-l-cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(cis-4'-aιnino-3', 5'-dimethylpiperidin- l-yl)-4-oxo-quinoUne-3-carboxylic cid.
The condensation of 5-amino-l-cyclopropyl-6, 7-difluoro -1, 4-dihydro- 4-oxo-quinoUne-3- carboxylic acid with cis-4-amino-3, 5-dimethylpiperidine in a simUar manner as described in example 1 gave the titled product. Yield 37 %, m.p 248-50 °C, C2ιH27FN404, m/z 419 (M+l).
Example 25 l-Cvclopropyl-6,8-difluoro-5-methyl-l,4-dihvdro -7-(4'-hvdroxy-3f-aminomethyl piperidin-l-yl)-4- oxo-ouinoUne-3-carboxyUc acid.
It was prepared in a simUar manner as described in example 24 where 4-hydroxy-3- aminomethylpiperidine was used in place of cis-4-amino-3, 5-dimethylpiperidine. Yield 42 %, m.p 270-75 °C, C2oH23F2N304, m/z 408 (M+l).
Example 26
5-Amino-l-cvclopropyl-6, 8-difluoro-l, 4-dihydro -7-(5^amino-2'-methyl-pyrroUdin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid.
The condensation of 5-amino-l-cycIopropyl-6, 7, 8-trifluoro -1, 4-dihydro- 4-oxo-quinoUne-3- carboxylic acid with 5-amino-2-methyl-pyrroUdine in a simUar manner as described in example 1 gave the titled product Yield 40 %, m.p 224-30 °C, ClsH2oF2N403, m z 379. (M+l)
Example 27 5-Amino-l-cvclopropyl-6, 8-difluoro-l, 4-dihvdro -7 3'-(L-Ala-L-Ala amino) pyrroUdin-l-yll-4- oxo-quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 26 where 3-(L-Ala-L-Ala amino) pyrroUdine was used in place of 5-amino-2-methyI-pyrrotidine. Yield SO %, m.p 234-36 °C, C23H27F2N6Os, m/z 506. (M+l) Example 28
5-Amino-l-cvclopropyl-6, 8-difluoro-l, 4-dihvdro -7-f4'-(N-di-n-butyIamino^ piperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 26 where 4-(N-di-n-butylamino) piperidine was used in place of 5-amino-2-methyl-pyrrolidine. Yield (63%), m.p >320 °C, C26H36F2N4θ3, m/z 491. (M+l)
Example 29 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihvdro -7-{4'-(-t-butoxycarbonyl amino-L-Ala-L-Ala) aminopiperidin-l-yll-4-oxo-quinoline-3-carboxylic acid.
A mixture of 5-amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{4-aminopiperidin-l-yl}-4-oxo- quinoUne-3-carboxyUc acid (200 mg, 0.52 mmole), t-butoxycarbonyl amino-L-Ala-L-Ala (134 mg, 0.52 mmole) and 2-ethoxy-N-ethoxycarbonyl-l,2-dihydroquinoUne (EEDQ) (128 mg 0.52 mmole) in dry methylene dichloride for 2hr, washed with water (10 ml) and organic layer was separated, dried over sodium sulphate and concentrated to give titled product Yield 54 % , m.p 164-68 C, C29H39F2N607, m z 622 (M+l).
Example 30
5-Amino-l-cvclopropyl-6, 8-difluoro-l, 4-dihvdro -7-(4'- propionoxy piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 26 where 4- propionoxy piperidine where was used in place of 5-amino-2-methyl-pyrrolidine.
Yield 46 %, m.p 224-26 °C, C2ιH23F2N305, m/z 436. (M+l)
Example 31
5-Amino-l-cvclopropyl-6, 8-difluoro-l, 4-dihvdro -7-(4'-hydroxy-3', 3'-dimethyl-piperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 26 where 4 -hydroxy-3, 3- dimethylpiperidine was used in place of 5-amino-2-methyl-pyrrolidine Yield 71 %, m.p 236-38 °C, C2oH23F2N3θ4, m/z 408. (M+l) Example 32
5-Amino-l-cvcIopropyl-6, 8-difluoro-l, 4-dihvdro -7-{4'-( -pyrroUdinyl) piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 26 where 4-(l-pyrroUdinyl) piperidine was used in place of 5-amino-2-methyl-pyrrolidine Yield 59%, m.p 224-26 °C, C22H26F2N403, m z 433. (M+l)
Example 33 5-Amino-l-cvclopropyl-6, 8-difluoro-l, 4-dihvdro -7-{4'-[N-(piperidin-4-yl) aminomethyll- piperidin-l-yl)-4-oxo-quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 26 where 4 -[N-(piperidin-4-yl) aminomethyl]piperidine was used in place of 5-amino-2-methyl-pyrroUdine. Yield 60 %, m.p 300(d) °C, C24H3ιF2N503, m/z 476. (M+l)
Example 34
5-Amino-l-cvclopropyl-6, 8-difluoro-l, 4-dihvdro -7-{N-l-2',2', 6,,6,-pentamethyllpiperidin-4- yl)methylamino-4-oxo-quinoUne-3-carboxylic acid and its salt.
It was prepared in a simUar manner as described in example 26 where amino- [N-l,N-4-2,2,6,6- hexamethyl]piperidine was used in place of 5-amino-2-methyI-pyrroUdine. Yield 41 %, m.p 200-02 °C, C24H32F2N403, m/z 463. (M+l)
Example 35
5-Amino-l-cvclopropyl-6,8-difluoro-l, 4-dihvdro -7-(3',5'-dimethyl morphoUn-l-yl)-4-oxo- quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 26 where 3,5-dimethyl morpholine was used in place of 5-amino-2-methyl-pyrroUdine. Yield 30 %, m.p 286-88 °C, Cι9H21F2N30 , m/z 412. (M+l)
Example 36
5-Aτnino-l-cvclopropyl-6, 8-difluoro-l, 4-dihvdro -7-(4'- cyclopropyl piperazin-l-vD-4-oxo- quinoUne-3-carboxyUc acid. It was prepared in a similar manner as described in example 26 where 4 -cyclopropyl piperazine was used in place of 5-amino-2-methyI-pyrroUdine Yield 46%, m.p 260(d) °C, C20H22F2N4O3, m/z 485. (M+l)
Example 37
5-Amino-l-cvclopropyl-6, 8-difluoro-l, 4-dihvdro -7-(3'.5'-dimethyl-4-pivaIoyl piperazin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 26 where 3,5-dimethyl-4-pivaloyl piperazine was used in place of 5-amino-2-methyl-pyrrolidine. Yield 30%, m.p 290-94 °C, C24H25F2N4O4, m/z 472 (M+l).
Example 38
Ethyl 6,8-Difluoro-7-(4-hvdroxypiperidin-l-yl)-l-(l-phenylthio-3(ιS,)-but-3-vIVl,4-dihvdro-4-oxo- quinoUne-3-carboxylate
A mixture of ethyl 6,7,8-trifluoro-l-(l-phenylthio-3( )-but-3-yl)-l,4-dihydro-4-oxo-quinoline-3- carboxylate (100 mg, 0.229 mmol), 4-hydroxypiperidine (46 mg, 0.45 mmol) and triethylamine (46 mg, 0.45 mmol) was stirred in acetonitrile (5.0 ml) at 85 °C (bath temperature) for 12 h. After completion of the reaction (monitored by tic), the solvent was evaporated under reduced pressure.
Diluted with water (20 ml) and extracted with chloroform (3 x 30 ml) and evaporated to give the crude product, which on sUica gel column purification using 5 % MeOH in chloroform gave 100 mg (84 %) of the product as viscous liquid. *H NMR (200 MHz, CDC13): δ 1.40 (t, J= 7.0 Hz, 3H, - CH2CH3), 1.60 (d, = 6.0 Hz, 3H, -CHCH3), 1.65-1.81 (m, 4H, 2 x -CH2-), 1.95-2.15 (4H, 2 x -CH2- ), 2.70 (quint., IH, H-C2'), 2.90 (quint, IH, H-C2'), 3.09-3.10 (m, 2H, -CH2S-), 3.80-3.98 (m, IH, - CHOH), 4.39 (q, 2H, -CH2CH3), 5.20-5.39 (m, IH, -CHCH3), 7.20 (s, 5H, arom), 7.95 (dd, J=12.5, 2.0 Hz, IH, H-C5), 8.45 (s, IH, H-C2); ( ESMS m/z 517 (Mϊ , 100 %).
Example 39 l- '-Trifluoromethylphenyl) -6-fluoro-l, 4-dihvdro- -7-C3'.3', 4' -trimethylpiperazin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid
The condensation of with l-(2'-trifluoromethylphenyl) -6, 7-difluoro-l, 4-dihydro-4-oxo-quinoUne- 3-carboxylic acid 3,3,4 -trimethylpiperazine in a simUar manner as described in example 1 gave the titled product. Yield 24%, m.p 238-42°C, C24H23F4N3O2, m/z 478. (M+l)
Example 40 5-Amino-l- (2'-trifluoromethylphenyI)-6,8-difluoro-l, 4-dihvdro -7-(morpholin-l-yl -4-oxo- quinoUne-3-carboxyUc acid.
The condensation of 5-amino-l-(2'-trifluoromethylphenyl) -6, 7, 8-trifluoro-l, 4-dihydro-4-oxo- quinoUne-3-carboxyUc acid with morpholine in a simUar manner as described in example 1 gave the titled product. Yield 52 %, m.p 228-30 °C, C2ιHι6F5N3O4, m/z 470. (M+l)
Example 41
5-Amino-l- (2'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihvdro -7-(3,,5,-dimethylmorpholin-l- yl)-4-oxo-quinoline-3-carboxyUc acid.
It was prepared in a similar manner as described in example 39 where 3,5-dimethyl morpholine was used in place morphoUne. Yield 49%, m.p 270-72 °C, C23H2oFsN3O4, m/z 498. (M+l)
Example 42
5-Amino-l- (2'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihvdro -7-(3',5'-dimethyl piperizine-1- yl)-4-oxo-quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 39 where 3,5-dimethyl piperazine was used in place of morpholine. Yield 60 %, m.p 190(d) °C, C23H2ιFsN4O3, m/z 497. (M+l)
Example 43
5-Amino-l- (4'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihvdro -7-(3,-aminopyrrolidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 39 where 3-amino pyrroUdine was used in place of morphoUne. Yield 50 %, m.p 258-60 °C, C21HnFsN4O3, m/z 469 (M+l).
Example 44
l-(4VFluorophenyl) -6-fluoro-l.4-dihvdro -7-{4'-ethylamino) piperidin-l-yl)-4-oxo-qninoline-3- carboxylic acid.
The condensation of l-(4'-fluorophenyl) -6, 7-difluoro-l, 4-dihydro -4-oxo-quinoUne-3-carboxyUc acid with 4-ethylaminopiperidine in a simUar manner as described in example 1 gave the titled product. Yield 51 %, m.p 270-72°C, C23H23F2N3O3, m z 428. (M+l) Example 45
l-(2', 4,-Difluorophenyl) -6-fluoro-l, 4-dihydro-7-( 3', 5'-dimethylpiperidin-l-ylV4-oxo-ouinoUne- 3-carboxylic acid.
The condensation of with l-(2', 4'-difluorophenyl)-6, 7-difluoro-l, 4-dihydro-4-oxo-quinoUne-3- carboxylic acid with 3, 5-dimethylpiperidine in a similar manner as described in example 1 gave the titled product. Yield 43%, m.p 224-26 °C, C23H21F3N203, m/z 431. (M+l) Example 46
5-Amino-l- (2f, 4'-difluorophenyl) -6, 8-difluoro-l, 4-dihvdro -7-(3,-hvdroxy-5f-methylpyrrolidin- l-yl)-4-oxo-quinoline-3-carboxylic acid.
The condensation of 5-Amino-l- (2', 4'-difluorophenyl) -6, 7, 8-trifluoro-l, 4-dihydro -4-oxo- quinoUne-3-carboxyUc acid with 3-hydroxy-5-methylpyrroUdine in a similar manner as described in example 1 gave the titled product. Yield 64%, m.p °C, C2ιH17F4N3θ4, m/z 453. (M+l)
Example 47
5-Amino-l- (2,,4'-difluorophenyl) -6, 8-difluoro-l, 4-dihvdro -7-f3\3,-dimethyl piperazin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 45 where 3,3-dimethyl piperazine was used in place of 3-hydroxy-5-methylpyrroUdine. Yield 41 %, m.p 212-14 °C, C22H2oF4N4O3, m z 465. (M+l)
Example 48
l-Cvclopropyl-6-fluoro-l.4-dihvdro -7-l(3'-aminoethoxycarbonyl)pyrroUdin-3-yl}-4-oxo- naphthyridine-3-carboxylic acid.
l-cyclopropyl-6, 7-difluoro-l, 4-dihydro-4-oxo-naphthyridine-3-carboxyUc acid (O.lg, 0.32 mmole) and (3-N-ethoxycarbonyl) aminopyrroUdine (0.14g, 14 mmole) in acetonitrU (5ml) was stirred at 80 °C for 4 hr and cooled. Solvent was concentrated to dryness. Water (25 ml) was added to reaction mixture and soUd obtained was purified to give the required product. Yield 23%, m.p.254-56 °C, C19H21FN4O5, m/z 406. (M+l) Example 49
l-CvcIopropyl-6-fluoro-l.4-dihvdro -7-fpyrroUdin-3-yl-amino)-4-oxo-l,8naphthyridine-3- carboxylic acid.
It was prepared in a similar manner as described in example 47 where 3-aminopyrrolidin was used in place of (3-N-ethoxycarbonyl) aminopyrroUdine. Yield 42%, m.p 122-24 °C, Cι6HπFN4O3, m/z 333. (M+l)
Example 50
l-(2', 4'-Difluorophenyl) -6-fluoro-l, 4-dihvdro -7-(piperidin-4-yl-amino)-4-oxo-l,8-naphthyridine- 3-carboxylic acid.
Ethyl 1- (2,4-difluorophenyl) -6,7-difluoro-l,4-dihydro-4-oxo-naphthyridine-3-carboxyIate (0.5 g, 1.3 mmole) and (3-N-ethoxycarbonyl) aminopyrroUdine (0.3 g, 1.74 mmole) in acetonitril (5 ml) was stirred at 80 °C for 3 hr and cooled. Solvent was concentrated to dryness and 5% aqueous sodium hydroxide (10ml) was added to reaction mixture and stirred for 2 hr, acidified with cone, hydrochloric acid soUd separated was filtered and dried to furnish the required product. Yield 74%, m.p >320 °C, C2oHi7F3N4O3, m/z 419. (M+l)
Example 51
Ethyl-1- (2', 4,-difluorophenyl) -6-fluoro-l, 4-dihvdro -7 floc,5oc,6ocl-3-N-benzyl-3-azabicyclo [3.1.01 hex-6-yl-amino -4-oxo-l,8-naphthyridine-3-carboxylate and its salt.
Ethyl 1- (2,4-difluorophenyl) -6,7-difluoro-l, 4-dihydro-4-oxo-naphthyridine-3-carboxylate (2 g, 5.2 mmole) and 6-amino- (loc, 5<x, 6oc)-3-N-benzyl-3-azabicyclo [3.1.0] hexane (1.16 g, 5.1 mmole) in acetonitrile (5 ml) was stirred at 80 °C for 3 hr and cooled. Solvent was concentrated to dryness and added water (15ml); soUd separated was filtered and dried to furnish the required product. Yield 36%, m.p 187-90 °C, C29H25F3N4O3, m/z 535. (M+l)
Example 52
Ethyl 6-fluoro-7-[l-Phenyl-4,5,6,7-tetrahvdropyrazolo[4.3-c]pyridin-l-yll-l-(2,4-difluorophenyl)- 4-oxo-l,4-dihvdro-l,8-naphthyridine-3-carboxyIate A mixture of ethyl-l-(2,4-difluorophenyl)- 6,7-difluoro-4-oxo-l,4-dihydro-l,8-naphthyridine-3- carboxylate(500 mg, 1.30 mmol), l-phenyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine (200 mg, 1.30 mmol) and triethylamine (260 mg, 2.61 mmol) was stirred in acetonitrUe (5.0 ml) at 85 °C (bath temperature) for 6 hr. Solvent was concentrated to dryness. Added water (20 ml) and extracted with chloroform (3 x 30 ml). Organic layer was separated, dried and removed to give crude product which was purified on siUca column to give titled product as a yellowish soUd. Yield 70 %, m.p 85-90°C, ESMS m/z 546 (MIT, 100 %).
Example 53 (S)-(-)-9-Fluoro-6.7-dihydro-8- (4'-carboxamidopiperidin-l-yl)-5-methyl-l-oxo-lH, 5H-benzo [i,il quinoUzine-2-carboxylic acid.
(O-B)-diacetoxy- {S- (-)-8,9-difluoro-5-methyl-6,7-dihydro -l-oxo-lH,5H-benzo[i,j] quinoUzine-2- carboxylic acidjborane was heated with 4-carboxamidopiperdine in acetonitrile for 6hr solvent was removed and borate complex was decomposed using 10ml of 5% aqueous sodium hydroxide and stirred for 2hr, acidified with cone, hydrochloride. Solid separated was filtered, dried and purified on sUica column to furnish required product Yield 34 %, m.p 0C, C20H22FN3O4, m z 388 (M+l).
Example 54
fS)-(-1-9-FIuoro-6.7-dihydro-8- (4,-hvdroxypiperidin-l-vI)-5-methyl-l-oxo-lH.5H-benzofi,i? quinoUzine-2-carboxylic acid L-arginine salt.
To a stirred suspension of (S)-(-)- 9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l- oxo-lH,5H-benzo[i,j]quinoUzine-2-carboxylic acid (5 g, 0.0138 m) in acetone (50 ml) was added finely powdered L-arginine (2.51 g, 0.0138 m) then distiUed water (20 ml) was added to it. Reaction mixture was warmed on water bath and two times water (5 ml) was added to it at the interval of 10 min. Clear solution was stirred for lhr. Solvent was removed under high vacuum and soUd was dried overnight under high vacuum to furnish title product. Yield 96%, m.p 234-37
°C, C25H35FN6O6, m/z) 535. (M+l)
Example 55
fSVf-V9-Fluoro-6.7-dihvdro-8-(4,-hvdroxy-3,,3'-dimethylpiperidin-l-ylV5-methyl-l-oxo-lH,5H- benzo Fi-.il quinoUzine-2-carboxylic acid. It was prepared in a similar manner as described in example 51 where 4-hydroxy-3, 3- dimethylpiperidine was used in place 4-carboxamidopiperdine. Yield 42%, m.p 220 °C, C2ιH25FN2O4, m/z 389. (M+l)
Example 56
(S)-(-)-N-methylpiperidino-9-fluoro-6,7-dihvdro-8-(4,-hvdroxypiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo[i,ilquinoUzine-2-carboxylate.
A mixture of (S)-(-) -9-fluoro-6.7-dihydro-8- (4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH, 5H- benzo[i,j]quinoUzine-2-carboxylic acid a (0.5 g, 1.38 mmole), N,N-dimethylamino pyridine ( 0.203 g, 1.66 mmole), N,N-dicyclohexylcarbodiimde (0.286 g, 1.38 mmole), triethylamine (0.2 ml, 1.9 mmole), N-methyl-4-hydroxypiperidine (0.192 g, 1.66 mmole) were dissolved in N,N- dimethylacetamide (20 ml) stirred at 100 °C for 24hr. Reaction mixture was cooled to room temp. and diluted with ethyl acetate (50 ml). Washed with 0.5N hydrochloride acid and saturated sodium bicarbonate. Organic layer was dried over sodium sulphate. Solvent removed and solid obtained was purified over sUica column to furnish title product. Yield 56 %, m.p 170-75 °C, C25H32FN3O4, m/z 458. (M+l)
Example 57
Ethoxy carbonylmethyl (R)-(+)- 9-fluoro-6,7-dihydro-8-(4'-hvdroxypiperidin-l-yl)-5-methyl-l- oxo-lH,5H-benzo [i,j 1 quinolizine-2-carboxylate.
A mixture of (R)-(+)- 9-fluoro-6.7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid (0.5 g, 1.388 mmole) and anhydrous potassium carbonate (0.192 g, 1.39 mmole) was suspended in dry N,N-dimethylformamide (20 ml) stirred at 50 °C for 7hr. Ethylbromoacetate (0.35 g, 2.08 mmole) was added and reaction mixture was stirred for 17hr. Solvent was removed and extracted with chloroform (25ml x 2). Organic layer was dried and solid obtained was crystaUized from chloroform: hexane (2:8) to furnish the title product. Yield 71 %, m.p 130-35 °C, C23H27FN2O6, m/z 447. (M+l)
Example 58
(Sl-f-)-MorphoUnoethyl-9-fluoro-6.7-dihvdro-8- (4'-hvdroxypiperidin-l-yl)-5-methyl-l-oxo-lH, 5H-benzo fi-.il quinolizine-2-carboxyUate. A mixture of (S)-(-) -9-fluoro-6.7-dihydro-8- (4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH, 5H- benzo[i,j]quinoUzine-2-carboxylic acid a (0.5 g, 1.38 mmole), N,N-dimethylamino pyridine ( 0.203 g, 1.66 mmole), N,N-dicyclohexylcarbodiimde (0.286 g, 1.38 mmole), triethylamine (0.2 ml, 1.9 mmole), N-(2-hydroxyethyl)morphoUne (0.218 g, 1.66 mmole) were dissolved in N,N- dimethylacetamide (20 ml) stirred at 100 °C for 24 hr. Reaction mixture was cooled to room temp, and diluted with ethyl acetate (50 ml). Washed with 0.5N hydrochloride acid and saturated sodium bicarbonate. Organic layer was dried over sodium sulphate. Solvent removed and solid obtained was purified over sUica column to furnish title product. Yield 58 %, m.p 245-50 °C, C25H32FN3Os, m/z 474. (M+l)
Some Preferred Compounds of the Invention Displaying Inhibition of the Efflux Pumps of Pseudomonas aeruginosa 23587 and E.coli 2051
Example 1 l-Cvclopropyl-6-fluoro-l, 4-dihvdro-5-methyl- 7-(4,-methoxypiperidin -l-yl)-4-oxo-quinoline-3- carboxylic acid.
A mixture of l-cyclopropyl-6, 7-difluoro-l, 4-dihydro-5-methyl- -4-oxo-quinoline-3-carboxylic acid (500 mg, 1.3 mmole), 4-methoxypiperidin -1-yl (600 mg, 5 mmole) and triethylamine (0.2 ml) in dimethyl sulfoxide (5 ml) was stirred at 140 °C for 24 hr and cooled. Solvent was concentrated to dryness triturated with water (25 ml) soUd thus separated was filtered and dried to furnish the required product. Yield 57 %, m.p 130-38 °C, C20H23FN2O4, m z 375 (M+l).
Example 2 7-Bromo-l-cvclopropyl-6-fluoro-5-methyl-l, 4-dihydro-4-oxo-quinoline-3-carboxyUc acid and its salts.
The preparation of the compound is described in PCT WO 89/06649.
Example 3 l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(4'-amino-3'-methylpiperidin-l-yl)-4-oxo- qninoUne-3-carboxyUc acid.
A mixture of [l-cyclopropyl-6,7-difluoro-l,4-dihydro-8-methoxy-4-oxo-quinoline-3-carboxylate- O3,04] difluoroboron chelate (0.1 g, 0.29 mmole) and 4-amino-3-methyl piperidine (0.2 g, 1.75 mmole) in acetonitrUe (20 ml) was refluxed for 6 hr. The reaction mixture was concentrated to dryness. The obtained residue was treated with triethylamine (3 ml) and ethanol (15 ml) and refluxed for 16 hr. The resulting mixture was concentrated to dryness; the solid thus obtained was triturated with water (10 ml), filtered, washed with water, dried and purified by preparative HPLC to furnish the required product. Yield 0.04 g (35%), m.p.238-40°C, C20H24FN3O4, m/z 390 (M+l), PMR (CD3OD): 0.84-1.42 (7H, m, 2 X CH2 & CH3), 1.8-2.4 (3H, m, CH & CH2), 3.02 (IH, m, N-CH), 3.18-3.72 (4H, m, 2 X N-CH2), 3.8 (3H, S, OCH3), 4.18 (IH, m, c-CH), 7.82 (IH, d, H-5, J=16 Hz), 8.9 (lH, s, H-2).
Example 4
5-Amino-l-cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(4'-amino-3'-methyl piperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid.
The condensation of 5-amino-l-cyclopropyl-6, 7-difluoro-8-methoxy -1, 4-dihydro- 4-oxo- quinoUne-3-carboxyUc acid with 4-amino-3-methylpiperidine was carried out in a simUar manner as described in example 1, gave the titled product. Yield 50 %, m.p 260-62 °C, C20H2SFN4O4, m/z 405 (M+l).
Example 5
5-Amino-l-cvclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{3'.3'-dimethyl-4'- ethylaminopiperidin-l-yll-4-oxo-quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 4 where 4-ethylamino-3,3- dimethylpiperidine was used in place of 4-amino-3-methylpiperidine. Yield 54 %, m.p 205 °C, C23H31FN4θ4, m z 447 (M+l).
Example 6 l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(4,-amino-3,-3'-dimethylpiperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid.
l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7-{4'-N-benzyloxycarbonyl-amino-3',3'- dimethyIpiperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid (5.5 g, 9.3 mmole) was stirred with
Cone. HCl (75 ml) for 2 hr at 30°C, concentrated to dryness, triturated with acetone and filtered.
The obtained hydrochloride was dissolved in water-methanol, neutraUzed with triethylamine (2 ml), concentrated and crystaUisation from methanol furnished the required product. Yield 3.8 g
(31 %), m.p.256-58 °C, C2ιH26FN304, m/z 404 (M+l). It was prepared in a similar manner as described in Example 3, where 4-amino-3,3- dimethylpiperidine was used in place of 4-amino-3-methylpiperidine. Yield 0.24 g (10%), m.p.258- 60°C, C2ιH26FN3O4, m/z 404 (M+l).
Example 7
l-Cvclopropyl-6-fluoro-8-methoxy-l,4-dihvdro-7-j4'-dimethylaminopiperidin-l-yll-4-oxo- quinoUne-3-carboxyUc acid.
The preparation of the compound is described in US 4822801 Example 8
l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(4'-hvdroxy-4f-methylpiperidin-l-yl)-4-oxo- quinoline-3-carboxyUc acid.
It was prepared in a similar manner as described in example 19 (NorA), where 4-hydroxy-4- methylpiperidine was used in place of 4-dimethylamino-3-methylpiperidine Yield 35 %, m.p 220- 24 °C, C2oH23FN2O5, m z 390 (M+l).
Example 9
l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(3', 3'-dimethyl-4'-hvdroxy-piperidin-l-yl)-4- oxo-quinoline-3-carboxyUc acid.
It was prepared in a similar manner as described in example 19 (NorA), where 4-hydroxy-3, 3- dimethylpiperidine was used in place of 4-dimethylamino-3-methylpiperidine Yield 56 %, m.p 240-42 °C, C2ιH2SFN2Os, m/z 404 (M+l).
Example 10
l-Cvclopropyl-6, 8-diflnoro-5-methyl-l, 4-dihvdro -7-(3'-aminomethyl-4f-hvdroxy- piperidin-1-vD- 4-oxo-quinoline-3-carboxylic acid.
The condensation of l-cyclopropyl-6, 7, 8-trifluoro -5-methyl-l, 4-dihydro- 4-oxo-quinoline-3- carboxylic acid with 3-aminomethyl-4-hydroxy-piperidine was carried out in a simUar manner as described in example 1 gave the titled product. Yield 45.9 %, m.p 270-75 °C, C20H23F2N3O , m/z 408 (M+l). Example 11
5-Amino-l- ιcyclopropyl)-6,8-difluoro-l, 4-dihvdro-7- (3'-aminomethyl-4,-hydroxy- piperidin-1- yl)-4-oxo-quinoline-3-carboxyUc aeid.
The condensation of 5-amino-l-cyclopropyl-6, 7, 8-trifluoro -1, 4-dihydro- 4-oxo-quinoUne-3- carboxylic acid with 3-aminomethyl-4-hydroxy-piperidine was carried out in a simUar manner as described in example 1, gave the titled product. Yield 52.8 %, m.p 202-04 °C, CwH22F2N4O4, m/z 409 (M+l).
Example 12 l-Ethyl-6, 8-difluoro-l, 4-dihvdro -7-(3'-5'-dimethylpiperazin-l-yl)-4-oxo-quinoline-3-carboxyUc acid.
The condensation of l-ethyl-6, 7, 8-trifluoro-l, 4-dihydro-4-oxo-quinoUne-3-carboxylic acid with 3-5-dimethylpiperazine was carried out in a similar manner as described in example 1, gave the titled product. Yield 58 %, m.p 230 °C (d), Ci8H22F2N3O3, m/z 367 (M+l).
Example 13 l-Cyclopropyl-6-fluoro-l, 4-dihvdro-7- (4'-ethyl-3,-methylpiperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid.
The condensation of l-cyclopropyl-6, 7-difluoro-l, 4-dihydro-4-oxo-quinoUne-3-carboxyUc acid with 4-ethyl-3-methylpiperazine was carried out in a similar manner as described in example 1 gave the titled product. Yield 51 %, m.p 200 °C, C20H24FN3O3, m/z 374 (M+l).
Example 14 l-Cyclopropyl-6-fluoro-l.4-dihvdro- -7-(3f-5'-dimethyl-4,-ethylpiperazin-l-ylV4-oxo-quinoUne-3- carboxylic acid.
It was prepared in a similar manner as described in example 13, where 3-5-dimethyl-4- ethylpiperazine was used in place of 4-ethyl-3-methylpiperazine. Yield 79 %, m.p 215-20 °C, C2ιH26FN3O3, m/z 388 (M+l).
Example 15 l-Ethyl-6, 8-difluoro-l, 4-dihvdro -7-1(1 oc, 5oc, 6oc)-6'-amino-3'-azabicvclo [3.1.01 hex-3-yl}-4-oxo- quinoUne-3-carboxyUc acid.
The condensation of (loc, 5oc, 6oc)-6-t-butoxycarbonylamino-3-azabicyclo [3.1.0]-hexane with 1- ethyl-6, 7, 8-trifluoro-l, 4-dihydro-4-oxo-quinoUne-3-carboxyUc acid was carried in similar manner as described in example 1, which on hydrolysis with cone. HCl furnished titled product. Yield 22.4 %, m.p 2243-26 °C, Cι7HπF2N3O3, m/z 350 M+l).
Example 16 5-Amino-l- (2 4'-diflnorophenyl) -6, 8-difluoro-l, 4-dihvdro -7-(3-aminopyrroUdine -l-yl)-4-oxo- guinoUne-3-carboxyUc acid.
The condensation of 5-amino-l- (2', 4'-difluorophenyl) -6, 7, 8-trifluoro-l, 4-dihydro-4- oxo- quinoUne-3-carboxyUc acid with 3-aminopyrrolidine was carried out in a simUar manner as described in example 1, gave the titled product. Yield 71 %, m.p 268 °C (d), C20HwF N4θ3, m z 437 (M+l).
Example 17
5-Amino-l- cvclopropyl-6, 8-difluoro-l, 4-dihydro-7- ((3'-amino ethoxycarbonylpyrroUdin-3-yl)-4- oxo-quinoUne-3-carboxyUc acid.
The condensation of 5-amino-l- cyclopropyl-6, 7, 8-trifluoro-l, 4-dihydro-4- oxo-quinoUne-3- carboxylic acid was carried out with 3-amino ethoxycarbonyl pyrroUdine in a simUar manner as described in example 1 gave the titled product. Yield 68.3 %, m.p 180-84 °C, C2oH2ιF2N4θ5, m/z 437 (M+l).
Example 18
l-CyclopropyI-6-fluoro-l, 4-dihvdro -7-(pyrroUdin-3'-ylamino)-4-oxo-naphthyridine-3-carboxyUc acid.
Prepared according to example 48 in the Ust of compounds for the NorA pump.
Example 19 l-(2', 4,-Difluorophenyl)-6-fluoro-l, 4-dihvdro-7- (piperidin-4,-ylaminoV4-oxo-naphthyridine-3- carboxylic acid. Prepared according to example 49 in the list of compounds for the NorA pump.
Example 20 l-Cvclopropyl-6-fluoro-l, 4-dihvdro -7-(4,-amino-3'-ethylpiperidin-l-yl)-4-oxo-naphthyridine-3- carboxylic acid.
The condensation of l-cyclopropyl-6, 7-difluoro-l, 4-dihydro-4-oxo-naphthyridine-3-carboxylic acid with 4-amino-3-ethylpiperidine was carried out in acetonitrUe in a similar manner as described in example 1, gave the titled product. Yield 71 %, m.p 218-20 °C, Ci9H23FN4θ3, m/z 375 (M+l).
Example 21
S- (-)-9-Fluoro-6, 7-dihydro-8- (4f-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH, 5H- benzo fi.il quinoUzine-2-carboxylic acid 0.2 hydrate.
S- (-)-9-Fluoro-6, 7-dihydro-8- (4'-hydroxypiperidin-l-yl)-5-methyI-l-oxo-lH, 5H-benzo[i,j] quinoUzine-2-carboxylic acid was crystallized from aqueous ethanol to furnish titled product. Yield 75 %, m.p 244-46 °C, d9H2ιFN204, m/z 361(M+1).
Example 22
S- f-V9-Fluoro-6. 7-dihvdro-8-f4f-hvdroxypiperidin-l-vn-5-methyl-l-oxo-lH.5H- benzo[i,ilquinoUzine-2-carboxylic acid, choline salt.
S- (-)-9-Fluoro-6, 7-dihydro-8- (4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH, 5H-benzo[i,j] quinoUzine-2-carboxylic acid (0.5 g, 1.388 mmole) was dissolved in methanol (50 ml) to it was added 45 % w/w solution of choline base (0.374 ml, 1.388 mmole) and stirred at 50 °C for 5 hr, and concentrated to dryness. Yield 80 %, m.p 190-92 °C, C24H35FN306, m/z 482 (M+l)
Example 23
S- (-)-9-Fluoro-6, 7-dihvdro-8-(4,-hvdroxypiperidin-l-ylV5-methyl-l-oxo-lH. 5H- benzofi,τlquinoUzine-2-carboxylic acid, 1-hvdroxyethvIpyrroUdine salt.
It was prepared according to procedure described in example 22, where 1-hydroxy ethylpyrroUdine (0.156 g, 1.388 mmole) was used in place of choline base. Yield 78 %, m.p 252 °C, C2SH33FN305, m z 476 (M+l). Example 24
S- (-V9-Fluoro-6.7-dihvdro-8- r4f-hvdroχypiperidin-l-vn-5-methyl-l-oxo-lH.5H- benzo[i,i1quinoUzine-2-carboxyUc acid, diethanolamine salt.
It was prepared according to procedure described in example 22, where diethanolamine (0.146 g, 1.388 mmole) was used in place of choline base. Yield 57 %, m.p 255-60 °C, C23H3ιFN306, m z 466 (M+l)
Example 25 (S)-(-)- 9-Fluoro-6.7-dihvdro-8- f4,-hvdroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,i1quinolizine-2-carboxylic acid (L) histidine salt.
It was prepared according to procedure described in example 22, where L-histidine (0.21 g, 1.38 mmole) was used in place of choline base. Yield 98 %, m.p 278-84 °C, C3ιH39FNsO8, m/z 671 (M+l)
Example 26
(RSV(±)-9-Fuoro-6. 7-dihvdro-8- {4'-(D-phenylalaninoxy) piperidin-l-yll-5-methyl-l-oxo-lH, 5H- benzo[i,i1quinolizine-2-carboxylic acid hydrochloride.
(RS)-(±)-9-Fuoro-6, 7-dihydro-8-(4-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH, 5H-benzo[i,j] quinolizine-2-carboxyUc acid (360 mg, 1mm), and triethylamine (0.145 ml, 1mm) are dissolved in dimethylacetamide (15 ml. t-Butyloxycarbonyl (D)-phenylalanine (265 mg, 1 mm) and dimethylamino pyridine (125 mg, 1 mm) were added, followed by dicyclohexyl carbodiimide under ice cooUng. Stirred 30 minutes at 0° C then at room temperature overnight. Dicyclohexylurea was filtered and the mixture dUuted with ethylacetate, transferred to a separating funnel, washed with 0.5 N hydrochloric acid, IN sodiumbicarbonate and brine, dried (sodium sulphate) and evaporated to give the t-butoxycarbonyl protected derivative.
Trifluoroacetic acid (10 ml) was added to the derivative obtained, stirred for 30 mins at room temp., the acid was evaporated and the trifluoroacetate salt was precipitated by addition of ether. Purified by RP-HPLC on a C18 column. Dissolved the trifluoroacetate salt in 0.1 N hydrochloride acid and freeze-dried provided the titled salt. Yield 75 %, m.p (hygroscopic) °C, C23H26FN307, m/z 543 (M+l)
Example 27 (RSVf±V9-FIuoro-6.7-dihvdro-8-(4'-rL-α-aspartyloxy)piperidin-l-yl|-5-methyl-l-oxo-lH,5H- benzofi.ilquinoUzine-2-carboxyIic acid hydrochloride.
It was prepared according to procedure described in example 26, where t-butoxycarbonyl (L)- asparticacid ( 133 mg, 1 mmole) was used in place t-Butyloxycarbonyl (D)-phenyIaIanine Yield 90 %, m.p (hygroscopic) °C, C23H26FN307, m/z 671 (M+l)
Example 28
(RS)-(+V9-Fluoro-6.7-dihvdro-8- (4,-ιL-leucyloxy)piperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,ilquinoUzine-2-carboxyUc acid hydrochloride.
It was prepared according to procedure described in example 26, where t-butoxycarbonyl (L)- asparticacid ( 131 mg, 1 mmole) was used in place t-Butyloxycarbonyl (L)-leucine. Yield 43 %, m.p 166 °C, C25H32FN305, m z 475.5 (M+l)
Example 29
fS)-(-)-9-Fluoro-6,7-dihvdro-8- (4,- )-leucyloxy piperidin-l-yl -5-methyl-l-oxo-lH,5H- benzofi,ilquinolizine-2-carboxylic acid hydrochloride.
It was prepared according to procedure described in example 26, where t-butoxycarbonyl (L)- asparticacid ( 131 mg, 1 mmole) was used in place t-Butyloxycarbonyl (D)-phenylalanine. Yield 94 %, m.p 220-23 °C, C2SH32FN3Os, m/z 671 (M+l)
Example 30
fSVf-V9-Fluoro-6,7-dihvdro-8- (4f-ιL-alanyloxy piperidin-l-vU-5-methyl-l-oxo-lH,5H- benzo li.il quinoUzine-2-carboxylic acid hydrochloride.
It was prepared according to procedure described in example 26, where t-butoxycarbonyl (L)- alanine ( 89 mg, 1 mmole) was used in place t-Butyloxycarbonyl (D)-phenylalanine. Yield 95 %, m.p 160-65 °C, C22H26FN305, m/z 467.5 (M+l).
Example 31 (S)-(-)-MorphoUnoethyl-9-fluoro-6.7-dihvdro-8- t4,-hvdroxypiperidin-l-yl)-5-methyI-l-oxo-lH, 5H-benzo[i,ilguinoIizine-2-carboxylate.
Prepared according to example 55 in the list of compounds for the NorA pump.
Example 32
(RVf+)-9.8-fluoro-8-fluoro-6, 7-dihvdro-5-methyl-l-oxo-lH, 5H-benzo ri.il quinoUzine-2- carboxamido phe-lys-OMe
R-Nadifloxacin (285 mg, 1 mmole), and triethylamine (0.145 ml, lmmole) are dissolved in dimethylacetamide (15 ml) . Isobutylchloroformate (0.13 ml, 1 mmole) is added under ice cooling, sirred for 5 min, a solution of S-Phe-S-Lys (2- chlorobenzyloxycarbonyl l)-methylester trifluoroacetate (0.6 g, 1 mmole) and triethylamine (0.14 ml, lmmole) in dimethylacetamide (10 ml) was added followed by dimethylaminopyridene (125 mg, 1 mmole) and the mixture was stirred at room temperature overnight. The mixture was then diluted with ethyl acetate, transferred in a separating funnel, washed with 0.5 N hydrochloric acid, IN sodium bicarbonate and brine, dried (sodium sulphate) and evaporated to dryness. The above product is dissolved in methanol- acetic acid -water (15-2-2 ml), and chlorobenzyloxycarbonyl protecting group was removed by bubbling hydrogen in presence of Palladium/charcoal. The catalyst was filtered and filtrates evaporated to gave syrup, which solidified on triturating with ether to gave the titled compound. The compound was purified by prep-HPLC using water-acetonitrile-0.1% trifluoroacetic acid system to get after freeze drying a white powder as trifluoro acetate salt. Yield 74 %, m.p 80-82 °C, C30H34F2N4O5, m/z 467.5 (M+l).
Example 33
(RS)-f+)-9-Fluoro-6. 7-dihvdro-8- (trans-4,-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l-oxo-lH, 5H-benzo fi.il quinoUzine-2-carboxyUc acid.
(0-B)-diacetoxy-{RS- (±)-8,9-difluoro-5-methyl-6, 7-dihydro -1-oxo-lH, 5H-benzo[i,j] quinoUzine- 2-carboxyIic acid}borane (471 mg, 1.15 mmole) was heated with trans-4-hydroxy-3- methylpiperidine (400 mg, 3.47 mmole) in acetonitrile (15 ml) for 6 hr, solvent was removed, and borate complex was decomposed using of 5% aqueous sodium hydroxide (10ml) and stirred for 2 hr, acidified with cone, hydrochloric acid. SoUd separated was filtered, dried and purified on sUica column to furnish titled product. Yield 66 %, m.p 150-52 °C, C20H23FN2O4, m/z 375 (M+l). Example 34
(RS)-(±V9-Fluoro-6.7-dihvdro-8- fcis-4,-hvdroxy-3'-methylpiperidin-l-vR-5-methyl-l-oxo-lH,5H- benzo [i,i1 quinoUzine-2-carboxylic acid.
It was prepared according to procedure described in example 33, where cis-4-hydroxy-3- methylpiperidine was used in place of trans-4-hydroxy-3-methylpiperidine. Yield 48 %, m.p 146- 48 °C, C20H23FN2O4, m/z 375 (M+l).
Example 35
S-(-)-9-Fluoro-6, 7-dihvdro-8- (trans-4>-hvdroxy-3'-methylpiperidin-l-yll-5-methyl-l-oxo-lH, 5H- benzo [i,il quinoUzine-2-carboxylic acid.
It was prepared according to procedure described in example 33, where (O-B)-diaeetoxy-(S)-(-)- 8,9-difluoro-5-methyl-6, 7-dihydro -1-oxo-lH, 5H-benzo[i,j] quinolizine-2-carboxyUc acid}borane was used in place of OB diacetoxy was used in place of (O-B)-diacetoxy-(RS- (±)-8,9-difluoro-5- methyl-6, 7-dihydro -1-oxo-lH, 5H-benzo[ij] quinolizine-2-carboxyUc acid}borane. Yield 42 %, m.p 184-86 °C, C20H23FN2O4, m/z 375 (M+l).
Example 36
7H-Pyridofl,2,3-del-l,4-benzoxazine-9-fluoro-2, 3-dihvdro-3-methyl-10- (4'-hvdroxy-3'- ethylpiperidin-l'-yl)-7-oxo-6-carboxylic acid.
The condensation of 7H-pyrido[l,2,3-de]-l,4-benzoxazine-9, 10-difluoro-2, 3-dihydro-3-methyl-7- oxo-6-carboxylic acid with 4-hydroxy-3-ethylpiperidine was carried out in a simUar manner as described in example 1, gave the titled product. Yield 86 %, m.p 178-80 °C, C20H23FN2O5, m/z 391 (M+l).
Example 37
10-Fluoro-ll- Kloc, 5oc, 6oc )-6-amino-3-azabicvclo[3.1.01hex-3yll-3,4-dihvdro-4(SVmethyl-8-oxo- 2H,8H-pyridofl,2,3-ef|-l,5-benzoxazipin-7-carboxylic acid. HCl.
A mixture of 10,ll-Difluoro-3, 4-dihydro-4 (S)-methyl-8-oxo-2H, 8H-pyrido[l,2,3-</e]-l,5- benzoxazepine-7-carboxylic acid (300 mg, 1.017 mmol), 6-amino-3-azabicyclo [3.1.0]hexane (201 mg, 1.017 mmol) and triethylamine (206 mg, 2.03 mmol) was stirred in acetonitrile (5 ml) at 85 °C for 96 hr. After completion of the reaction (monitored by tic), the solvent was evaporated under reduced pressure. Diluted with water (20 ml) and extracted with chloroform (4 x 25 ml). The chloroform extracts were concentrated and the residue was dissolved in 2.0 N HCl (20 ml) and washed with ethyl acetate (2x20 ml) to remove the unreacted material if any. The aqueous layer was filtered and lyophUized to give titled product. Yield 48 %, m.p. 200-204 °C, d9H2ιClFN3O4, m/z 411 (M+l).
Some Preferred Compounds of the Invention Displaying Inhibition of the Efflux Pumps of E.coli 2051
The compounds listed in Table 3 are common with the respective compounds in Table 2. Their preparation is described under the examples for the efflux pump inhibitors described under Pseudomonas aeruginosa.
Some preferred Compounds with EPI activity against Mef pumps of Streptococcus pneumonia 3514 and Streptococcus pyoegenes 26-00
Example 1
l-CvcIopropyl-6-fluoro-8-methoxy-l.4-dihvdro -7-(4'-amino-3'-methyl piperidin-l-vf)-4-oxo- quinoUne-3-carboxyUc acid.
It was prepared as described in example 3 in the list of EPIs active against Pseudomonas aeruginosa.
Example 2
5-Amino-l-cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-{4'-(methylamino)-3'.3'- dimethylpiperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid.
The condensation of 5-amino-l-cyclopropyl-6, 7-difluoro-8-methoxy-l, 4-dihydro- 4-oxo- quinoUne-3-carboxyUc acid with 4-methylamino-3, 3-dimethylpiperidine was carried out in a simUar manner as described in example 1 (NorA), gave the titled product. Yield 54 %, m.p 250 °C, C22H29FN4O4, m/z 433 (M+l).
Example 3 i-Propγl l-cvclopropyI-6-fluoro-8-methoxy-l,4-dihvdro -7-(4'-amino-3',3'-dimethyl- piperidin-1- yl)-4-oxo-quinoline-3-carboxylate.
In a dry dimethylformaide (15 ml) was taken a mixture of l-cyclopropyl-6-fluoro-8-methoxy-l, 4- dihydro -7-(4'-t-butoxycarbonylamino-3', 3'-dimethylpiperidin-l-yl)-4-oxo-quinoline-3-carboxyUc acid (1 g, 1.98 mmole), potassium carbonate (0.275 g, 1.98 mmole) was stirred at 70 °C for 7hr. Added 1-iodopropane (0.5 g, 2.98 mmole) to reaction mixture and stirred at the same temperature for 16hr. Solvent was concentrated up to dryness and (15 ml) water was added to it and extracted with chloroform (25 ml x 2). Organic layer was separated, dried, concentrated and the residue was hydrolysied with trifluoroacetic acid in methylene dichloride and purified on sUica column to furnish titled product. Yield 45 %, m.p 140-42 °C, C24H32FN3O4, m/z 446 (M+l).
Example 4
n-Butyl l-cvcIopropyl-6-fluoro-8-methoxy-l,4-dihvdro -7-(4/-amino-3,,3,-dimethyl-piperidin-l-yl)- 4-oxo-quinoUne-3-carboxylate.
It was in a simUar manner as described in example 3, where 1-iodobutane was used in place of 1- iodopropane.Yield 55 %, m.p 120-25 °C, C2SH34FN3O4, m z 460 (M+l).
Example 5
Ethoxycarbonv methyl l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(4'-amino-3', 3'- dimethvIpiperidin-l-yl -oxo-quinoline-3-carboxylate.
It was in a simUar manner as described in example 3, where bromo ethyl acetate was used in place of 1-iodopropane.Yield 87 %, m.p 135-40 °C, C25H32FN3O6, m/z 489 (M+l).
Example 6
Benzyl l-cvclopropyI-6-fluoro-8-methoxy-l, 4-dihvdro -7-(4-N-t-butoxycarbonyl)-amino-3', 3'- dimethylpiperidin-l-ylV4-oxo-quinoline-3-carboxylate. It was in a simUar manner as described in example 3, where benzyl bromide was used in place of 1-iodopropane. Yield 67 %, m.p 152-54 °C,
Figure imgf000076_0001
m/z 594 (M+l).
Example 7
l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(4f-N- t-b^toxycarbonyl-L-al nyl -amino-3,, 3'- dimethylpiperidin-l-vU-4-oxo-quinoline-3-carboxylic acid hydrochloride.
l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-amino-3', 3'-dimethylpiperidin-l-yl}-4-oxo- quinoUne-3-carboxyUc acid(1.0 gm, 2.48 mmole), N- t-butoxycarbonyl-(L)-alanine (0.94 gm, 4.96 mmole) and 2-ethoxy-N-ethyoxycarbonyl dihydro quinoline (EEDQ) (061 gm, 2.48 mmole) were dissolved in dichromethane (300 ml)and the mixture is stirred at room temperature for 48 hr. The mixture is washed with water, separate the layer, dried and concentrated. Product purified by siUca gel column to furnish titled product. Yield 84 %, m.p 170-75 °C, C29H39FN407, m/z 575 (M+l).
Example 8
l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro ^-^'-( yalaninylanMno-S', 3'-dimethylpiperidin- l-yl)-4-oxo-quinoUne-3-carboxylic acid hydrochloride.
l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-(N-t-butoxycarbonyl-L-alanyl) amino-3', 3'- dimethylpiperidin-l-yl}-4-oxo-quinoline-3-carboxyIic acid (0.9 gm ) is hydrolysed with 6N HCl (20 ml) at room temperature for 1 hr. The mixture is concentrated to furnish the titled product. Yield 75 %, m.p 245-50°C, C24H31FN4Os.HCl m/z 475 (M+l).
Example 9
l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(3', 3,-dimethyl-4,-N-(t-butoxycarbonyl-L- valyl)-aminopiperidip-l-yll-4-oxo-quinoUne-3-carboxyUc acid and its salts.
l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-amino-3', 3'-dimethylpiperidin-l-yI}-4-oxo- quinoUne-3-carboxylic acid(1.0 gm, 2.48 mmole), N- t-butoxycarbonyl -(L)-vaIine (1.07 gm, 4.96 mmole) and 2-ethoxy-N-ethyoxycarbonyl dihydro quinoline (EEDQ) (0.61 gm, 2.48 mmole) were dissolved in dichromethane (300 ml)and the mixture is stirred at room temperature for 48 hr. The mixture is washed with water, separate the layer, dried and concentrated. Product purified by siUca gel column to furnish titled product. Yield 37 %, m.p 80-82 °C, C31H43FN407, m/z 603 (M+l). Example 10
l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(3', 3'-dimethyl-4'-L-vaUnyl aminopjperidin-l- yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride.
l-CycIopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-(N-t-butoxycarbonyl-L-vaIyI) amino-3', 3'- dimethylpiperidin-l-yl}-4-oxo-quinoIine-3-carboxyIic acid (0.4 gm) is hydrolysed with 6N hydrochloride acid (20 ml) at room temperature for 1 hr. The mixture is concentrated to furnish the titled product. Yield 75 %, m.p 150-55°C, C26H35FN4O5.HCl m/z 503 (M+l).
Example 11
l-Cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-(4'-(L)-aspartylamino-3f, 3'-dimethyl piperidin- l-yl)-4-oxo-quinoUne-3-carboxyUe acid hydrochloride.
l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-amino-3', 3'-dimethyIpiperidin-l-yI}-4-oxo- quinoUne-3-carboxyUc acid(1.0 gm, 2.48 mmole), N-Boc-L-aspartic acid (1.15 gm, 4.96 mmole) and 2-ethoxy-N-ethyoxycarbonyl dihydro quinoline (EEDQ) (0.61 gm, 2.48 mmole) were dissolved in dichromethane (300 ml)and the mixture is stirred at room temperature for 48 hr. The mixture is washed with water, separate the layer, dried and concentrated. Which was hydrolysed with 6N hydrochloric acid and at room temperature for 1 hr and concentrate to furnish titled product. Yield 54 %, m.p 250-55 °C, C2SH31FN407.HC1 m/z 618 (M+l).
Example 12
l-Ethyl-6, 8-difluoro-l, 4-dihvdro-7- (4 -ethylaminopiperidin-l,-yl)-4-oxo-quinoline-3-carboxylic acid and its salts.
It was prepared in a similar manner as described in example 5 (NorA), where 4-ethyl aminopiperidine was used in place of 3-amino-5-methylpyrrolidine. Yield 44 %, m.p 260-62 °C, C19H24F2N4O3, m/z 395 (M+l)
Example 13
5-Amino-l- cyclopropyl-6, 8-difluoro-l, 4-dihvdro-7- (4,-amino-3'-methylpiperidin-l-ylV4-oxo- quinoUne-3-carboxyUc acid. It was in a simUar manner as described in example 26 in the list of EPIs active against NorA, where 4-amino-3-methylpiperidine was used in place of 5-amino-2-methylpyrrolidine. Yield 55 %, m.p 228-30 °C, Cι9H22F2N406, m/z 393 (M+l).
Example 14
5- Amino-l-cyclopropyI-6, 8-difluoro-l, 4-dihvdro-7-(3,-quinuclidinyl-3,-yl-amino)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
It was prepared in a similar manner as described in example 26 in the Ust of EPIs active against NorA, where 3-aminoquinuclidine was used in place of 5-amino-2-methyl-pyrroUdine. Yield 53 %, m.p 280-82 °C, C20H22F2N4O3, m/z 404 (M+l) Example 15
5-Amino-l-cvclopropyl-6, 8-difluoro-l, 4-dihvdro-7- {(loc, 5oc, 6oc)-6-amino-N-benzyl-3-azabicyclo [3.1.0] hex-6-yl?-4-oxo-quinoUne-3-carboxyUc acid and its salts.
It was prepared in a similar manner as described in example 26 in the Ust of EPIs active against NorA, where {(loc, 5oc, 6oc)-6-amino-N-benzyl-3-azabicyclo [3.1.0] hexane was used in place of 5- amino-2-methyl-pyrrolidine. Yield 75 %, m.p 270-72 °C, C25H24F2N4θ3, m/z 467 (M+l)
Example 16
l-(3'-Fluorophenyl)-6-fluoro -1.4-dihvdro -7-(4,-methylpiperazin-l'-yl)-4-oxo-quinoline-3- carboxylic acid and its salts.
The condensation of l-(3'-fluorophenyl) -6, 7-difluoro-l, 4-dihydro -4-oxo-quinoUne-3-carboxyUc acid with 4-methylpiperazine in a simUar manner as described in example 1 in the list of EPIs active against NorA, gave the titled product. Yield 58 %, m.p 298-02 °C, C2ιHι9F2N303, m/z 400. (M+l)
Example 17
l-(2', 4'-DifluorophenvD-6-fluoro-l.4-dihvdro -7-(4,-ethylaminopiperidin-l,-ylV4-oxo-quinoUne-3- carboxylic acid . It was in a simUar manner as described in example 45 in the Ust of EPIs active against NorA, where 4-ethylamino piperidine was used in place of 3,3-dimethylpiperidine. Yield 62 %, m.p 240- 42°C, C23H22F3N303, m/z 446 (M+l).
Example 18
l-(2'.4'-Difluorophenyl)-6-fluoro-5-methyl-l, 4-dihvdro -7-(4 -aminopiperidin-l,-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
The condensation of 1- (2, 4-difluorophenyl) -6, 7, 8-trifluoro -5-methyl-l, 4-dihydro- 4-oxo- quinoUne-3-carboxyUc acid with 4-aminopiperidine in a similar manner as described in example 1 in the Ust of EPIs active against NorA, gave the titled product. Yield 58 %, m.p 236-38 °C, C22H20F3N3O3, m/z 432 (M+l)
Example 19
l-(2', 4'-Difluorophenyl)-6-fluoro-5-methyl-l, 4-dihvdro -7-(4,-methylaminopiperidin-l,-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts.
It was prepared in a similar manner as described in example 18, where 4-methylamino piperidine was used in place of 4-aminopiperidine. Yield 52%, m.p 204-06 °C, C23H22F3N3θ3, m z 346 (M+l)
Example 20
l-Cvclopropyl-6-fluoro-l, 4-dihvdro-7- (3,-aminopyrrolidin-3,-yl)-4-oxo-l,8-naphthyridine-3- carboxylic acid.
It was prepared in a similar manner as described in example 47 in the Ust of EPIs active against NorA, where 3-amino pyrroUdine was used in place of 3-amino ethoxycarbonylpyrrolidine. Yield 47 %, m.p 120-22 °C, Cι6HπFN403, m/z 323 (M+l)
Example 21
l-CycIopropyl-6-fluoro-l.4-dihydro-7- ((loc, 5oc, 6oc)-6-amino-N-benzyl-3-azabicvclo [3.1.01 hex-6- yll-4-oxo-l,8-naphthyridine-3-carboxyUc acid It was prepared in a similar manner as described in example 47 in the Ust of EPIs active against NorA, where {(loc, 5oc, 6oc)-6-amino-N-benzyl-3-azabicycIo [3.1.0] hexane was used in place of 3- amino ethoxycarbonylpyrroUdine Yield 67 %, m.p 290-92 °C, C24H23FN4θ3, m/z 434 (M+l)
Example 22
l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihvdro-7-(3'-aminopyrroUdin-3'-yl> 4-oxo-l,8- naphthyridine-3-carboxyUc acid.
It was prepared in a simUar manner as described in example 49 in the Ust of EPIs active against NorA, where 3-amino pyrroUdine was used in place of 4-amino ethoxycarbonylpiperidine. Yield 97 %, m.p 268-70 °C, C2ιHι9F3N403, m/z 433 (M+l)
Example 23 l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihvdro-7- ((loc, 5oc, 6oc)-6-amino-N-benzyl-3-azabicvclo [3.1.01 hex-6-yl - 4-oxo-l,8-naphthyridine-3-carboxylic acid.
It was prepared in a similar manner as described in example 49 in the Ust of EPIs active against NorA, where {(loc, 5oc, 6oc)-6-amino-N-benzyl-3-azabicyclo [3.1.0] hexane was used in place of 4- amino ethoxycarbonypiperidine. Yield 74 %, m.p 236-38 °C, C27H2ιF3N403, m/z 507 (M+l)
Example 24
l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihvdro-7- (3', 3,-dimethyl-4,-hydroxypiperdin-l-yl)-4-oxo- naphthyridine-3-carboxylic acid.
It was prepared in a similar manner as described in example 49 in the Ust of EPIs active against NorA, where 4-hydroxy-3', 3'-dimethyIpiperidine was used in place of 3-amino ethoxycarbonylpyrroUdine Yield 76 %, m.p 194-98 °C, C22H20F3N3O4, m/z 448 (M+l)
Example 25
(RS)-(±V9-Fluoro-6. 7-dihvdro-8- (4'-(X-α-aspartyloxV> piperidin-l-yl -5-methyl-l-oxo-lH.5H- benzofi,ilquinoUzine-2-carboxylic acid hydrochloride. It was prepared in a simUar manner as described in example 51 in the Ust of EPIs active against NorA, where 4-(L-α-aspartyloxy) piperidine was used in place of 4-carboxamidopiperidine. Yield 68 %, m.p 210-12 °C, C23H26FN307, m/z 513 (M+l).
Example 26
7H-Pyridofl.2.3-del-l,4-benzoxazine-9-fl^oro-2, 3-dihvdro-3-methvI-10- (4,-hydroxy-3,- ethylpiperidin-l,-yl)-7-oxo-6-carboxylic acid.
It was prepared as described in example 35 in the list of EPIs active against Pseudomonas aeruginosa.
Example 27
7H-Pyridofl,2.3-del-l,4-benzoxazine-9-fluoro-2, -dihydro-3-methyl- 0- (3'-amino methyl-4'- hvdroxypiperidin-l'-yl)-7-oxo-6-carboxyUc acid.
It was prepared in a similar manner as described in example 26, where 3-aminomethyI-4- hydroxypiperidine was used in place of 4-hydroxy-3-ethylpiperidine. Yield 69 %, m.p 278-80 °C,
Ci9H22FN3Os, m z 392 (M+l).
Example 28
l-Cyclopropyl-6, 8-difluoro-5-methyl-l, 4-dihvdro -7-(3', 3'-dimethyl-4'-ethylaminopiperidin-l-ylV 4-oxo-quinoline-3-carboxylic acid.
It was prepared in a similar manner as described in example 10 of Pseudomonas aeruginosa, where 3, 3-dimethyl-4-ethyIaminopiperidine was used in place of 3-aminomethyI-4- hydroxypiperidine. Yield 52 %, m.p 156-58 °C, C23H30FN3O3, m/z 415 (M+l).
Example 29 l-cyclopropyl-6,7, 8-trifluoro-5-methyl-l, 4-dihvdro - 4-oxo-quinoUne-3-carboxyUc acid.
Known compound (PCT WO 89/06649)
Example 30 (S)-f-V9-Fluoro-6.7-dihvdro-8- (3,. 3,-dimethyl-4,-ethylaminopiperidin-l-vn-5-methyl-l-oxo-lH, 5H-benzo fi.i[quinoUzine-2-carboxyUc acid.
It was prepared in a similar manner as described in example 51 in the Ust of EPIs active against NorA, where 3, 3-dimethyl-4-ethylaminopiperidine was used in place 4-carboxamidopiperidine. Yield 51%, m.p 302-04 °C, C23H30FN3O3, m/z 415. (M+l)
Example 31
l-Cvclopropyl-6-fluoro-l, 4-dihvdro-7- (3'-aminomethyl-4'-hvdroxypiperidin l-yl)-4-oxo- quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 13 in the Ust of EPIs active against Pseudomonas aeruginosa, where 3-amino methyl-4-hydroxypiperidin was used in place 4-ethyl-3- methylpiperazine. Yield 63%, m.p 230-34 °C, Cι8H2ιFN404, m/z 378. (M+l)
Example 32 l-Cvclopropyl-6-fluoro-l.4-dihvdro-7- (4,-dimethylamino-3,-methylpiperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid.
It was prepared in a similar manner as described in example 13 in the Ust of EPIs active against Pseudomonas aeruginosa, where 4-dimethylamino-3- methylpiperidine was used in place 4-ethyl-3- methylpiperazine. Yield 41%, m.p 180-88 °C, C20H24FN3θ3, m/z 374. (M+l)
Example 33
5-Amino-l- cvclopropyl-6-fluoro-8-methoxy-l, 4-dihydro-7- (4'-cyclopropyIaminopiperidin-l-yl)- 4-oxo-quinoline-3-carboxylic acid.
It was in a simUar manner as described in example 24 in the list of EPIs active against NorA, where 4-cyclopropylamino piperidine was used in place of 3,3-dimethylpiperidine. Yield 65 %, m.p 218-20°C, C23H29F2N404, m/z 445 (M+l).
Example 34
l-CvcIopropyl-6-fluoro-8-methoχy-l, 4-dihvdro -7-{-4'-(t-butoxycarbonyl (L)-Ala-Ala) amino 3', 3 '-dimethvIpiperidin-l-vI}-4-oxo-quinoUne-3-carboxylic acid l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-amino-3', 3'-dimethylpiperidin-l-yl}-4-oxo- quinoUne-3-carboxyUc acid (1.0 gm, 2.48 mmole), 4-(N-t-butoxycarbonyl)-L-alanine (0.94 gm, 4.96 mmole) and 2-ethoxy-N-ethyoxycarbonyl dihydroquinoUne (EEDQ) (0.61 gm, 2.48 mmole) were dissolved in dichromethane (300 ml) and the mixture is stirred at room temperature for 48 hr. The mixture is washed with water, separate the layer, dried and concentrated. Product purified by siUca gel column to furnish titled product. Yield 84 %, m.p. 170-75 °C, C29H39FN407, m/z 575 (M+l).
Example 35
5-Amino-l-cvclopropyl-6-fluoro-8-methoxy-l, 4-dihvdro -7-{4'-ethylamino-3', 5'- dimethylpiperidin-l-vU-4-oxo-quinoline-3-carboxylic acid.
It was prepared in a similar manner as described in example 2, where 4-ethylamino-3, 5- dimethylpiperidine was used in place of 4-methylamino-3, 3-dimethylpiperidine. Yield 38 %, m.p 255-58 °C, C;23H31FN404, m/z 447 (M+l) Example 36
Ethyl l-(2,4-difluorophenyl) -6-fluoro -1.4-dihvdro-7- (4-amino-3-ethylpiperidin-l-yl)- 4-oxo-l,8- naphthyridine-3-carboxylate
It was prepared in a similar manner as described in example 49 in the Ust of EPIs active against NorA, where 4-amino-3-ethylpiperidine was used in place of 4-amino ethoxycarbonylpiperidine. Yield 48 %, m.p 178-80 °C, C24H25F3N4O3, m/z 475 (M+l)
Example 37
l-(2,4-difluorophenyl) -6-fluoro-l, 4-dihydro-7- (4-amino-3, 5-dimethylpiperidin-l-vD- 4-oxo-l,8- naphthyridine-3-carboxylic acid.
It was prepared in a similar manner as described in example 49 in the Ust of EPIs active against NorA, where 4-amino-3, 5-dimethylpiperidine was used in place of 4-amino ethoxycarbonylpiperidine. Yield 73 %, m.p 180-82 °C, C22H2ιF3N4O3, m/z 447 (M+l)
Example 38 Ethyl l-(2.4-difluorophenylV6-fluoro-5-methyl-l, 4-dihydro-7- (4-amino-3, 3-dimethyIpiperidin-l- yl)- 4-oxo-1.8-naphthyridine-3-carboxyIate
It was prepared in a similar manner as described in example 49 in the Ust of EPIs active against NorA, where 4-amino-3,3-dimethylpiperidine was used in place of 4-amino ethoxycarbonylpiperidine. Yield 67 %, m.p 148-52 °C, C2SH27F3N4O3, m/z 489 (M+l)
Example 39
(S)-(-V9-Fluoro-6.7-dihvdro-8-(4,-hvdrox 3,-fluoropiperidin-l-vn-5-methyl-l-oxo-lH, 5H- benzo f i,il quinolizine-2-carboxyUc acid.
It was prepared in a similar manner as described in example 51 in the Ust of EPIs active against NorA, where 4-hydroxy-3-fluoropiperidine was used in place 4-carboxamidopiperdine. Yield 46 %, m.p 180 °C, Cι9H20F2N2O4, m/z 379 (M+l)
Example 40
10-Fluoro-ll- (4-aminopiperidin-l-yl)-3.4-dihvdro-4(SVmethyl-8-oxo-2H.8H-pyridofl,2,3-efl-l,5- benzoxazepin-7-carboxyUc acid, hydrochloride.
It was prepared in a similar manner as described in example 36 in the Ust of EPIs active against Pseudomonas aeruginosa, where 4-amino piperidine was used in place [(loc, 5oc, 6oc)-6-amino-3- azabicyclo [3.1.0] hexane. Yield 56 %, m.p 208-10 °C, Cι9H23ClFN304, m z 413 (M+l).
Example 41
(RS)-(±V6. 7-dihvdro-8- (trans-4'-hvdroxy-3f-methylpiperidin-l-vI)-5-methyl-l-oxo-lH, 5H- benzo fi,il quinolizine-2-carboxyUc acid.
It was prepared in a similar manner as described in example 32 in the Ust of EPIs active against Pseudomonas aeruginosa, Yield 59 %, m.p 152-54 °C, C20H24N2O4, m/z 356 (M+l).
Example 42
(RS)-(±V6, 7-dihvdro-8- (cis-4'-hvdroxy-3'-methylpiperidin-l-ylV5-methyl-l-oxo-lH, 5H- benzo fi,il quinoUzine-2-carboxylic acid. It was prepared in a similar manner as described in example 32 in the Ust of EPIs active against Pseudomonas aeruginosa, Yield 62 %, m.p 162-64 °C, C20H24N2O4, m/z 356 (M+l).
Example 43
(RSW±V6, 7-dihvdro-8- (4'-hvdroxy-3'.3'-dimethylpiperidin-l-vn-5-methyl-l-oxo-lH, 5H- benzo fi.il quinoUzine-2-carboxylic acid.
It was prepared in a simUar manner as described in example 32 in the Ust active against P. aeruginosa, Yield 43 %, m.p 258-60 °C, C2ιH26N20 , m/z 370 (M+l)
Susceptibility Testing
Particular exemplary efflux pump inhibitor compounds within the generic descriptions of the compounds of this invention were evaluated for potentiation effect. The in vitro microbiological data for antibiotic potentiation is presented in Tables 1 - 5.
Testing method for inhibition of the efflux pump of Staphylococcus aureus 1199B NorA+
Compounds disclosed herein were studied for potentiation effect by determining the Fractional Inhibition Concentration (FIC) index of compounds and ciprofloxacin. Potentiation effect is observed by the reduction of minimal inhibitory concentration (MIC) of ciprofloxacin in the presence of the experimental efflux pump inhibitor. The activity of an efflux pump inhibitor in combination with a fluoroquinolone such as ciprofloxacin is assessed by the checkerboard assay and the FIC index was calculated. An FIC index value of ≤ 0.5 is synergistic, of 0.5 - 2.0 is additive and > 2.0 is antagonistic (Antimicrobial Combination In Antibiotics in Laboratory Medicine, Ed. Victor Lorian, MD, Fourth edition 1996, pp 333-338).
In short, the assay involves broth microdilution method performed as recommended by the National Committee for CUnical Laboratory Standards (NCCLS) 1997 (Methods for Dilution of Antimicrobial Susceptibility Tests for Bacteria that Grow AerobicaUy, Fourth edition; Approved
Standard, NCCLS document M7-A4, vol. 17, No.2). The test organism used for the assay is Staphylococcus aureus 1199 B NorA+.
In this assay, multiple dilution of two drugs viz. the experimental efflux pump inhibitor and ciprofloxacin are being tested, alone and in combination, at concentrations equal to above and below the respective MICs. In the case of the efflux pump inhibitors of the invention, a number of compounds display intrinsic antimicrobial activity, but are tested at sub-MIC concentrations of 4 meg - 20 mcg/ml.
Stock solutions of the efflux pump inhibitors tested are prepared in dimethyl sulfoxide (DMSO) at a final concentration of 5 mg/ml. Stock solutions are further dUuted in Mueller Hinton Broth as per the need of the assay. Ciprofloxacin is dissolved in water.
The checkerboard assay is performed in microtiter plates. Ciprofloxacin is diluted in the X-axis, each column containing a single concentration of ciprofloxacin. The efflux pump inhibitor is diluted in the Y-axis, each row containing an equal concentration of efflux pump inhibitor. The result of these manipulations is that each well of the microtiter plate contains a unique combination of concentrations of the two agents. Bacterial inoculum is added at 5 x 10s CFU/ml. Microtiter plates are incubated at 35°C for 20 hours. Reading is done by visibly noting turbidity and confirmed using a microtiter plate reader (Molecular Devices). The FIC index is calculated as
(A) (B) + = FICA + FICB = FIC Index
(MICA) (MICB)
(A) is the concentration of the experimental efflux pump inhibitor in the weU that is the lowest inhibitory concentration in the Y-axis. (MIC A) is the MIC of Staphylococcus aureus to experimental efflux pump inhibitor alone. FICA is the fractional inhibitory concentration of an experimental efflux pump inhibitor. (B) is the concentration of the ciprofloxacin in the weU that is the lowest inhibitory concentration in the X-axis. FICB is the fractional inhibitory concentration of ciprofloxacin. (Antimicrobial Combination In Antibiotics in Laboratory Medicine, Ed. Victor Lorian, MD, Fourth edition 1996, pp 333-338).
Testing method for inhibition of the efflux pumps of Pseudomonas aeruginosa 23587, E.coli 2051, Streptococcus pneumoniae 3514 and Streptococcus pyogenus 26-00
Antibiotic Diffusion Assay
The activity of efflux pump inhibitor was also assessed using an antibiotic diffusion assay. For this assay Pseudomonas aeruginosa 23587 is used. Pseudomonas aeruginosa 23587 is a cUnical isolate containing multiple efflux pumps which can be mexAB, mexCD, mexEF but not Umited to mex classification only. Pseudomonas aeruginosa are grown in tryptic soya broth for 20 hours at 35°C. Two antibiotic assay plates are prepared in Mueller Hinton Agar using above inoculum. The bacterial count in a plate is 1 x 106 ceUs/ml. In one of the plates, levofloxacin is incorporated at 5 mcg/ml, whUe in the control plate an equivalent amount of water is added. An experimental efflux pump inhibitor is evaluated by adding a series of concentrations of the test compound ranging from 0.025 meg to 200 mcg./well in agar plate. The plates are incubated at 35°C for 20 hours and the zone of inhibition was recorded in mm (table 2). The difference in the diameter of zone of inhibition was calculated by subtracting from the diameter of the zone of inhibition in the levofloxacin containing plate the diameter of the zone of inhibition in the water containing control plate. Example, if the diameter of the zone of inhibition in the levofloxacin plate is X mm and the diameter of the zone of inhibition in the control plate is Y mm, the difference Z = X - Y and is a measure of the activity of the efflux pump inhibitor.
The activity of an efflux pump inhibitor of E.coli 2051 was also assessed using an antibiotic diffusion assay. For this assay Exoli 2051 is used. E.coli 2051 is a clinical isolate containing multiple efflux pumps. E.coli 2051 are grown in tryptic soya broth for 20 hours at 35°C. Two antibiotic assay plates are prepared in Mueller Hinton Agar using above inoculum. The bacterial count in a plate is 1 x 106 cells/ml. In one of the plates, levofloxacin is incorporated at 15 mcg/ml, whUe in the control plate an equivalent amount of water is added. An experimental efflux pump inhibitor is evaluated by adding a series of concentrations of the test compound ranging from 0.025 meg to 200 mcg./well in agar plate. The plates are incubated at 35°C for 20 hours and the zone of inhibition was recorded in mm (table 3) . The difference in the diameter of zone of inhibition was calculated by subtracting from the zone of inhibition in the levofloxacin containing plate the diameter of the zone of inhibition in the control plate.
To detect the macroUde efflux pump (Mef) inhibitor, Streptococcus pneumoniae 3514 (Mef+) is used which was obtained from the Centre for Disease Control (CDC), Atlanta. A simUar 2 plate assay method as described above is used with small modifications. Streptococcus pneumoniae 3514 (Mef+) is grown in Columbia blood agar for 18 hours at 25°C. The growth was suspended in sterile todd hewitt broth and CFU were adjusted using macfarland's standard to 1 x 10s CFU/ml. 0.5 ml of this is added to the MueUer Hinton agar supplemented with 5% sheep blood, final bacterial count was 106 ceUs/ml. In one of the two plates 0.5 mcg/ml azithromycin is incorporated and to the control plate an equivalent amount of water is added. The plates are incubated at 35°C for 20 hours and the zone of inhibition was recorded in mm (table 4). The difference in the diameter of zone of inhibition was calculated by subtracting from the diameter of the zone of inhibition in the azithromycin containing plate the diameter of the zone of inhibition in the control plate.
To detect the macroUde efflux pump (Mef) inhibitor, Streptococcus pyogenus 26-00 is used which was obtained from the Centre for Disease Control (CDC), Atlanta. A similar 2 plate assay method as described above is used with small modifications. Streptococcus pyogenus 26-00 (Mef+) is grown in Columbia blood agar for 18 hours at 25°C. The growth was suspended in sterUe todd hewitt broth and CFU were adjusted using macfarland's standard to 1 x 10s CFU/ml. 0.5 ml of this is added to the Mueller Hinton agar supplemented with 5% sheep blood, final bacterial count was 106 ceUs/ml. In one of the two plates 0.5 mcg/ml azithromycin is incorporated and to the control plate an equivalent amount of water is added. The plates are incubated at 35°C for 20 hours and the zone of inhibition was recorded in mm (table 4). The difference in the diameter of zone of inhibition was calculated by subtracting from the diameter of the zone of inhibition in the azithromycin containing plate the diameter of the zone of inhibition in the control plate. The results of the screening are provided in the following tables:
Table 1 Some Preferred Compounds of the Invention Displaying Inhibition of the Efflux Pump of Staphylococcus aureus 1199 B (Nor A ^)
Figure imgf000090_0001
oe so
Figure imgf000090_0002
Figure imgf000091_0001
Figure imgf000092_0001
S-isomer; ** R-isomer; Absence of an asterisk indicates that the substance is a racemic compound.
Examples of Bis compounds of the invention Displaying Inhibition of the Efflux Pump of Staphylococcus aureus 1199 B (Nor A )
Figure imgf000093_0002
Figure imgf000093_0001
Figure imgf000094_0001
LO o LO
H H Table 2 Some Preferred Compounds of the Invention Displaying Inhibition of the Efflux Pumps of Pseudomonas aeruginosa 23587
Figure imgf000095_0001
Figure imgf000095_0002
Figure imgf000096_0001
*Z = the difference of the diameter of the zone of inhibition in the levofloxacin containing plate minus the diameter of the zone of inhibition in the water containing control plate. * S-isomer; ** R-isomer; Absence of an asterisk indicates that the substance is a racemic compound.
Table 3
Some Preferred Compounds of the Invention Displaying Inhibition of the Efflux Pumps of Escherischia coli 2051
Figure imgf000097_0001
Figure imgf000097_0002
Z = the difference of the diameter of the zone of inhibition in the levofloxacin containing plate minus the diameter of the zone of inhibition in the water containing control plate.
* S-isomer; ** R-isomer; Absence of an asterisk indicates that the substance is a racemic compound.
Table 4 Some Preferred Compounds of the Invention Displaying Inhibition of the Mef Efflux Pump of Streptococcus pneumoniae 351 and Streptococcus pyogenes 26-00
Figure imgf000098_0001
Figure imgf000098_0002
oe
Figure imgf000099_0001
*Z = the difference of the diameter of the zone of inhibition in the levofloxacin containing plate minus the diameter of the zone of inhibition in the water containing control plate. * S-isomer; ** R-isomer; Absence of an asterisk indicates that the substance is a racemic compound.
10
Figure imgf000100_0001
Figure imgf000100_0002
*Z = the difference of the diameter of the zone of inhibition in the levofloxacin containing plate minus the diameter of the zone of inhibition in the water containing control plate. * S-isomer; ** R-isomer; Absence of an asterisk indicates that the substance is a racemic compound.
By "comprising" is meant including, but not limited to, whatever follows the word "comprising". Thus, use of the term "comprising" indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present. By "consisting of is meant including, and limited to, whatever follows the phrase "consisting of. Thus, the phrase "consisting of indicates that the listed elements may be present. By "consisting essentially of is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase "consisting essentially of" indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements.

Claims

Claims
1. A method for treating a microbial infection in an animal, comprising administering to an animal suffering from said infection an antimicrobial agent and an efflux pump inhibitor in an amount sufficient to reduce efflux pump activity, wherein said efflux pump inhibitor increases the susceptibUity of said microbe to said antimicrobial agent, and
wherein said efflux pump inhibitor has the chemical structure of structure 1 below:
Figure imgf000102_0001
Structure 1 wherein,
Rj = H, Cι-6 alkyl, C3.6 cycloalkyl, or optionaUy substituted aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2, or when X is C and the nitrogen atom to which Ri is linked forms an optionaUy substituted 4-, 5-, 6- or 7-membered ring with X of the adjacent ring, the ring optionally containing one or more hetero atoms selected from nitrogen, oxygen or sulfur atoms said heteroatom(s) represented by Y, preferably Ri is - CH2CH2-,
CH2Y-, CH2CH2CH2-, CH2CH2Y-, CH2CH2CH2CH2- and CH2CH2CH2Y- where Y represents NH, O, or S. If the ring is substituted, the substituent is Ci.6 alkyl group; R2 = H, CHO, COOR3, or CONHR13; where RJ3 = H or the NHRJ3 of CONHR13 is the residue of one of the 20 naturaUy occurring amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proUne, serine, threonine, tryptophan, tyrosine, valine or the opticaUy active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;
R3 = H, Cι-6 alkyl, C3.6 cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2,
(CH2)nCH(R14) OC(=0)Rιs, (CH2)nCH(Rι4) C(=0)ORι5 wherein n = 0-6, R14 = H or CH3; and RiS = C2H5 or C(CH3)3 ;
Figure imgf000103_0001
wherein B=CH or N, and when B=CH, Z=NH or NCH3, and when B=N, Z=CH, O, NH, S or NCH3; p=0-2; q=0-2, Ri = H, ta = H, or R4 and R»a taken together are oxo (=0), or thio (=S); Rs = H, Cι_s alkyl, amino, alkylamino, or acylamino; Re = H, C1.6 alkyl, halo ,amino, or hydroxy; R7 = OH, halo or
NR9 Rio wherein R9 and Rw are the same or different and represent H, Cι.6 alkyl or (CH2)nOA,
or R9 is H and Rio is a 4-membered, 5-membered, 6-membered, or 7-membered carbocycUc, mono or bicyclic ring, or mono or bicyclic heterocycUc ring Unked to the nitrogen of NR9 ι0 through an atom of the heterocycle other than the heterocyclic atom, or R9 and R10 taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocycUc, bicycUc, and said carbocycle and heterocycle is optionally substitued;
or R7 = NHOA, NHCOORn, or NH(CH2)nNR9Rι0;
or N, and when Z=CH, W=NH or
Figure imgf000103_0002
or where n=0,l,or 2
Figure imgf000103_0003
wherein the R7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R7 moiety has one of its link bonds linked to the core formula of Formula I and the second of its Unk bonds is Unked to an optionaUy substituted phenyl carboxylic acid or ester moiety thereof,
A = H, C1.6 alkyl, glycosyl, aralkyl, Cι_6 alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or vaUne; or. A is C6Hn06, S03H, or P03H2,
R11 = H, Cι-6 alkyl, C3.6 cycloalkyl, or heterocyclic group,
X = CH, C-F, C-Cl, C-CH3, C-CF3, C-OCH3, C-OCHF2, C-OCF3, N or when X is equal to C it forms together with the nitrogen atom of the adjacent ring an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, containing carbon atoms and optionally Y atoms representing one or more nitrogen, oxygen or sulfur atoms; if the ring is substituted, the substituent is Cι.6 alkyl group; and their pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.
2. A method according to claim 1 wherein the efflux pump inhibitor has structure 2
Figure imgf000104_0001
Structure 2 wherein, RI, R2, R5, R7, X and Y are as defined in claim 1.
3. A method according to claim 1 wherein the efflux pump inhibitor has structure 3
Figure imgf000104_0002
Structure 3 wherein RI, R2, R5, R7, X and Y are as defined in claim 1.
4. A method for prophylactic treatment of an animal at risk for developing a microbial infection comprising administering to the animal an antimicrobial agent and an efflux pump inhibitor in an amount sufficient to reduce efflux pump activity, wherein said efflux pump inhibitor increases the susceptibUity of said microbe to said antimicrobial agent, and wherein said efflux pump inhibitor has the chemical structure of structure 1 below:
Figure imgf000105_0001
Structure 1 Wherein, Ri = H, Cι_6 alkyl, C3.6 cycloalkyl, or optionaUy substituted aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2, or when X is C and the nitrogen atom to which Ri is linked forms an optionaUy substituted
4-, 5-, 6- or 7-membered ring with X of the adjacent ring, the ring optionally containing one or more hetero atoms selected from nitrogen , oxygen or sulfur atoms said heteroatom(s) represented by Y, preferably Ri is - CH2CH2-, CH2Y-, CH2CH2CH2-,
CH2CH2Y-, CH2CH2CH2CH2- and CH2CH2CH2Y- where Y represents NH, O, or S. If the ring is substituted, the substituent is Cι.6 alkyl group;
R2 = H, CHO, COOR3, or CONHRι3; where Ri3 = H or the NHR13 of CONHR13 is the residue of one of the 20 naturaUy occurring amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proUne, serine, threonine, tryptophan, tyrosine, vaUne or the opticaUy active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;
R3 = H, Cι.6 alkyl, C3.6 cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2,
(CH2)„CH(Rι4) OC(=0)Rιs, (CH2)nCH(Rι4) C(=0)ORιS wherein n = 0-6, R14 = H or CH3;
Figure imgf000105_0002
wherein B=CH or N, and when B=CH, Z=NH or NCH3, and when B=N, Z=CH, O, NH, S or NCH3; p=0-2; q=0-2, R4 = H, R4a = H, or R4 and R4a taken together are oxo (=0), or thio (=S); Rs = H, C1-5 alkyl, amino, alkylamino, or acylamino; Re = H, Cι-6 alkyl, halo ,amino, or hydroxy; R7 = OH, halo or
NR9 Rio wherein R9 and Rι0 are the same or different and represent H, Cι.6 alkyl or (CH2)nOA,
or R9 is H and R10 is a 4-membered, 5-membered, 6-membered, or 7-membered carbocycUc, mono or bicycUc ring, or mono or bicyclic heterocycUc ring Unked to the nitrogen of NR9Rι0 through an atom of the heterocycle other than the heterocyclic atom, or R9 and Rι0 taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocycUc, bicycUc, and said carbocycle and heterocycle is optionally substitued;
or R7 = NHOA, NHCOORn, or NH(CH2)nNR9Rι0;
3, Z=CH or N, and when Z=CH, W=NH or
Figure imgf000106_0001
is absent;
or where n=0,l,or 2
Figure imgf000106_0002
wherein the R7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R7 moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is Unked to an optionaUy substituted phenyl carboxylic acid or ester moiety thereof,
A = H, Cι_6 alkyl, glycosyl, aralkyl, C^ alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proUne, serine, threonine, tryptophan, tyrosine, or vaUne; or.
A is C6Hιι06, S03H, or P03H2,
Rii = H, Cι-6 alkyl, C3.6 cycloalkyl, or heterocyclic group,
X = CH, C-F, C-Cl, C-CH3, C-CF3, C-OCH3, C-OCHF2, C-OCF3, N or when X is equal to C it forms together with the nitrogen atom of the adjacent ring an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, containing carbon atoms and optionaUy Y atoms representing one or more nitrogen , oxygen or sulfur atoms; if the ring is substituted, the substituent is Cι.6 alkyl group; and their pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.
5. A method according to claim 4 wherein the efflux pump inhibitor has structure 2
Figure imgf000107_0001
Structure 2 wherein Ri, R2, Rs, R7, X and Y are as defined in claim 1.
6. A method according to claim 1 wherein the efflux pump inhibitor has structure 3
Structure 3 wherein Ri, R2, R5, R7, X and Y are as defined in claim 1.
7. The method of any one of claims 1-6 wherein said animal is a mammal.
8. A method of enhancing the antimicrobial activity of an antimicrobial agent against a microbe, comprising contacting said microbe with said antimicrobial agent and an efflux pump inhibitor in an amount effective to inhibit an efflux pump in said microbe, wherein said efflux pump inhibitor has the chemical structure of structure 1 below:
Figure imgf000108_0001
Structure 1 wherein,
Ri = H, Cι.6 alkyl, C3.6 cycloalkyl, or optionaUy substituted aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2, or when X is C and the nitrogen atom to which Ri is linked forms an optionaUy substituted 4-, 5-, 6- or 7-membered ring with X of the adjacent ring, the ring ^optionally containing one or more hetero atoms selected from nitrogen , oxygen or sulfur atoms said heteroatom(s) represented by Y, preferably Rj is - CH2CH2-, CH2Y-, CH2CH2CH2-, CH2CH2Y-, CH2CH2CH2CH2- and CH2CH2CH2Y- where Y represents NH, O, or S. If the ring is substituted, the substituent is Cι.6 alkyl group;
R2 = H, CHO, COOR3, or CONHR13, where R13 = H or the NHR13 of CONHRι3 is the residue of one of the 20 naturaUy occurring amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proUne, serine, threonine, tryptophan, tyrosine, vaUne or the opticaUy active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;
R3 = H, Cι-6 alkyl, C3.6 cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2,
(CH2)„CH(Rι4) OC(=0)Rιs, (CH2)nCH(RM) C(=0)ORι5 wherein n = 0-6, RM = H or CH3;
Figure imgf000108_0002
or R3 is -(CH2)p— B Γ~Λ
wherein B=CH or N, and when B=CH, Z=NH or NCH3, and when B=N, Z=CH, O, NH, S or
NCH3; p=0-2; q=0-2, R4 = H, ja = H, or R4 and R»a taken together are oxo (=0), or thio (=S); Rs = H, Ci.s alkyl, amino, alkylamino, or acylamino; Re = H, Cι-6 alkyl, halo , amino, or hydroxy; R7 = OH, halo or NR9 Rio wherein R9 and Rio are the same or different and represent H, Cι.6 alkyl or
(CH2)nOA, or R9 is H and Rι0 is a 4-membered, 5-membered, 6-membered, or 7-membered carbocycUc, mono or bicycUc ring or mono or bicyclic heterocyclic ring linked to the nitrogen of NR9Rι0 through an atom of the heterocycle other than the heterocyclic atom, or R9 and R10 taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocycUc, bicycUc, and said carbocycle and heterocycle is optionally substitued;
or R7 = NHOA, NHCOORn, or NH(CH2)nNR9R 105
where n=l,2 or 3, Z=CH or N, and when Z=CH, W=NH or
Figure imgf000109_0001
when Z=N, W is absent;
or — N (ώ2Λ — NH — where n=0,l,or 2
wherein the R7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R7 moiety has one of its link bonds linked to the core formula of
Formula I and the second of its Unk bonds is Unked to an optionaUy substituted phenyl carboxylic acid or ester moiety thereof,
A = H, Ci.6 alkyl, glycosyl, aralkyl, Cι„6 alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or vaUne; or.
A is C6Hn06, SO3H, or PO3H2,
Rπ = H, C1-6 alkyl, C3_6 cycloalkyl, or heterocyclic group, X = CH, C-F, C-CI, C-CH3, C-CF3, C-OCH3, C-OCHF2, C-OCF3, N or when X is equal to C it forms together with the nitrogen atom of the adjacent ring an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, containing carbon atoms and optionally Y atoms representing one or more nitrogen , oxygen or sulfur atoms; if the ring is substituted, the substituent is Cι_6 alkyl group; and their pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.
9. The method of claim 8 wherein said efflux pump inhibitor has structure 2
Figure imgf000110_0001
Structure 2 wherein Ri, R2, Rs, R7, X and Y are as defined in claim 1.
10. A method according to claim 8 wherein the efflux pump inhibitor has structure 3
Figure imgf000110_0002
Structure 3 wherein Ri, R2, R5, R7, X and Y are as defined in claim 1.
11. The method of suppressing growth of a microbe expressing an efflux pump, comprising contacting said microbe with an efflux pump inhibitor in the presence of a concentration of antimicrobial agent below the MIC of said microbe, whrein said efflux pump inhibitor has the chemical structure of structure 1 below:
Figure imgf000110_0003
wherein,
Ri = H, Cι-6 alkyl, C3.6 cycloalkyl, or optionaUy substituted aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(O)talkyl, where t=0,l or 2, or when X is C and the nitrogen atom to which Rx is linked forms an optionaUy substituted 4-, 5-, 6- or 7-membered ring with X of the adjacent ring, the ring optionally containing one or more hetero atoms selected from nitrogen, oxygen or sulfur atoms said heteroatom(s) represented by Y, preferably, Ri is - CH2CH2-, CH2Y-, CH2CH2CH2-, CH2CH2Y-, CH2CH2CH2CH2- and CH2CH2CH2Y- where Y represents NH, O, or S. If the ring is substituted, the substituent is Cι.6 alkyl group; R2 = H, CHO, COOR3, or CONHRι3; where RJ3 = H or the NHRι3 of CONHRι3 is the residue of one of the 20 naturaUy occurring amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proUne, serine, threonine, tryptophan, tyrosine, vaUne or the opticaUy active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;
R3 = H, Cj.6 alkyl, C3.6 cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2,
(CH2)nCH(Rι4) OC(=0)Rls, (CH2)nCH(Rι4) C(=0)ORιS wherein n = 0-6, Ru = H or CH3; and RiS = C2H5 or C(CH3)3 ;
Figure imgf000111_0001
wherein B=CH or N, and when B=CH, Z=NH or NCH3, and when B=N, Z=CH, O, NH, S or
NCH3; p=0-2; q=0-2, R4 = H, ta = H, or R4 and (a taken together are oxo (=0), or thio (=S); R5 = H, Cι„5 alkyl, amino, alkylamino, or acylamino; Re = H, Cι-6 alkyl, halo ,amino, or hydroxy; R7 = OH, halo or
NR9 Rio wherein R9 and Rxo are the same or different and represent H, Cι.6 alkyl or
(CH2)nOA, or R9 is H and Rι0 is a 4-membered, 5-membered, 6-membered, or 7-membered carbocycUc, mono or bicycUc ring or mono or bicyclic heterocyclic ring linked to the nitrogen of NR9R10 through an atom of the heterocycle other than the heterocyclic atom or R9 and Rw taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocycUc, bicyclic, and said carbocycle and heterocycle is optionally substitued; or R7 = NHOA, NHCOORn, or NH(CH2)nNR9Rι0; or R7 =
_N z— W where n=l> 2 or 3> Z=CH or N, and when Z=CH, W=NH or ( )({ when Z=N, W is absent; or where n=0,l,or 2
Figure imgf000112_0001
wherein the R7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R7 moiety has one of its link bonds linked to the core formula of Formula I and the second of its Unk bonds is Unked to an optionaUy substituted phenyl carboxylic acid or ester moiety thereof,
A = H, Cι.6 alkyl, glycosyl, aralkyl, Cι.6 alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or vaUne; or.
A is C6Hιι06, S03H, or P03H2,
R11 = H, d-6 alkyl, C3.6 cycloalkyl, or heterocyclic group,
X = CH, C-F, C-Cl, C-CH3, C-CF3, C-OCH3, C-OCHF2, C-OCF3, N or when X is equal to C it forms together with the nitrogen atom of the adjacent ring an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, containing carbon atoms and optionally Y atoms representing one or more nitrogen, oxygen or sulfur atoms; if the ring is substituted, the substituent is Cι.6 alkyl group; and their pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.
12.The method of claim 11 wherein said efflux pump inhibitor has structure 2
Figure imgf000112_0002
Structure 2 wherein Rl5 R2, R5, R7, X and Y are as defined in claim 1.
Ill
13. A method according to claim 11 wherein the efflux pump inhibitor has structure 3
Figure imgf000113_0001
Structure 3 wherein Rl5 R2, R5, R7, X and Y are as defined in claim 1
14. The method of any one of claims 11 tol3, wherein said efflux pump is a Mef A or MefE pump.
15. The method of any one of claims 11 to 13, wherein said efflux pump is a NorA, Bmr, PmrA or QacA or QacB pump.
16. The method of any one of claims 11 to 13, wherein said microbe expressing an efflux pump is a Gram negative organism-bearing MexAB-OprM, MexCD-OprJ, MexEF-OprM, MexXY-OprM, ARcrAB-TolC, AcrEF, Mar A, SoxS, or/and Tet pump/s.
17. The method of any one of claims 1 to 16, wherein said microbe is a bacterium.
18. The method of claim 17, wherein said bacterium is selected from the group consisting of Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenotrophomonas maltophilia, Burkholderia cepacia, Burkholderia pseudomallei, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella enterica Serovar typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Francisella tularensis, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Branhamella catarrhalis, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Borrelia burgdorferi, Vibrio cholerae, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Gardnerella vaginalis, Bacteroides fragilis, Bacteroides distasonis, Bacteroides 3452A homology group, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, Bacteroides splanchnicus, Clostridium difficile, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium leprae, Corynebacterium diphtheriae, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium and Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus saccharolyticus, and Rickettsia prowazsekii.
19. The method of claim 18, wherein said bacterium is selected from the group consisting of Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherischia coli, and Staphylococcus aureus.
20. The method of any one of claims 1 to 19 wherein said microbial infection is a bacterial infection and said antimicrobial agent is an antibacterial agent.
21. The method of claim 20, wherein said antibacterial agent i ; s a quinolone.
22. The method of claim 20, wherein said antibacterial agent i : s a tetracycUne.
23. The method of claim 20, wherein said antibacterial agent is a beta-lactam.
24. The method of claim 20, wherein said antibacterial agent is a coumermycin.
25. The method of claim 20, wherein said antibacterial agent is chloramphenicol.
26. The method of claim 20, wherein said antibacterial agent is a glycopeptide.
27. The method of claim 20, wherein said antibacterial agent is an aminoglycoside.
28. The method of claim 20, wherein said antibacterial agent is a macroUde.
29. The method of claim 20, wherein said antibacterial agent is a rifamycin.
30. The method of claim 20, wherein said antibacterial agent is an oxazolidonone.
31. The method of any of claims 1, 4, 8 or 11 wherein said antimicrobial agent is effluxed by a microbe.
32. An efflux inhibitor compound, wherein said compound has the chemical structure 1 below:
Figure imgf000114_0001
Structure 1 wherein,
Ri = H, Ci.6 alkyl, C3.6 cycloalkyl, or optionaUy substituted aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2, or when X is C and the nitrogen atom to which Ri is linked forms an optionaUy substituted 4-, 5-, 6- or 7-membered ring with X of the adjacent ring, the ring optionally containing one or more hetero atoms selected from nitrogen, oxygen or sulfur atoms said heteroatom(s) represented by Y, preferably Ri is - CH2CH2-, CH2Y-, CH2CH2CH2-, CH2CH2Y-, CH2CH2CH2CH2- and CH2CH2CH2Y- where Y represents NH, O, or S. If the ring is substituted, the substituent is Cι.6 alkyl group; R2 = H, CHO, COOR3, or CONHR^ where Rι3 = H or the NHR13 of CONHR13 is the residue of one of the 20 naturaUy occurring amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine or the opticaUy active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues; aryloxyalkyl, erein n = 0-6, RM = H or CH3;
Figure imgf000115_0001
wherein B=CH or N, and when B=CH, Z=NH or NCH3, and when B=N, Z=CH, O, NH, S or
NCH3; p=0-2; q=0-2, Ri = H, R4a = H, or Ri and R.,, taken together are oxo (=0), or thio (=S); Rs = H, Ci-s alkyl, amino, alkylamino, or acylamino; Re = H, Ci.6 alkyl, halo ,amino, or hydroxy; R7 = OH, halo or
NR9 Rio wherein R9 and Rι0 are the same or different and represent H, Cι„6 alkyl or (CH2)nOA, or R9 is H and Rio is a 4-membered, 5-membered, 6-membered, or 7-membered carbocycUc, mono or bicycUc ring or mono or bicyclic heterocyclic ring linked to the nitrogen of NR9Rι0 through an atom of the heterocycle other than the heterocyclic atom or R9 and R]0 taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocycUc, bicycUc, and said carbocycle and heterocycle is optionally substitued; or R7 = NHOA, NHCOORn, or NH(CH2)nNR9R ■105
or N> and hen Z=CH, W=NH or
Figure imgf000115_0002
or where n=0,l,or 2
Figure imgf000115_0003
wherein the R7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R7 moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is linked to an optionally substituted phenyl carboxylic acid or ester moiety thereof,
A = H, C1.6 alkyl, glycosyl, aralkyl, Cι.6 alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or vaUne; or.
A is C6Hn06, S03H, or P03H2, Rn = H, Cι-6 alkyl, C3-6 cycloalkyl, or heterocyclic group,
X = CH, C-F, C-CI, C-CH3, C-CF3, C-OCH3, C-OCHF2, C-OCF3, N or when X is equal to C it forms together with the nitrogen atom of the adjacent ring an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, containing carbon atoms and optionally Y atoms representing one or more nitrogen, oxygen or sulfur atoms; if the ring is substituted, the substituent is Cι.6 alkyl group; and their pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.
33. An efflux inhibitor compound according to claim 32, wherein said compound has the chemical structure 2 below
Figure imgf000116_0001
Structure 2 wherein Rt, R2, Rs, R7, X and Y are as defined in claim 1.
34. An efflux inhibitor compound according to claim 32, wherein said compound has the chemical structure 3 below
Figure imgf000116_0002
Structure 3 wherein Ri, R2, R5, R7, X and Y are as defined in claim 1.
35. An efflux pump inhibitor of the Mef pump wherein said efflux pump inhibitor has the Structure 1 below
Figure imgf000117_0001
Structure 1 wherein,
Ri = H, Ci.6 alkyl, C3.6 cycloalkyl, or optionaUy substituted aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2, or when X is C and the nitrogen atom to which Ri is linked forms an optionaUy substituted 4-, 5-, 6- or 7-membered ring with X of the adjacent ring, the ring optionally containing one or more hetero atoms selected from nitrogen, oxygen or sulfur atoms said heteroatom(s) represented by Y, preferably Ri is - CH2CH2-, CH2Y-, CH2CH2CH2-, CH2CH2Y-, CH2CH2CH2CH2- and CH2CH2CH2Y- where Y represents NH, O, or S. If the ring is substituted, the substituent is Cι.6 alkyl group;
R2 = H, CHO, COOR3, or CONHRι3j where R13 = H or the NHR13 of CONHRι3 is the residue of one of the 20 naturaUy occurring amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proUne, serine, threonine, tryptophan, tyrosine, valine or the opticaUy active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;
R3 = H, Cι-6 alkyl, C3.6 cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2,
(CH2)nCH(RI4) 0C(=0)R1S, (CH2)nCH(Rι4) C(=0)ORιS wherein n = 0-6, Ru = H or CH3;
Figure imgf000117_0002
or R3 is -(CH2)p— B ~
-{ )i wherein B=CH or N, and when B=CH, Z=NH or NCH3, and when B=N, Z=CH, O, NH, S or
NCH3; p=0-2; q=0-2, j = H, R4a = H, or R, and Ria taken together are oxo (=0), or thio (=S); Rs = H, Ci-s alkyl, amino, alkylamino, or acylamino; Re = H, Ci.6 alkyl, halo ,amino, or hydroxy; R7 = OH, halo or
NR9 Rio wherein R9 and R10 are the same or different and represent H, Cι.6 alkyl or (CH2)nOA,
or R9 is H and Rι0 is a 4-membered, 5-membered, 6-membered, or 7-membered carbocycUc, mono or bicycUc ring, or mono or bicyclic heterocyclic ring Unked to the nitrogen of NR9R10 through an atom of the heterocycle other than the heterocyclic atom, or R9 and Rι0 taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocycUc, bicyclic, and said carbocycle and heterocycle is optionaUy substitued;
or R7 = NHOA, NHCOORn, or NH(CH2)nNR9Rι0;
or
Figure imgf000118_0001
or where n=0,l,or 2
Figure imgf000118_0002
wherein the R7 moiety is Unked either to 2 core molecules of the Formula I to form a bis compound or the R7 moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is Unked to an optionaUy substituted phenyl carboxylic acid or ester moiety thereof,
A - H, Cι.6 alkyl, glycosyl, aralkyl, Cι_6 alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the opticaUy active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or vaUne; or.
A is C6Hn06, SO3H, or PO3H2,
Ru = H, Cι-6 alkyl, C3_6 cycloalkyl, or heterocyclic group,
X = CH, C-F, C-Cl, C-CH3, C-CF3, C-OCH3, C-OCHF2, C-OCF3, N or when X is equal to C it forms together with the nitrogen atom of the adjacent ring an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, containing carbon atoms and optionaUy Y atoms representing one or more nitrogen , oxygen or sulfur atoms; if the ring is substituted, the substituent is Cι.6 alkyl group; and their pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.
36. The efflux pump inhibitor according to claim 35 selected from: l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-amino-3'-methyI piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-(methylamino)-3',3'- dimethylpiperidin-l-yI}-4-oxo-quinoline-3-carboxylic acid and its salts; i-PropyI l-cyclopropyI-6-fluoro-8-methoxy-l,4-dihydro -7-(4'-amino-3',3'-dimethyl-piperidin-l- yl}-4-oxo-quinoline-3-carboxylate and its salts; n-Butyl l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-(4'-amino-3',3'-dimethyl-piperidin-l- yl}-4-oxo-quinoline-3-carboxylate and its salts;
Ethoxycarbonylmethyl l-cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-amino-3',3'- dimethylpiperidin-l-yl)-4-oxo-quinoline-3-carboxylate and its salts;
Benzyl l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-{4'-(t-butoxycarbonyl amino)-3',3' dimethylpiperidin-l-yI)-4-oxo-quinoline-3-carboxylate and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-N-(t-butoxycarbonyl-L-alanyl) amino-3',3'- dimethylpiperidin-l-yl}-4-oxo-quinoIine-3-carboxylic acid hydrochloride; l-CycIopropyI-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-L-aIanyIamino-3',3'-dimethylpiperidin-l- )-4-oxo-quinoIine-3-carboxylic acid hydrochloride; l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(3',3'-dimethyl-4'-(t-butoxy- carbonylvalinylamino)piperidin-l-yl}-4-oxo-quinoUne-3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-(3',3'-dimethyl-4'-(L)-valyl-aminopiperidin-l- yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-(L)-aspartylamino-3',3'-dimethylpiperidin-l- yI}-4-oxo-quinoline-3-carboxyIic acid hydrochloride; l-Ethyl-6,8-difluoro-l,4-dihydro-7-(4'-ethylaminopiperidin-l'-yl)-4-oxo- quinoUne-3- carboxylic acid and its salts;
5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(4'-amino-3'-methyl piperidin -l-yI)-4-oxo- quinoUne-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(quinuclidinyl-3-yl-amino)-4-oxo-quinoUne-3- carboxylic acid and its salts;
5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro-7- {(loc,5oc,6oc)-6-amino-N-benzyl-3-azabicyclo [3.1.0] hex-6-yl}-4-oxo-quinoUne-3-carboxylic acid and its salts; l-(3'-Fluorophenyl)-6-fluoro -1, 4-dihydro -7-(4'-methylpiperazin-l'-yl)-4-oxo-quinoline-3- carboxylic acid and its salts; l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihydro-7- (4'-ethylaminopiperidin-l'-yl)- 4-oxo-quinoUne-3- carboxylic acid and its salts; l-(2',4'-Difluorophenyl)-6-fluoro-5-methyl-l, 4-dihydro -7-(4'-aminopiperidin-l '-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-(2f,4'-DifluorophenyI)-6-fluoro-5-methyl-l,4-dihydro-7-(4'-methyIamino piperidin-l'-yI)-4-oxo- quinoUne-3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(3'-aminopyrrolidin-l'-yl)-4-oxo-l,8-naphthyridine-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-{(loc,5oc,6oc)-6-amino~N-benzyl-3-azabicyclo [3.1.0] hex-6- yl}-4-oxo-l,8-naphthyridine-3-carboxylic acid and its salts; l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihydro-7-(3'-aminopyrroUdin-l'-yl)- 4-oxo-l,8- naphthyridine-3-carboxylic acid and its salts; l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihydro-7-{(loc,5oc,6oc)-6-amino-N-benzyl-3-azabicyclo [3.1.0]hex-6-yl}~ 4-oxo-l,8-naphthyridine-3-carboxylic acid and its salts; l-(2,4-Difluorophenyl)-6-fluoro-l,4-dihydro-7-(3',3'-dimethyl-4'-hydroxy piperdin- -yl)-4-oxo- l,8-naphthyridine-3-carboxyUc acid and its salts;
(RS)-(±)-9-Fluoro-6, 7-dihydro-8-{4'-(L-α-aspartyloxy)piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo [i,j] quinolizine-2-carboxyUc acid hydrochloride;
7H-Pyrido[l,2,3-de]-l,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(3'-ethyl '- hydroxypiperidin-l'-yl)-7-oxo-6-carboxyUc acid and its salts; 7H-Pyrido[l,2,3-de]-l,4-benzoxazine-9-fluoro-2, 3-dihydro-3-methyl-10- (3'-amino methyl-4'- hydroxypiperidin-l'-yl)-7-oxo-6-carboxyUc acid and its salt; l-Cyclopropyl-6, 8-difluoro-5-methyl-l, 4-dihydro -7-(3', 3'-dimethyl-4'-ethylamino piperidin-1- yl)-4-oxo-quinoline-3-carboxyUc acid and its salt; l-Cyclopropyl-6,7,8-trifluoro-5-methyl-l,4-dihydro - 4-oxo-quinoline-3-carboxylic acid;
(S)-(-)-9-Fluoro-6,7-dihydro-8- (3', 3'-dimethyl-4'-ethylaminopiperidin-l-yl)-5-methyl-l-oxo-lH, 5H-benzo[i,j]quinoUzine-2-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-7- (3'-aminomethyl-4'-hydroxypiperidin l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-7- (4'-dimethylamino-3'-methylpiperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-cyclopropyl aminopiperidin-l-yl}-4- oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-(t-butoxycarbonyl (L)-Ala-Ala)amino-3', 3'- dimethyl piperidin-l-yl}-4-oxo-quinoUne-3-carboxyIic acid hydrochloride;
5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-ethylamino-3', 5'- dimethylpiperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;
Ethyl l-(2,4-difluorophenyl) -6-fluoro -1, 4-dihydro-7- (4-amino-3-ethylpiperidin-l-yl)- 4-oxo-l,8- naphthyridine-3-carboxylate; l-(2,4-difluorophenyl) -6-fluoro-l, 4-dihydro-7- (4-amino-3, 5-dimethylpiperidin-l-yl)- 4-oxo-l,8- naphthyridine-3-carboxylic acid and its salts; Ethyl l-(2,4-difluorophenyl) -6-fluoro-5-methyl-l, 4-dihydro-7- (4-amino-3, 3-dimethyIpiperidin-l- yl)- 4-oxo-l,8-naphthyridine-3-carboxylate;
(S)-(-)-9-fluoro-6.7-dihydro-8- (4'-hydroxy- 3'-fluoropiperidin-l-yl)-5-methyl-l-oxo-lH, 5H- benzo[i,j]quinoUzine-2-carboxylic acid and its salts;
10-Fluoro-ll- (4-aminopiperidin-l-yl)-3,4-dihydro-4 (S)-methyl-8-oxo-2H, 8H-pyrido[l,2,3-ef]-l,5- benzoxazepin-7-carboxyUc acid and its salt;
(RS)-(±)-6, 7-dihydro-8- (trans-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l-oxo-lH, 5H- benzo[i,j]quinoUzine-2-carboxylic acid and its salts;
(RS)-(±)-6, 7-dihydro-8- (cis-4'-hydroxy-3'-methyIpiperidin-l-yl)-5-methyI-l-oxo-lH, 5H- benzo[i,j]quinoUzine-2-carboxylic acid and its salts; or
(RS)-(±)-6, 7-dihydro-8- (4'-hydroxy-3', 3'-dimethylpiperidin-l-yl)-5-methyl-l-oxo-lH, 5H- benzo[i,j]quinoHzine-2-carboxylic acid and its salts.
37. An efflux pump inhibitor of the NorA, Bmr, Pmr A, QacA and/or QacB pump/s wherein said efflux pump inhibitor has the Structure 1 below
Figure imgf000121_0001
Structure 1 wherein,
Ri = H, Cj.6 alkyl, C3.6 cycloalkyl, or optionaUy substituted aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, aryIS(0)taIkyI, where t=0,l or 2, or when X is C and the nitrogen atom to which Ri is linked forms an optionaUy substituted 4-, 5-, 6- or 7-membered ring with X of the adjacent ring, the ring optionally containing one or more hetero atoms selected from nitrogen, oxygen or sulfur atoms said heteroatom(s) represented by Y, preferably Ri is - CH2CH2-, CH2Y-, CH2CH2CH2-, CH2CH2Y-, CH2CH2CH2CH2- and CH2CH2CH2Y- where Y represents NH, O, or S. If the ring is substituted, the substituent is Cι_6 alkyl group;
R2 = H, CHO, COOR3, or CONHRι3; where Ri3 = H or the NHRι3 of CONHRJ3 is the residue of one of the 20 naturaUy occurring amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proUne, serine, threonine, tryptophan, tyrosine, valine or the opticaUy active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;
R3 = H, Ci.6 alkyl, C3.6 cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2,
(CH2)»CH(Rι4) 0C(=0)R1S, (CH2)nCH(Rι4) C(=0)ORιS wherein n = 0-6, R]4 = H or CH3; and Rιs = C2Hs or C(CH3)3 ;
Figure imgf000121_0002
wherein B=CH or N, and when B=CH, Z=NH or NCH3, and when B=N, Z=CH, O, NH, S or
NCH3; p=0-2; q=0-2, R» = H, ja =H, or R, and R»a taken together are oxo (=0), or thio (=S); Rs = H, C1.5 alkyl, amino, alkylamino, or acylamino; Re = H, C].fi alkyl, halo ,amino, or hydroxy; R7 = OH, halo or
NR9 Rio wherein R9 and R10 are the same or different and represent H, Cι.6 alkyl or (CH2)nOA, or R9 is H and Rio is a 4-membered, 5-membered, 6-membered, or 7-membered carbocycUc, mono or bicycUc ring, or mono or bicyclic heterocycUc ring Unked to the nitrogen of NR9R10 through an atom of the heterocycle other than the heterocyclic atom, or R9 and Rι0 taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocycUc, bicycUc, and said carbocycle and heterocycle is optionally substituted; or R7 = NHOA, NHCOORn, or NH(CH2)nNR9R 10,
where n=l,2 or 3, Z=CH or N, and when Z=CH, W=NH or
Figure imgf000122_0001
when Z=N, W is absent;
o orr where n=0,l,or 2
Figure imgf000122_0002
wherein the R7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R7 moiety has one of its link bonds linked to the core formula of Formula I and the second of its Unk bonds is Unked to an optionaUy substituted phenyl carboxylic acid or ester moiety thereof,
A = H, C1.6 alkyl, glycosyl, aralkyl, Cι_6 alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or vaUne; or.
A is C6Hn06, S03H, or P03H2,
Ru = H, Ci_6 alkyl, C _6 cycloalkyl, or heterocyclic group,
X = CH, C-F, C-Cl, C-CH3, C-CF3, C-OCH3, C-OCHF2, C-OCF3, N or when X is equal to C it forms together with the nitrogen atom of the adjacent ring an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, containing carbon atoms and optionaUy Y atoms representing one or more nitrogen , oxygen or sulfur atoms; if the ring is substituted, the substituent is Cι_6 alkyl group; and their pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.
38. The efflux pump inhibitor according to claim 37 selected from : l-Ethyl-6-fluoro-l, 4-dihydro -7-(l', 2',3',4'-tetrahydroisoquinolin-2-yl)-4-oxo-quinoline-3- carboxylic acid and its salts; l-Ethyl-6,8-fluoro-l, 4-dihydro -7-(4'-acetoxypiperidin-l-yl)-4-oxo-quinoline-3-carboxyUc acid and its salts; l-Ethyl-6,8-fluoro-l, 4-dihydro -7-(4'-{2'-(2'-oxazolidin-l-yI) ethyl} piperazin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
1- Ethyl-6, 8-difluoro-l, 4-dihydro -7-{(loc,5oc,6oc)-6-amino-3-azabicyclo [3.1.0]-hex-3-yl}-4-oxo- quinoUne-3-carboxyUc acid and its salts; 5-Amino-l- ethyl -6, 8-difluoro-l, 4-dihydro -7-(3'-amino-5'-methyl pyrrolidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l- ethyl-6, 8-difluoro-l, 4-dihydro -7-(4'-aminopiperidin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts;
5-Amino-l- ethyl -6, 8-difluoro-l, 4-dihydro -7-{4'-(acetamido) piperidin-l-yl}-4-oxo-quinoIine-3- carboxylic acid and its salts;
5-Amino-l- ethyl-6, 8-difluoro-l, 4-dihydro -7-{(loc,5oc,6oc)-6'-(t-butoxycarbonyl amino)-3- azabicyclo [3.1.0]-hex-3-yl}-4-oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l,.4-dihydro-7-(3'-acetamido-5'-methylpyrroUdin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-7-(3'-amino-5'-methylpyrroUdin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts; l-CycIopropyl-6-fluoro-l,4-dihydro— 7-(4'-acetoxypiperidin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts; l-CycIopropyl-6-fluoro-l,4-dihydro -7-{4'-(dimethylamino) piperidin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(3',5'-dimethylpiperidin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro -7-(4'-hydroxy-3',5'-dimethylpiperidin-l-yl)-4-oxo-quinoUne-
3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro- -7-(3', 4', 5'-trimethyl piperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts; l-CycIopropyl-6-fluoro-l, 4-dihydro- 7-(3', 5'-dimethyl-4'-ethyl piperazin-l-yl)-4-oxo-quinoIine-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-5-methyI- 7-(4'-ethoxypiperidin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl- 7-(3', 3'-dimethylpiperazin-l-yl)-4-oxo-quinoUne-3- ' carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-(dimethylamino)-3'-methyl piperidin-l-yl}-4- oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-3'-isobutyI piperidin-l-yl)-4-oxo- quinoline-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-3',3'-dimethyl piperidin-l-yl)-4-oxo- quinoline-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-3 5'-dimethyl piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(3'-methylpiperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts;
5-Amino-l-cyclopropyl-.6-fluoro-8-methoxy-l,4-dihydro-7-(cis-4'-amino-3',5'-dimethylpiperidin-l- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts; l-Cyclopropyl-6,8-difluoro-5-methyl-l,4-dihydro-7-(4'-hydroxy-3'-aminomethyl piperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts;
5-Anύno-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(5'amino-2'-methyl-pyrroIidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{3'-(L-Ala-L-Ala) amino pyrroUdin-l-yl}-4- oxo-quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cycIopropyl-6, 8-difluoro-l, 4-dihydro -7-{4'-(di-n-butylamino) piperidin-l-yI)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{4'-(t-butoxycarbonyl-L-AIa-L- Ala)aminopiperidin-l-yl}-4-oxo-quinoline-3-carboxyIic acid and its salts; 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-(4'- propionoxy piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyI-6, 8-difluoro-l, 4-dihydro -7-(4'-hydroxy-3',3'-dimethyl-piperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6,8-difluoro-l, 4-dihydro -7-{4'-(l-pyrroUdinyl) piperidin-l-yl)-4-oxo- quinoHne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-{4'-[(piperidin-4-yl) aminomethyl]-piperidin-l- yl}-4-oxo-quinoline-3-carboxylic acid and its salts;
5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{(l,2',2', 6',6'-pentamethyl piperidin-4- yl)methylamino}-4-oxo-quinoUne-3-carboxylic acid and its salts;
5-Amino-l-cycIopropyl-6,8-difluoro-l, 4-dihydro -7-(3',5'-dimethyl morphoUn-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-(4'-cyclopropyl piperazin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-(3', 5'-dimethyl-4-pivaloyl piperazin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts;
Ethyl 6,8-Difluoro-7-(4-hydroxypiperidin-l-yl)-l-(l-phenylthio-3(5)-but-3-yl)-l,4-dihydro-4-oxo- quinoUne-3-carboxylate;
1- (2'-Trifluoromethylphenyl) -6-fluoro-l, 4-dihydro- -7-(3', 3', 4'-trimethyl piperazin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l- (2'-trifluoromethylphenyl)-6,8-difluoro-l, 4-dihydro -7-(morpholin-l-yl)-4-oxo- quinoline-3-carboxyUc acid and its salts;
5-Amino-l- (2'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihydro -7-(3',5'-dimethylmorphoUn-l- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts; 5-Amino-l- (2'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihydro -7-(3',5'-dimethyl piperazinyl-1- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts;
5-Amino-l- (4'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihydro -7-(3'-aminopyrroIidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts;
1- (4'-Fluorophenyl) -6-fluoro-l,4-dihydro -7-{4'-ethylamino)piperidin-l-yl)-4-oxo-quinoline-3- carboxyUc acid and its salts;
1- (2',4'-Difluorophenyl) -6-fluoro-l, 4-dihydro-7-(3', 5'-dimethyl piperidin-l-yl)-4-oxo-quinotine- 3-carboxylic acid and its salts;
5-Amino-l- (2',4'-difluorophenyl) -6, 8-difluoro-l, 4-dihydro -7-(3'-hydroxy-5'-methylpyrroUdin-l- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts; 5-Amino-l- (2',4'-difluorophenyl) -6, 8-difluoro-l, 4-dihydro -7-(3',3'-dimethyl piperazinyl-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro -7-{(3'-aminoethoxycarbonyl)pyrroUdin-3-yl}-4-oxo- naphthyridine-3-carboxylic acid and its salts l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(pyrroUdin-3-yl-amino)-4-oxo-naphthyridine-3-carboxyUc acid and its salts;
1- (2',4'-Difluorophenyl) -6-fluoro-l, 4-dihydro -7-(piperidin-4-yl-amino)-4-oxo-naphthyridine-3- carboxylic acid and its salts;
Ethyl-l- (2',4'-difluorophenyl) -6-fluoro-l, 4-dihydro -7-{[lcc,5oc,6oc]-3-N-benzyl-3- azabicyclo[3.1.0]hex-6-yl-amino}-4-oxo-naphthyridine-3-carboxylate and its salts; l-(2,4-difluorophenyl) -6-fluoro-7-(l-phenyl-4,5,6,7-tetrahydropyrazolo
[4,3-c]pyridin-l-yl-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid and is salts;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-carboxamidopiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid and its salts;
(R)-(+)-9-FIuoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid L-arginine salt;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxy-3',3'-dimethylpiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid and its salts;
(S)-(-)-N-methylpiperidin-l-yl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo[i,j]quinoUzine-2-carboxylate; (S)-(-)-MorphoUnoethyl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxyIate and its salts;
Ethoxycarbonylmethyl (R)-(+)- 9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo [i,j] quinoUzine-2-carboxylate; N-l-{7-(l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-quinoline-3-carboxylic acid)}-N-3-amino-{7-(l-
(2,4-difluorophenyl)-6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid)}- pyrrolidine;
N-l-{7-(l-cyclopropyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid)}-N-3- amino-{7-(l-cyclopropyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid)}- pyrroUdine;
N-l-{7-(l-cyclopropyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid)}-N-3- amino-{7-(l-cyclopropyl -6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoUne-3-carboxyUc acid)}- pyrroUdine;
N-l-{7-(l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxyUc acid)}-N-4-{7- (l-cycIopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoline-3-carboxylic acid)}-piperazine;
N-l-{7-(l-cyclopropyl-6-fluoro-5-methyl-l,4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N-3- amino-{7-( l-(2,4-difluorophenyl) -6-fluoro- 1, 4-dihydro-4-oxo-l, 8-naphthyridine-3-carboxylic acid)}-pyrroUdine;
N-l- {7-(l-cyclopropyl-6-fluoro-5-methyl-l, 4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N-4- amino {7-(l-cyclopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoUne-3-carboxylic acid)}- piperidine;
N-l- {7-(l-cyclopropyl-6-fluoro-5-methyl-l, 4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N-3- amino{7-(l-cyclopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoline-3-carboxylic acid)}- pyrrolidine; N-l- {7-(l-(2,4-difluorophenyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid)}-N-4- {7-(l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-quinoline-3-carboxylic acid)}- piperazine;
N-3-azabycyclo {7-(l-(2,4-difluorophenyl)-6-fluoro-l ,4-dihydro-4-oxo-l ,8-naphthyridine-3- carboxylic acid)}-[loc,5oc,6oc]-N-6-amino-{7-l-(2,4-difluorophenyl)-6-fluoro-l,4-dihydro-4-oxo-l,8- naphthyridine-3-carboxylic acid)}-[3.1.0] hexane; or
N-l- {7-(l-cyclopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N- 4-amino-{ethyl 2,3,6-trifluorophenyI-4-carboxyIate}-piperidine.
39. An efflux pump inhibitor of the MexAB-OprM, MexCD-Opr J, MexEF-OprM, MexXY-OprM, AcrAB-TolC, AcrEF, MarA, SoxS and/or Tet pump/s, wherein said efflux pump inhibitor has the Structure 1 below
Figure imgf000125_0001
Structure 1 wherein,
Ri = H, Cι-6 alkyl, C3.6 cycloalkyl, or optionally substituted aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2, or when X is C and the nitrogen atom to which Rt is linked forms an optionaUy substituted 4-, 5-, 6- or 7-membered ring with X of the adjacent ring, the ring optionally containing one or more hetero atoms selected from nitrogen, oxygen or sulfur atoms said heteroatom(s) represented by Y, preferably Rj is - CH2CH2-, CH2Y-, CH2CH2CH2-, CH2CH2Y-, CH2CH2CH2CH2- and CH2CH2CH2Y- where Y represents NH, O, or S. If the ring is substituted, the substituent is Cι.6 alkyl group;
R2 = H, CHO, COOR3, or CONHRι3, where R13 = H or the NHRι3 of CONHRι3 is the residue of one of the 20 naturaUy occurring amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine or the opticaUy active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;
R3 = H, Ci.6 alkyl, C3.6 cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2, wherein n = 0-6, RM = H or CH3;
Figure imgf000126_0001
or R3 is / \
-(CH2)p- ■B Z
/
-( )q wherein B=CH or N, and when B=CH, Z=NH or NCH3, and when B=N, Z=CH, O, NH, S or
NCH3; p=0-2; q=0-2, R» = H, ja = H, or R4 and ja taken together are oxo (=0), or tbio (=S); Rs = H, C1.5 alkyl, amino, alkylamino, or acylamino; Re = H, Cι_6 alkyl, halo ,amino, or hydroxy; R7 = OH, halo or
NR9 Rio wherein R9 and Rι0 are the same or different and represent H, Cι_6 alkyl or (CH2)nOA, or R9 is H and Rι0 is a 4-membered, 5-membered, 6-membered, or 7-membered carbocycUc, mono or bicycUc ring, or mono or bicyclic heterocycUc ring Unked to the nitrogen of NR9Rιo through an atom of the heterocycle other than the heterocyclic atom, or R9 and 0 taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocycUc, bicyclic, and said carbocycle and heterocycle is optionally substitued; or R7 = NHOA, NHCOOR„, or NH(CH2)nNR9R 10?
where n=l,2 or 3, Z=CH or N, and when Z=CH, W=NH or
Figure imgf000126_0002
when Z=N, W is absent;
or where n=0,l,or 2
Figure imgf000126_0003
wherein the R7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R7 moiety has one of its link bonds Unked to the core formula of Formula I and the second of its Unk bonds is Unked to an optionaUy substituted phenyl carboxylic acid or ester moiety thereof, A = H, Cι.6 alkyl, glycosyl, aralkyl, Cι.6 alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine; or. A is C6H„06, S03H, or P03H2,
Ru = H, .6 alkyl, C3.6 cycloalkyl, or heterocyclic group, X = CH, C-F, C-Cl, C-CH3, C-CF3, C-OCH3, C-OCHF2, C-OCF3, N or when X is equal to C it forms together with the nitrogen atom of the adjacent ring an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, containing carbon atoms and optionally Y atoms representing one or more nitrogen, oxygen or sulfur atoms; if the ring is substituted, the substituent is Cι„6 alkyl group; and their pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.
40. The efflux pump inhibitor according to claim 39 selected from: l-Cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl- 7-(4'-methoxypiperidin -l-yl)-4-oxo-quinoline- 3-carboxylic acid and its salts;
7-Bromo-l-cyclopropyl-6-fluoro-5-methyl-l,4-dihydro-4-oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-amino-3'-methylpiperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-amino-3'-methyl piperidin-1-yl)-
4-oxo-quinoline-3-carboxylic acid and its salts;
5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-{3,3-dimethyl-4'-ethylamino piperidin-l-yI}-4-oxo-quinoUne-3-carboxyUc acid and its salts; l-CycIopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-amino-3'-3'-dimethyl piperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-(dimethylamino)piperidin-l-yl}-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-4'-methylpiperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(3',3'-dimethyl-4'-hydroxypiperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6,8-difluoro-5-methyl-l,4-dihydro-7-(3'-aminomethyl-4'-hydroxypiperidin-l- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(3'-aminomethyl-4'-hydroxypiperidin-l-yl)- 4-oxo-quinoline-3-carboxylic acid and its salts; l-Ethyl-6,8-difluoro-l,4-dihydro-7-(3'-5'-dimethyIpiperazin-l-yl)-4-oxo-quinoline-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(4'-ethyl-3'-methylpiperazin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(3'-5'-dimethyl-4'-ethyIpiperazin-l-yl)-4-oxo-quinoline-
3-carboxylic acid and its salts; l-EthyI-6, 8-difluoro-l, 4-dihydro -7-{(loc,5oc,6oc)-6'-amino-3'-azabicyclo [3.1.0] hex-3'-yl}-4- oxo-quinoline-3-carboxyUc acid and its salts;
5-Amino-l-(2',4'-difluorophenyl)-6,8-difluoro-l,4-dihydro-7-(3'-aminopyrroUdin-l-yl)-4-oxo- quinoline-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-{(3'-amimoethoxycarbonyl pyrrolidin-3- yl}-4-oxo-quinoline-3-carboxyIic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(pyrroUdin-3'-ylamino)-4-oxo-naphthyridine-3- carboxylic acid and its salts; l-(2',4'-Difluorophenyl)-6-fluoro-l,4-dihydro-7-(piperidin-4'-ylamino)-4-oxo-naphthyridine-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro -7-(4'-amino-3'-ethylpiperidin-l-yl)-4-oxo-naphthyridine- 3-carboxylic acid and its salts;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid 0.2 hydrate; (S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid, choline salt;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[id]quinoUzine-2-carboxylic acid, 1-hydroxyethylpyrroUdine salt.
(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo [i,j] quinoUzine-2-carboxylic acid, diethanolamine salt;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinolizine-2-carboxylate. L-histidine salt;
(RS)-(±)-9-Fluoro-6,7-dihydro-8-{4'-(D-phenylalanyloxy) piperidin-l-yl}-5-methyl-l-oxo- , lH,5H-benzo[i,j]quinolizine-2-carboxyUc acid hydrochloride; (RS)-(±)-9-Fluoro-6,7-dihydro-8-{4'-(L-α-aspartyloxy) piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid hydrochloride;
(±)-9-FIuoro-6,7-dihydro-8-{4'-(L-leucyloxy)piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid hydrochloride;
(_).9.Fluoro-6,7-dihydro-8-{4'-(D-leucyloxy)piperidin-l-yl}-5-methyI-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid hydrochloride;
(S)-(-)-9-Fluoro-6,7-dihydro-8-{4'-(L-alanyloxy)piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxyUc acid hydrochloride;
(S)-(-)-MorphoUnoethyl-9-fluoro-6.7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo[i,j]quinoUzine-2-carboxylate and its salts; (R)-(+)-8,9-difluoro-6,7-dihydro-5-methyl-l-oxo-lH,5H-benzo [i,j] quinolizine-2- [S- phenylalanyl-S-lysine methyl ester] carboxamide; (RS)-(±)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo[i,j]quinoUzine-2-carboxyUc acid and its salts;
(RS)-(±)-9-Fluoro-6,7-dihydro-8-(cis-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo[i,j]quinoUzine-2-carboxyUc acid and its salts;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo[i,j]quinoUzine-2-carboxyUc acid and its salts;
7H-Pyrido[l,2,3-de]-l,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(4'-hydroxy-3'- ethylpiperidin-l'-yl)-7-oxo-6-carboxylic acid and its salts;
10-Fluoro-ll-[(loc,5oc,6oc )-6-amino-3-azabicycIo[3.1.0]hex-3-yl]-3,4-dihydro-4(S)-methyl-8- oxo-2H,8H-pyrido[l,2,3-ef]-l,5-benzoxazepine-7-carboxylic acid, hydrochloride;
41. A pharmaceutical composition effective for treatment of an infection of an animal by a microbe, comprising an efflux pump inhibitor and a pharmaceutically acceptable carrier, wherein said efflux pump inhibitor has the chemical structure of structure 1 below:
Figure imgf000129_0001
wherein,
Ri = H, Ci.6 alkyl, C3.6 cycloalkyl, or optionaUy substituted aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2, or when X is C and the nitrogen atom to which Rx is linked forms an optionaUy substituted 4-, 5-, 6- or 7-membered ring with X of the adjacent ring, the ring optionally containing one or more hetero atoms selected from nitrogen, oxygen or sulfur atoms said heteroatom(s) represented by Y, preferably Ri is - CH2CH2-, CH2Y-, CH2CH2CH2-, CH2CH2Y-, CH2CH2CH2CH2- and CH2CH2CH2Y- where Y represents NH, O, or S. If the ring is substituted, the substituent is Cι.6 alkyl group;
R2 = H, CHO, COOR3, or CONHRi3, where R13 = H or the NHRι3 of CONHRι3 is the residue of one of the 20 naturaUy occurring amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proUne, serine, threonine, tryptophan, tyrosine, valine or the opticaUy active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;
R3 = H, Ci.6 alkyl, C3.6 cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(0)talkyl, where t=0,l or 2, wherein n = 0-6, R14 = H or CH3;
Figure imgf000129_0002
wherein B=CH or N, and when B=CH, Z=NH or NCH3, and when B=N, Z=CH, O, NH, S or
NCH3; p=0-2; q=0-2, R4 = H, ja = H, or R4 and R,a taken together are oxo (=0), or thio (=S); Rs = H, Cι.5 alkyl, amino, alkylamino, or acylamino; Re = H, Cι.6 alkyl, halo ,amino, or hydroxy; R7 = OH, halo or
NR9 R10 wherein R9 and RJ0 are the same or different and represent H, Cι.6 alkyl or (CH2)nOA, or R9 is H and Rio is a 4-membered, 5-membered, 6-membered, or 7-membered carbocycUc, mono or bicycUc ring, or mono or bicyclic heterocycUc ring Unked to the nitrogen of NR9RX0 through an atom of the heterocycle other than the heterocyclic atom, or R9 and R10 taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocycUc, bicycUc, and said carbocycle and heterocycle is optionally substitued; or R7 = NHOA, NHCOORn, or NH(CH2)„NR9R10;
or N, and when Z=CH, W=NH or
Figure imgf000130_0001
or where n=0,l,or 2
Figure imgf000130_0002
wherein the R7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R7 moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is Unked to an optionaUy substituted phenyl carboxylic acid or ester moiety thereof,
A = H, Cι.6 alkyl, glycosyl, aralkyl, Cx.6 alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or vaUne; or. A is C6Hn06, S03H, or P03H2,
Ru = H, Ci.6 alkyl, C3.6 cycloalkyl, or heterocyclic group,
X = CH, C-F, C-Cl, C-CH3, C-CF3, C-OCH3, C-OCHF2, C-OCF3, N or when X is equal to C it forms together with the nitrogen atom of the adjacent ring an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, containing carbon atoms and optionally Y atoms representing one or more nitrogen , oxygen or sulfur atoms; if the ring is substituted, the substituent is Cι_6 alkyl group; and their pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs;
42. A pharmaceutical composition according to claim 41 wherein said efflux pump inhibitor has structure 2
Figure imgf000131_0001
Structure 2 wherein Ri, R2, R5, R7, X and Y are as defined in claim 1.
43. A pharmaceutical composition according to claim 41, wherein said efflux pump inhibitor has the chemical structure 3 below
Figure imgf000131_0002
Structure 3 wherein Rx, R2, R5, R7, X and Y are as defined in claim 1.
44. The pharmaceutical composition of claim 41, wherein said microbe is a bacterium.
45. The pharmaceutical composition of claim 41 further comprising an antimicrobial agent.
46. The pharmaceutical composition of claim 45, wherein said microbe is a bacterium.
47. The pharmaceutical composition of claims 41 and 46, wherein said antimicrobial agent is an antibacterial agent.
48. The pharmaceutical composition of claims 41 further comprising a macroUde.
49. The pharmaceutical composition of claim 48, wherein the said macrolide/ketolide is selected from the group consisting of azithromycin, teUthromycin, clarithromycin, erythromycin, rokitamycin, roxithromycin, spiramycin and josamycin.
50. The pharmaceutical composition of claims 41 and 49, wherein the said efflux pump inhibitor is l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-amino-3'-methyl piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-(methylamino)-3',3'- dimethylpiperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid and its salts; i-Propyl l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-(4'-amino-3',3'-dimethyl-piperidin-l- yl}-4-oxo-quinoline-3-carboxylate and its salts; n-Butyl l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-(4'-amino-3',3'-dimethyl-piperidin-l- yl}-4-oxo-quinoline-3-carboxylate and its salts; Ethoxycarbonylmethyl l-cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-amino-3',3'- dimethylpiperidin-l-yl)-4-oxo-quinoline-3-carboxylate and its salts;
Benzyl l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-{4'-(t-butoxycarbonyl amino)-3',3'- dimethylpiperidin-l-yl)-4-oxo-quinoline-3-carboxylate and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-N-(t-butoxycarbonyl-L-alanyl) amino-3',3'- dimethyIpiperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride; l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-L-alanylamino-3',3'-dimethylpiperidin-l- yl}-4-oxo-quinoline-3-carboxyUc acid hydrochloride; l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(3',3'-dimethyl-4'-(t-butoxy- carbonylvalinylamino)piperidin-l-yl}-4-oxo-quinoUne-3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-(3',3'-dimethyl-4'-(L)-valyI-aminopiperidin-l- yl}-4-oxo-quinoUne-3-carboxylic acid hydrochloride; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-(L)-aspartylamino-3',3'-dimethylpiperidin-l- yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride; l-Ethyl-6,8-difluoro-l,4-dihydro-7-(4'-ethylaminopiperidin-l'-yl)-4-oxo-quinoline-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(4'-amino-3'-methyl piperidin -l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(quinuclidinyl-3-yl-amino)-4-oxo-quinoUne-3- carboxylic acid and its salts; 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro-7- {(loc,5oc,6oc)-6-amino-N-benzyl-3-azabicyclo [3.1.0] hex-6-yl}-4-oxo-quinoUne-3-carboxylic acid and its salts; l-(3'-Fluorophenyl)-6-fluoro -1, 4-dihydro -7-(4'-methylpiperazin-l'-yl)-4-oxo-quinoline-3- carboxylic acid and its salts; l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihydro-7- (4'-ethylaminopiperidin-l'-yI)- 4-oxo-quinoIine-3- carboxylic acid and its salts; l-(2',4'-Difluorophenyl)-6-fluoro-5-methyl-l, 4-dihydro -7-(4'-aminopiperidin-l'-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-(2',4'-Difluorophenyl)-6-fluoro-5-methyl-l,4-dihydro-7-(4'-methylamino piperidin-l'-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(3'-aminopyrrolidin-l'-yl)-4-oxo-l,8-naphthyridine-3- carboxylic acid and its salts; l-CyclopropyI-6-fluoro-l,4-dihydro-7-{(loc,5oc,6oc)-6-amino~N-benzyl-3-azabicyclo [3.1.0] hex-6- yl}-4-oxo-l,8-naphthyridine-3-carboxyUc acid and its salts; l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihydro-7-(3'-aminopyrroUdin-l'-yl)- 4-oxo-l,8- naphthyridine-3-carboxylic acid and its salts; l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihydro-7-{(loc,5oc,6oc)-6-amino-N-benzyI-3-azabicyclo
[3.1.0]hex-6-yl}- 4-oxo-l,8-naphthyridine-3-carboxylic acid and its salts; l-(2,4-Difluorophenyl)-6-fluoro-l,4-dihydro-7-(3',3'-dimethyl-4'-hydroxy piperdin-l'-yl)-4-oxo- l,8-naphthyridine-3-carboxyUc acid and its salts;
(RS)-(±)-9-Fluoro-6, 7-dihydro-8-{4'-(L-α-aspartyloxy)piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid hydrochloride;
7H-Pyrido[l,2,3-de]-l,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(3'-ethyl 4'- hydroxypiperidin-l'-yl)-7-oxo-6-carboxyUc acid and its salts;
7H-Pyrido[l,2,3-de]-l,4-benzoxazine-9-fluoro-2, 3-dihydro-3-methyl-10- (3'-amino methyl-4'- hydroxypiperidin-l'-yl)-7-oxo-6-carboxyUc acid and its salt; l-Cyclopropyl-6, 8-difluoro-5-methyl-l, 4-dihydro -7-(3', 3'-dimethyl-4'-ethylamino piperidin-1- yl)-4-oxo-quinoline-3-carboxyUc acid and its salt; l-cyclopropyl-6,7,8-trifluoro-5-methyl-l,4-dihydro - 4-oxo-quinoUne-3-carboxylic acid;
(S)-(-)-9-Fluoro-6,7-dihydro-8- (3', 3'-dimethyl-4'-ethylaminopiperidin-l-yl)-5-methyl-l-oxo-lH,
5H-benzo[ij]quinoUzine-2-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-7- (3'-aminomethyl-4'-hydroxypiperidin l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-7- (4'-dimethylamino-3'-methylpiperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-cyclopropyl aminopiperidin-l-yl}-4- oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-(t-butoxycarbonyl (L)-Ala-AIa)amino-3', 3'- dimethyl piperidin-l-yl}-4-oxo-quinoUne-3-carboxylic acid hydrochloride; 5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-ethylamino-3', 5'- dimethylpiperidin-l-yl}-4-oxo-quinoline-3-carboxyIic acid and its salts; Ethyl l-(2,4-difluorophenyl) -6-fluoro -1, 4-dihydro-7- (4-amino-3-ethylpiperidin-l-yl)- 4-oxo-l,8- naphthyridine-3-carboxylate; l-(2,4-difluorophenyl) -6-fluoro-l, 4-dihydro-7- (4-amino-3, 5-dimethylpiperidin-l-yl)- 4-oxo-l,8- naphthyridine-3-carboxyUc acid and its salts;
Ethyl l-(2,4-difluorophenyl) -6-fluoro-5-methyl-l, 4-dihydro-7- (4-amino-3, 3-dimethylpiperidin-l- yl)- 4-oxo-l,8-naphthyridine-3-carboxylate; (S)-(-)-9-fluoro-6.7-dihydro-8- (4'-hydroxy- 3'-fluoropiperidin-l-yl)-5-methyl-l-oxo-lH, 5H- benzo[i,j]quinoUzine-2-carboxylic acid and its salts;
10-Fluoro-ll- (4-aminopiperidin-l-yl)-3,4-dihydro-4 (S)-methyl-8-oxo-2H, 8H-pyrido[l,2,3-ef]-l,5- benzoxazipin-7-carboxylic acid and its salt; (RS)-(±)-6, 7-dihydro-8- (trans-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l-oxo-lH, 5H- benzo[i,j]quinolizine-2-carboxylic acid and its salts;
(RS)-(±)-6, 7-dihydro-8- (cis-4'-hydroxy-3'-methyIpiperidin-l-yl)-5-methyl-l-oxo-lH, 5H- benzo[i,j]quinoUzine-2-carboxylic acid and its salts; or
(RS)-(±)-6, 7-dihydro-8- (4'-hydroxy-3', 3'-dimethylpiperidin-l-yl)-5-methyl-l-oxo-lH, 5H- benzo [i,j] quinolizine-2-carboxylic acid and its salts.
51. The pharmaceutical composition of Claim 41 further comprising a fluoroquinolone.
52. The pharmaceutical composition of claim 51, wherein the said fluoroquinolone is selected from the group consisting of ciprofloxacin, norfloxacin, levofloxacin, cUnafloxacin, sitafloxacin, gatifloxacin, moxifloxacin, trovafloxacin, gemifloxacin and nadifloxacin.
53. The pharmaceutical composition of claims 41 and 52, wherein the said efflux pump inhibitor is: l-Ethyl-6-fluoro-l, 4-dihydro -7-(l', 2',3',4'-tetrahydroisoquinolin-2-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-EthyI-6, 8-fluoro-l, 4-dihydro -7-(4'-acetoxypiperidin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts; l-Ethyl-6, 8-fluoro-l, 4-dihydro -7-(4'-{2'-(2'-oxazolidin-l-yl) ethyl} piperazin-l-yl)-4-oxo- quinoline-3-carboxyUc acid and its salts;
1- Ethyl-6, 8-difluoro-l, 4-dihydro -7-{(loc,5oc,6oc)-6-amino-3-azabicyclo [3.1.0]-hex-3-yl}-4-oxo- quinoUne-3-carboxyUc acid and its salts; 5-Amino-l- ethyl -6, 8-difluoro-l, 4-dihydro -7-(3'-amino-5'-methyl pyrroUdin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l- ethyl-6, 8-difluoro-l, 4-dihydro -7-(4'-aminopiperidin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts;
5-Amino-l- ethyl -6, 8-difluoro-l, 4-dihydro -7-{4'-(acetamido) piperidin-l-yl}-4-oxo-quinoline-3- carboxylic acid and its salts;
5-Amino-l- ethyl-6, 8-difluoro-l, 4-dihydro -7-{(loc,5oc,6oc)-6'-(t-butoxycarbonyl amino)-3- azabicyclo [3.1.0]-hex-3-yl}-4-oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-7-(3'-acetamido-5'-methylpyrroUdin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-7-(3'-amino-5'-methylpyrroUdin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-CycIopropyl-6-fluoro-l,4-dihydro~7-(4'-acetoxypiperidin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro -7-{4'-(dimethyIamino) piperidin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(3',5'-dimethylpiperidin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro -7-(4'-hydroxy-3',5'-dimethylpiperidin-l-yl)-4-oxo-quinoUne- 3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro- -7-(3', 4', 5'-trimethyl piperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro- 7-(3', 5'-dimethyl-4'-ethyl piperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl- 7-(4'-ethoxypiperidin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl- 7-(3', 3'-dimethylpiperazin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-(dimethylamino)-3'-methyl piperidin-l-yl}-4- oxo-quinoUne-3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-3'-isobutyl piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-3',3'-dimethyl piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-3',5'-dimethyl piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-CycIopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(3'-methylpiperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts; 5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(cis-4'-amino-3',5'-dimethyIpiperidin-l- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts; l-Cyclopropyl-6,8-difluoro-5-methyl-l,4-dihydro-7-(4'-hydroxy-3'-aminomethyl piperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(5'amino-2'-methyl-pyrrolidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{3'-(L-Ala-L-Ala) amino pyrroUdin-l-yl}-4- oxo-quinoUne-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{4'-(di-n-butylamino) piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{4'-(t-butoxycarbonyl-L-Ala-L-
Ala)aminopiperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid and its salts; 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-(4'- propionoxy piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-(4'-hydroxy-3',3'-dimethyl-piperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6,8-difluoro-l, 4-dihydro -7-{4'-(l-pyrroUdinyl) piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-{4'-[(piperidin-4-yl) aminomethyl]-piperidin-l- yl}-4-oxo-quinoUne-3-carboxylic acid and its salts;
5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{(l,2',2', 6',6'-pentamethyl piperidin-4- yl)methylamino}-4-oxo-quinoUne-3-carboxylic acid and its salts; 5-Amino-l-cyclopropyl-6,8-difluoro-l, 4-dihydro -7-(3',5'-dimethyl morphoUn-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-(4'-cycIopropyl piperazin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-(3', 5'-dimethyl-4-pivaloyl piperazin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts;
Ethyl 6,8-Difluoro-7-(4-hydroxypiperidin-l-yl)-l-(l-phenylthio-3(5,)-but-3-yl)-l,4-dihydro-4-oxo- quinotine-3-carboxylate;
1- (2'-Trifluoromethylphenyl) -6-fluoro-l, 4-dihydro- -7-(3', 3', 4'-trimethyl piperazin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; 5-Amino-l- (2'-trifluoromethylphenyl)-6,8-difluoro-l, 4-dihydro -7-(morpholin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l- (2'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihydro -7-(3',5'-dimethylmorphoUn-l- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts;
5-Amino-l- (2'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihydro -7-(3',5'-dimethyl piperazinyl-1- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts;
5-Amino-l- (4'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihydro -7-(3'-aminopyrrolidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts;
1- (4'-Fluorophenyl) -6-fluoro-l,4-dihydro -7-{4'-ethyIamino)piperidin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts; 1- (2',4'-Difluorophenyl) -6-fluoro-l, 4-dihydro-7-(3', 5'-dimethyl piperidin-l-yl)-4-oxo-quinoUne- 3-carboxylic acid and its salts; 5-Amino-l- (2',4'-difluorophenyl) -6, 8-difluoro-l, 4-dihydro -7-(3'-hydroxy-5'-methylpyrroUdin-l- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts;
5-Amino-l- (2',4'-difluorophenyl) -6, 8-difluoro-l, 4-dihydro -7-(3',3'-dimethyl piperazinyl-l-yl)-4- oxo-quinoline-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro -7-{(3'-aminoethoxycarbonyl)pyrroUdin-3-yl}-4-oxo- naphthyridine-3-carboxylic acid and its salts; l-CycIopropyl-6-fluoro-l,4-dihydro-7-(pyrroUdin-3-yl-amino)-4-oxo-naphthyridine-3-carboxylic acid and its salts;
1- (2',4'-Difluorophenyl) -6-fluoro-l, 4-dihydro -7-(piperidin-4-yl-amino)-4-oxo-naphthyridine-3- carboxylic acid and its salts;
Ethyl-1- (2',4'-difluorophenyl) -6-fluoro-l, 4-dihydro -7-{[loc,5oc,6oc]-3-N-benzyl-3- azabicyclo[3.1.0]hex-6-yl-amino}-4-oxo-naphthyridine-3-carboxylate and its salts; l-(2,4-difluorophenyl) -6-fluoro-7-(l-phenyl-4,5,6,7-tetrahydropyrazolo
[4,3-c]pyridin-l-yl-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxyUc acid and is salts; (S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-carboxamidopiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid and its salts;
(R)-(+)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinolizine-2-carboxyϋc acid L-arginine salt;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxy-3',3'-dimethylpiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo [i,j] quinoUzine-2-carboxyUc acid and its salts;
(S)-(-)-N-methylpiperidin-l-yl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo [i,j] quinoHzine-2-carboxyIate;
(S)-(-)-MorjlhoUnoethyl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylate and its salts; Ethoxycarbonylmethyl (R)-(+)- 9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo [i,j] quinoUzine-2-carboxylate;
N-l-{7-(l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-quinoline-3-carboxylic acid)}-N-3-amino-{7-(l-
(2,4-difluorophenyl)-6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid)}- pyrroUdine; N-l-{7-(l-cycIopropyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid)}-N-3- amino-{7-(l-cydopropyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid)}- pyrroUdine;
N-l-{7-(l-cyclopropyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid)}-N-3- amino-{7-(l-cyclopropyl -6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoUne-3-carboxyUc acid)}- pyrroUdine;
N-l-{7-(l-cycIopropyl-6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxyUc acid)}-N-4-{7-
(l-cyclopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoline-3-carboxyUc acid)}-piperazine; N-l-{7-(l-cyclopropyl-6-fluoro-5-methyl-l,4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N-3- amino-{7-( l-(2,4-difluorophenyl) -6-fluoro- 1, 4-dihydro-4-oxo-l, 8-naphthyridine-3-carboxylic acid)}-pyrroUdine;
N-l- {7-(l-cyclopropyl-6-fluoro-5-methyl-l, 4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N-4- amino {7-(l-cyclopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoUne-3-carboxylic acid)}- piperidine;
N-l- {7-(l-cyclopropyl-6-fluoro-5-methyl-l, 4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N-3- amino{7-(l-cyclopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoIine-3-carboxyIic acid)}- pyrroUdine; N-l- {7-(l -(2,4-difluorophenyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid)}-N-4- {7-(l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-quinoline-3-carboxyUc acid)}- piperazine;
N-3-azabycyclo{7-(l-(2,4-difluorophenyl)-6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3- carboxylic cid)}-[loc,5oc,6oc]-N-6-amino-{7-l-(2,4-difluorophenyl)-6-fluoro-l,4-dihydro-4-oxo-l,8- naphthyridine-3-carboxylic acid)}-[3.1.0] hexane; or
N-l- {7-(l-cyclopropyl-6,8-dUluoro-5-amino-l, 4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N-
4-amino-{ethyl 2,3,6-trifluorophenyl-4-carboxyIate}-piperidine.
54. The pharmaceutical composition of Claim 41 further comprising antimicrobial agents selected from the group of ciprofloxacin, levofloxacin, ofloxacin, gemifloxacin, nadifloxacin azithromycin, erythromycin, tetracycUne, linezolid and novobiocin.
55. The pharmaceutical composition of claim 41 and 54, wherein the said efflux pump inhibitor is l-Cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl- 7-(4'-methoxypiperidin -l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts;
7-Bromo-l-cyclopropyl-6-fluoro-5-methyI-l,4-dihydro-4-oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-amino-3'-methylpiperidin-l-yl)-4-oxo- quinoline-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-amino-3'-methyl piperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-{3,3-dimethyl-4'-ethylamino piperidin- l-yl}-4-oxo-quinoline-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-amino-3'-3'-dimethyl piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-(dimethylamino)piperidin-l-yl}-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-4'-methylpiperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(3',3'-dimethyl-4'-hydroxypiperidin-l-yl)-4-oxo- quinoUne-3-carboxylic acid and its salts; l-CycIopropyl-6,8-difluoro-5-methyl-l,4-dihydro-7-(3'-aminomethyl-4'-hydroxypiperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(3'-aminomethyl-4'-hydroxypiperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts; l-Ethyl-6,8-difluoro-l,4-dihydro-7-(3'-5'-dimethylpiperazin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(4'-ethyI-3'-methylpiperazin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(3'-5'-dimethyl-4'-ethylpiperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts; l-Ethyl-6, 8-difluoro-l, 4-dihydro -7-{(loc,5oc,6oc)-6'-amino-3'-azabicyclo [3.1.0] hex-3'-yl}-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-(2',4'-difluorophenyl)-6,8-difluoro-l,4-dihydro-7-(3'-aminopyrroUdin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-{(3'-amimoethoxycarbonyl pyrrolidin-3-yl}-4- oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(pyrroUdin-3'-ylamino)-4-oxo-naphthyridine-3-carboxyUc acid and its salts; l-(2',4'-Difluorophenyl)-6-fluoro-l,4-dihydro-7-(piperidin-4'-ylamino)-4-oxo-naphthyridine-3- carboxylic acid and its salts; l-CycIopropyl-6-fluoro-l, 4-dihydro -7-(4'-amino-3'-ethylpiperidin-l-yl)-4-oxo-naphthyridine-3- carboxylic acid and its salts;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid 0.2 hydrate; (S)-(-)-9-FIuoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo [i,j] quinoUzine-2-carboxylic acid, choline salt;
(S)-(.)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid, 1-hydroxyethylpyrrolidine salt; (S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid, diethanolamine salt; (S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylate, L-histidine salt; (RS)-(±)-9-Fluoro-6,7-dihydro-8-{4'-(D-phenylaIanyloxy) piperidin-l-yI}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxyUc acid hydrochloride;
(RS)-(±)-9-Fluoro-6,7-dihydro-8-{4'-(L-α-aspartyloxy) piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid hydrochloride; (RS)-(±)-9-FIuoro-6,7-dihydro-8-{4'-(L-leucyIoxy)piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid hydrochloride;
(S)-(-)-9-Fluoro-6,7-dihydro-8-{4'-(D-leucyloxy)piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinolizine-2-carboxyIic acid hydrochloride;
(S)-(-)-9-FIuoro-6,7-dihydro-8-{4'-(L-alanyloxy)piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo [i,j] quinoUzine-2-carboxylic acid hydrochloride;
(S)-(-)-MorphoUnoethyl-9-fluoro-6.7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyI-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylate and its salts;
(R)-(+)-8,9-difluoro-6,7-dihydro-5-methyl-l-oxo-lH,5H-benzo[i,j]quinolizine-2- [S-phenylalanyl-S- lysine methyl ester] carboxamide; (RS)-(+)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methyIpiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo[i,j]quinoUzine-2-carboxyUc acid and its salts;
(RS)-(±)-9-Fluoro-6,7-dihydro-8-(cis-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid and its salts;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo [i,j] quinolizine-2-carboxylic acid and its salts;
7H-Pyrido[l,2,3-de]-l,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(4'-hydroxy-3'- ethylpiperidin-l'-yl)-7-oxo-6-carboxylic acid and its salts; or
10-Fluoro-ll-[(loc,5oc,6oc )-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3,4-dihydro-4(S)-methyl-8-oxo- 2H,8H-pyrido[l,2,3-ef[-l,5-benzoxazepine-7-carboxyUc acid, hydrochloride.
56. The method according to any one of claims 1,4,8, or 11 wherein the efflux pump inhibitor is selected from: l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-amino-3'-methyl piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-(methylamino)-3',3'- dimethylpiperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid and its salts; i-Propyl l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-(4'-amino-3',3'-dimethyl-piperidin-l- yl}-4-oxo-quinoline-3-carboxylate and its salts; n-Butyl l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-(4'-amino-3',3'-dimethyI-piperidin-l- yl}-4-oxo-quinoline-3-carboxylate and its salts; Ethoxycarbonylmethyl l-cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-amino-3',3'- dimethylpiperidin-l-yl)-4-oxo-quinoline-3-carboxylate and its salts;
Benzyl l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-{4'-(t-butoxycarbonyl amino)-3',3'- dimethylpiperidin-l-yl)-4-oxo-quinoline-3-carboxylate and its salts; l-CycIopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-N-(t-butoxycarbonyl-L-alanyl) amino-3',3'- dimethylpiperidin-l-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride; l-CyclopropyI-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-L-alanylamino-3',3'-dimethylpiperidin-l- yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride; l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(3',3'-dimethyl-4'-(t-butoxy- carbonylvalinyIamino)piperidin-l-yI}-4-oxo-quinoUne-3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-(3',3'-dimethyI-4'-(L)-valyl-aminopiperidin-l- yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-(L)-aspartylamino-3',3'-dimethylpiperidin-l- yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride; l-Ethyl-6,8-difluoro-l,4-dihydro-7-(4'-ethylaminopiperidin-l'-yl)-4-oxo- quinoUne-3- carboxylic acid and its salts;
5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(4'-amino-3'-methyl piperidin -l-yl)-4-oxo- quinoline-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(quinuclidinyl-3-yl-amino)-4-oxo-quinoUne-3- carboxylic acid and its salts;
5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro-7- {(loc,5oc,6oc)-6-amino-N-benzyl-3-azabicyclo [3.1.0] hex-6-yl}-4-oxo-quinoUne-3-carboxylic acid and its salts; l-(3'-Fluorophenyl)-6-fluoro -1, 4-dihydro -7-(4'-methyIpiperazin-l'-yl)-4-oxo-quinoline-3- carboxylic acid and its salts; l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihydro-7- (4'-ethylaminopiperidin-l'-yl)- 4-oxo-quinoline-3- carboxylic acid and its salts; l-(2',4'-Difluorophenyl)-6-fluoro-5-methyl-l, 4-dihydro -7-(4'-aminopiperidin-l'-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-(2',4'-DifluorophenyI)-6-fluoro-5-methyl-l,4-dihydro-7-(4'-methyIamino piperidin-l'-yI)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(3'-aminopyrroIidin-l'-yl)-4-oxo-l,8-naphthyridine-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-{(loc,5oc,6oc)-6-amino~N-benzyl-3-azabicyclo [3.1.0] hex-6- yl}-4-oxo-l,8-naphthyridine-3-carboxyUc acid and its salts; l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihydro-7-(3'-aminopyrroUdin-l'-yl)- 4-oxo-l,8- naphthyridine-3-carboxylic acid and its salts; l-(2,4-Difluorophenyl) -6-fluoro-l, 4-dihydro-7-{(loc,5oc,6oc)-6-amino-N-benzyl-3-azabicyclo
[3.1.0]hex-6-yl}- 4-oxo-l,8-naphthyridine-3-carboxylic acid and its salts; l-(2,4-Difluorophenyl)-6-fluoro-l,4-dihydro-7-(3',3'-dimethyl-4'-hydroxy piperdin-l'-yl)-4-oxo- l,8-naphthyridine-3-carboxyUc acid and its salts; (RS)-(±)-9-Fluoro-6, 7-dihydro-8-{4'-(L-α-aspartyloxy)piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid hydrochloride;
7H-Pyrido[l,2,3-de]-l,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(3'-ethyl 4'- hydroxypiperidin-l'-yl)-7-oxo-6-carboxyUc acid and its salts;
7H-Pyrido[l,2,3-de]-l,4-benzoxazine-9-fluoro-2, 3-dihydro-3-methyl-10- (3'-amino methyl-4'- hydroxypiperidin-l'-yl)-7-oxo-6-carboxyUc acid and its salt; l-Cyclopropyl-6, 8-difluoro-5-methyl-l, 4-dihydro -7-(3', 3'-dimethyl-4'-ethylamino piperidin-1- yl)-4-oxo-quinoline-3-carboxyUc acid and its salt; l-cyclopropyl-6,7,8-trifluoro-5-methyl-l,4-dihydro - 4-oxo-quinoUne-3-carboxylic acid.
(S)-(-)-9-Fluoro-6,7-dihydro-8- (3', 3'-dimethyl-4'-ethylaminopiperidin-l-yl)-5-methyl-l-oxo-lH, 5H-benzo[i,j]quinoUzine-2-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-7- (3'-aminomethyl-4'-hydroxypiperidin l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-7- (4'-dimethylamino-3'-methylpiperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-cycIopropyl aminopiperidin-l-yl}-4- oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-(t-butoxycarbonyl (L)-Ala-Ala)amino-3', 3'- dimethyl piperidin-l-yl}-4-oxo-quinoUne-3-carboxylic acid hydrochloride;
5-Amino-l-cyclopropyI-6-fluoro-8-methoxy-l, 4-dihydro -7-{4'-ethylamino-3', 5'- dimethylpiperidin-l-yl}-4-oxo-quinoline-3-carboxyUc acid and its salts;
Ethyl l-(2,4-difluorophenyl) -6-fluoro -1, 4-dihydro-7- (4-amino-3-ethylpiperidin-l-yl)- 4-oxo-l,8- naphthyridine-3-carboxylate; l-(2,4-difluorophenyl) -6-fluoro-l, 4-dihydro-7- (4-amino-3, 5-dimethylpiperidin-l-yl)- 4-oxo-l,8- naphthyridine-3-carboxylic acid and its salts; Ethyl l-(2,4-difluorophenyl) -6-fluoro-5-methyl-l, 4-dihydro-7- (4-amino-3, 3-dimethylpiperidin-l- yl)- 4-oxo-l,8-naphthyridine-3-carboxylate;
(S)-(-)-9-fluoro-6.7-dihydro-8- (4'-hydroxy- 3'-fluoropiperidin-l-yl)-5-methyl-l-oxo-lH, 5H- benzo[i,j]quinoUzine-2-carboxylic acid and its salts;
10-Fluoro-ll- (4-aminopiperidin-l-yl)-3,4-dihydro-4 (S)-methyl-8-oxo-2H, 8H-pyrido[l,2,3-ef]-l,5- benzoxazipin-7-carboxylic acid and its salt; (RS)-(±)-6, 7-dihydro-8- (trans-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l-oxo-lH, 5H- benzo[i,j]quinolizine-2-carboxylic acid and its salts;
(RS)-(±)-6, 7-dihydro-8- (cis-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyI-l-oxo-lH, 5H- benzo[i,j]quinoUzine-2-carboxylic acid and its salts; or (RS)-(±)-6, 7-dihydro-8- (4'-hydroxy-3', 3'-dimethylpiperidin-l-yl)-5-methyl-l-oxo-lH, 5H- benzo[i,j]quinolizine-2-carboxylic acid and its salts.
57. The method according to any one of claims 1, 4, 8, or 11 wherein the efflux pump inhibitor is selected from: l-Ethyl-6-fluoro-l, 4-dihydro -7-(l', 2',3',4'-tetrahydroisoquinolin-2-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-Ethyl-6, 8-fluoro-l, 4-dihydro -7-(4'-acetoxypiperidin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts; l-Ethyl-6, 8-fluoro-l, 4-dihydro -7-(4'-{2'-(2'-oxazolidin-l-yl) ethyl} piperazin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
1- Ethyl-6, 8-difluoro-l, 4-dihydro -7-{(loc,5oc,6oc)-6-amino-3-azabicyclo [3.1.0]-hex-3-yl}-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l- ethyl -6, 8-difluoro-l, 4-dihydro -7-(3'-amino-5'-methyl pyrrolidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; 5-Amino-l- ethyl-6, 8-difluoro-l, 4-dihydro -7-(4'-aminopiperidin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts;
5-Amino-l- ethyl -6, 8-difluoro-l, 4-dihydro -7-{4'-(acetamido) piperidin-l-yl}-4-oxo-quinoline-3- carboxylic acid and its salts;
5-Amino-l- ethyl-6, 8-difluoro-l, 4-dihydro -7-{(loc,5cc,6°c)-6'-(t-butoxycarbonyl amino)-3- azabicyclo [3.1.0]-hex-3-yl}-4-oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-7-(3'-acetamido-5'-methylpyrroUdin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-7-(3'-amino-5'-methylpyrroUdin-l-yl)-4-oxo-quinoline-3- carboxyϋc acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro~7-(4'-acetoxypiperidin-l-yl)-4-oxo-quinoUne-3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro -7-{4'-(dimethylamino) piperidin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(3',5'-dimethylpiperidin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro -7-(4'-hydroxy-3',5'-dimethylpiperidin-l-yl)-4-oxo-quinoUne-
3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro- -7-(3', 4', 5'-trimethyl piperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro- 7-(3', 5'-dimethyl-4'-ethyl piperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts; l-CyclopropyI-6-fluoro-l, 4-dihydro-5-methyl- 7-(4'-ethoxypiperidin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl- 7-(3', 3'-dimethyIpiperazin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-(dimethylamino)-3'-methyl piperidin-l-yl}-4- oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-3'-isobutyI piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-3',3'-dimethyl piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-3',5'-dimethyl piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(3'-methylpiperazin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts;
5-Amino-l-cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(cis-4'-amino-3',5'-dimethylpiperidin-l- yl)-4-oxo-quinoline-3-carboxylic acid and its salts; l-CycIopropyl-6,8-difluoro-5-methyI-l,4-dihydro-7-(4'-hydroxy-3'-aminomethyI piperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(5'amino-2'-methyl-pyrrolidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{3'-(L-Ala-L-AIa) amino pyrrolidin-l-yl}-4- oxo-quinoUne-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{4'-(di-n-butylamino) piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{4'-(t-butoxycarbonyl-L-Ala-L- Ala)aminopiperidin-l-yI}-4-oxo-quinoline-3-carboxylic acid and its salts; 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-(4'- propionoxy piperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-(4'-hydroxy-3',3'-dimethyl-piperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6,8-difluoro-l, 4-dihydro -7-{4'-(l-pyrroUdinyl) piperidin-l-yl)-4-oxo- quinoUne-3-carboxylic acid and its salts;
5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-{4'-[(piperidin-4-yl) aminomethyl]-piperidin-l- yl}-4-oxo-quinoline-3-carboxylic acid and its salts; 5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-{(l,2',2', 6',6'-pentamethyI piperidin-4- yI)methylamino}-4-oxo-quinoUne-3-carboxylic acid and its salts;
5-Amino-l-cyclopropyl-6,8-difluoro-l, 4-dihydro -7-(3',5'-dimethyl morphoUn-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyl-6, 8-difluoro-l, 4-dihydro -7-(4'-cyclopropyl piperazin-l-yI)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cycIopropyl-6, 8-difluoro-l, 4-dihydro -7-(3', 5'-dimethyl-4-pivaloyI piperazin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts;
Ethyl 6,8-Difluoro-7-(4-hydroxypiperidin-l-yl)-l-(l-phenyIthio-3(5 -but-3-yl)-l,4-dihydro-4-oxo- quinoUne-3-carboxylate; 1- (2'-Trifluoromethylphenyl) -6-fluoro-l, 4-dihydro- -7-(3', 3', 4'-trimethyl piperazin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l- (2'-trifluoromethylphenyl)-6,8-difluoro-l, 4-dihydro -7-(morphoUn-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l- (2'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihydro -7-(3',5'-dimethylmorphoUn-l- yl)-4-oxo-quinoUne-3-carboxyUc acid and its salts;
5-Amino-l- (2'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihydro -7-(3',5'-dimethyl piperazinyl-1- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts;
5-Amino-l- (4'-trifluoromethylphenyl) -6, 8-difluoro-l, 4-dihydro -7-(3'-aminopyrrolidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts; 1- (4'-Fluorophenyl) -6-fluoro-l,4-dihydro -7-{4'-ethylamino)piperidin-l-yl)-4-oxo-quinoline-3- carboxylic acid and its salts;
1- (2',4'-Difluorophenyl) -6-fluoro-l, 4-dihydro-7-(3', 5'-dimethyl piperidin-l-yl)-4-oxo-quinoUne- 3-carboxyUc acid and its salts; 5-Amino-l- (2',4'-difluorophenyl) -6, 8-difluoro-l, 4-dihydro -7-(3'-hydroxy-5'-methylpyrrotidin-l- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts;
5-Amino-l- (2',4'-difluorophenyl) -6, 8-difluoro-l, 4-dihydro -7-(3',3'-dimethyl piperazinyl-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro -7-{(3'-aminoethoxycarbonyl)pyrroUdin-3-yl}-4-oxo- naphthyridine-3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(pyrroUdin-3-yl-amino)-4-oxo-naphthyridine-3-carboxyUc acid and its salts; 1- (2',4'-Difluorophenyl) -6-fluoro-l, 4-dihydro -7-(piperidin-4-yl-amino)-4-oxo-naphthyridine-3- carboxylic acid and its salts;
Ethyl-1- (2',4'-difluorophenyl) -6-fluoro-l, 4-dihydro -7-{[loc,5oc,6oc]-3-N-benzyl-3- azabicyclo[3.1.0]hex-6-yl-amino}-4-oxo-naphthyridine-3-carboxylate and its salts; l-(2,4-difluorophenyl) -6-fluoro-7-(l-phenyl-4,5,6,7-tetrahydropyrazolo
[4,3-c]pyridin-l-yl-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid and is salts;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-carboxamidopiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid and its salts;
(R)-(+)-9-FIuoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo [i,j] quinoUzine-2-carboxylic acid L-arginine salt;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxy-3',3'-dimethylpiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid and its salts;
(S)-(-)-N-methylpiperidin-l-yl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo [i,j] quinoUzine-2-carboxylate; (S)-(-)-MorphoUnoethyI-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyI-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylate and its salts;
Ethoxycarbonylmethyl (R)-(+)- 9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo [i,j] quinoUzine-2-carboxylate;
N-l-{7-(l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-quinoline-3-carboxylic acid)}-N-3-amino-{7-(l- (2,4-difluorophenyl)-6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxyUc acid)}- pyrroUdine;
N-l-{7-(l -cyclopropyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxyUc acid)}-N-3- amino-{7-(l-cyclopropyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid)}- pyrroUdine; N-l-{7-(l-cyclopropyl) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid)}-N-3- amino-{7-(l-cyclopropyl -6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoUne-3-carboxylic acid)}- pyrrolidine;
N-l-{7-(l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxyUc acid)}-N-4-{7-
(l-cycIopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoline-3-carboxylic acid)}-piperazine; N-l-{7-(l-cyclopropyl-6-fluoro-5-methyl-l,4-dihydro-4-oxo-quinoIone-3-carboxylic acid)}-N-3- amino-{7-( l-(2,4-difluorophenyl) -6-fluoro- 1, 4-dihydro-4-oxo-l, 8-naphthyridine-3-carboxylic acid)}-pyrroUdine;
N-l- {7-(l-cyclopropyl-6-fluoro-5-methyl-l, 4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N-4- amino {7-(l-cycIopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoUne-3-carboxylic acid)}- piperidine; N-l- {7-(l-cyclopropyl-6-fluoro-5-methyl-l, 4-dihydro-4-oxo-quinolone-3-carboxyIic acid)}-N-3- amino{7-(l-cycIopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinoIine-3-carboxyIic acid)}- pyrrolidine;
N-l- {7-(l-(2,4-difluorophenyI) -6-fluoro-l, 4-dihydro-4-oxo-l, 8-naphthyridine- 3-carboxylic acid)}-N-4- {7-(l-cyclopropyl-6-fluoro-l, 4-dihydro-4-oxo-quinoline-3-carboxyIic acid)}- piperazine;
N-3-azabycyclo{7-(l-(2,4-difluorophenyl)-6-fluoro-l,4-dihydro-4-oxo-l,8-naphthyridine-3- carboxylic acid)}-[loc,5oc,6oc]-N-6-amino-{7-l-(2,4-difluorophenyI)-6-fluoro-l,4-dihydro-4-oxo-l,8- naphthyridine-3-carboxylic acid)}-.[3.1.0] hexane; or N-l- {7-(l-cyclopropyl-6,8-difluoro-5-amino-l, 4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N- 4-amino-{ethyl 2,3,6-trifluorophenyl-4-carboxyIate}-piperidine.
58. The method according to any one of claims 1, 4, 8, or 11 wherein the efflux pump inhibitor is selected from: l-Cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl- 7-(4'-methoxypiperidin -l-yl)-4-oxo-quinoline-
3-carboxylic acid and its salts;
7-Bromo-l-cyclopropyl-6-fluoro-5-methyl-l,4-dihydro-4-oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l, 4-dihydro -7-(4'-amino-3'-methylpiperidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cyclopropyI-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-amino-3'-methyI piperidin-l-yl)- 4-oxo-quinoIine-3-carboxylic acid and its salts;
5-Amino-l-cycIopropyl-6-fluoro-8-methoxy-l,4-dihydro -7-{3,3-dimethyI-4'-ethylamino piperidin-l-yl}-4-oxo-quinoUne-3-carboxylic acid and its salts; l-CyclopropyI-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-amino-3'-3'-dimethyI piperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-{4'-(dimethylamino)piperidin-l-yl}-4-oxo- quinoUne-3-carboxylic acid and its salts; l-CycIopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(4'-hydroxy-4'-methylpiperidin-l-yl)-4-oxo- quinoline-3-carboxyUc acid and its salts; l-Cyclopropyl-6-fluoro-8-methoxy-l,4-dihydro-7-(3',3'-dimethyl-4'-hydroxypiperidin-l-yl)-4- oxo-quinoUne-3-carboxyUc acid and its salts; l-Cyclopropyl-6,8-difluoro-5-methyl-l,4-dihydro-7-(3'-aminomethyl-4'-hydroxypiperidin-l- yl)-4-oxo-quinoline-3-carboxyUc acid and its salts; 5-Amino-l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(3'-aminomethyl-4'-hydroxypiperidin-l-yl)-
4-oxo-quinoline-3-carboxylic acid and its salts; l-Ethyl-6,8-difluoro-l,4-dihydro-7-(3'-5'-dimethylpiperazin-l-yl)-4-oxo-quinoline-3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(4'-ethyI-3'-methylpiperazin-l-yl)-4-oxo-quinoUne-3- carboxylic acid and its salts; l-CyclopropyI-6-fluoro-l,4-dihydro-7-(3'-5'-dimethyl-4'-ethylpiperazin-l-yl)-4-oxo-quinoline-
3-carboxylic acid and its salts; l-Ethyl-6, 8-difluoro-l, 4-dihydro -7-{(loc,5oc,6oc)-6'-amino-3'-azabicyclo [3.1.0] hex-3'-yl}-4- oxo-quinoUne-3-carboxyUc acid and its salts;
5-Annno-l-(2 4'-difluorophenyI)-6,8-difluoro-l,4-dihydro-7-(3'-aminopyrrolidin-l-yl)-4-oxo- quinoUne-3-carboxyUc acid and its salts;
5-Amino-l-cycIopropyl-6,8-difluoro-l,4-dihydro-7-{(3'-amimoethoxycarbonyl pyrrolidin-3- yl}-4-oxo-quinoline-3-carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l,4-dihydro-7-(pyrroUdin-3'-ylamino)-4-oxo-naphthyridine-3- carboxylic acid and its salts; l-(2',4'-Difluorophenyl)-6-fluoro-l,4-dihydro-7-(piperidin-4'-ylamino)-4-oxo-naphthyridine-3- carboxylic acid and its salts; l-Cyclopropyl-6-fluoro-l, 4-dihydro -7-(4'-amino-3'-ethylpiperidin-l-yl)-4-oxo-naphthyridine- 3-carboxylic acid and its salts;
(S)-(-)-9-FIuoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo [i,j]quinoUzine-2-carboxylic acid 0.2 hydrate;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid, choline salt;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid, 1-dydroxyethylpyrroUdine salt. (S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid, diethanolamine salt;
(S)-(-)-9-FIuoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylate, L-histidine salt;
(RS)-(±)-9-Fluoro-6,7-dihydro-8-{4'-(D-phenylalanyloxy) piperidin-l-yl}-5-methyl-l-oxo- lH,5H-benzo [i,j] quinoUzine-2-carboxylic acid hydrochloride;
(RS)-(±)-9-Fluoro-6,7-dihydro-8-{4'-(L-α-aspartyloxy) piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;
(±)-9-Fluoro-6,7-dihydro-8-{4'-(L-leucyloxy)piperidin-l-yI}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid hydrochloride; (-)-9-Fluoro-6,7-dihydro-8-{4'-(D-leucyloxy)piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid hydrochloride; (S)-(-)-9-FIuoro-6,7-dihydro-8-{4'-(L-alanyloxy)piperidin-l-yl}-5-methyl-l-oxo-lH,5H- benzo[i,j]quinoUzine-2-carboxylic acid hydrochloride;
(S)-(-)-MorphoUnoethyl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo[i,j]quinoUzine-2-carboxylate and its salts; (R)-(+)-8,9-difluoro-6,7-dihydro-5-methyl-l-oxo-lH,5H-benzo [ij ] quinolizine-2- [S- phenylalanyl-S-lysine methyl ester] carboxamide;
(RS)-(±)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo[ij]quinoUzine-2-carboxyUc acid and its salts;
(RS)-(±)-9-Fluoro-6,7-dihydro-8-(cis-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo[i,j]quinoUzine-2-carboxyUc acid and its salts;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-l-yl)-5-methyl-l-oxo- lH,5H-benzo[i,j]quinoUzine-2-carboxylic acid and its salts;
7H-Pyrido[l,2,3-de]-l,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(4'-hydroxy-3'- ethylpiperidin-l'-yl)-7-oxo-6-carboxylic acid and its salts; 10-Fluoro-ll-[(loc,5oc,6oc )-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3,4-dUιydro-4(S)-methyl-8- oxo-2H,8H-pyrido [1 ,2,3-ef] -1 ,5-benzoxazepine-7-carboxyUc acid, hydrochloride.
PCT/IN2001/000139 2000-08-01 2001-07-31 Inhibitors of cellular efflux pumps of microbes WO2002009758A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002417799A CA2417799A1 (en) 2000-08-01 2001-07-31 Inhibitors of cellular efflux pumps of microbes
AU2001280091A AU2001280091A1 (en) 2000-08-01 2001-07-31 Inhibitors of cellular efflux pumps of microbes
EP01958373A EP1305048A2 (en) 2000-08-01 2001-07-31 Inhibitors of cellular efflux pumps of microbes

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US22220100P 2000-08-01 2000-08-01
US60/222,201 2000-08-01
US09/640,947 2000-08-17
US09/640,947 US6750224B1 (en) 1999-05-07 2000-08-17 Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment
IN0000111 2000-11-22
INPCT/IN00/00111 2000-11-22
US28629101P 2001-04-25 2001-04-25
US60/286,291 2001-04-25
US09/850,669 2001-05-07
US09/850,669 US6608078B2 (en) 2000-05-08 2001-05-07 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
INPCT/IN01/00100 2001-05-08
PCT/IN2001/000100 WO2001085728A2 (en) 2000-05-08 2001-05-08 Antibacterial chiral 8-(substituted piperidino)-benzo [i, j] quinolizines, processes, compositions and methods of treatment

Publications (2)

Publication Number Publication Date
WO2002009758A2 true WO2002009758A2 (en) 2002-02-07
WO2002009758A3 WO2002009758A3 (en) 2002-12-27

Family

ID=27517699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2001/000139 WO2002009758A2 (en) 2000-08-01 2001-07-31 Inhibitors of cellular efflux pumps of microbes

Country Status (4)

Country Link
EP (1) EP1305048A2 (en)
AU (1) AU2001280091A1 (en)
CA (1) CA2417799A1 (en)
WO (1) WO2002009758A2 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085886A2 (en) * 2001-04-25 2002-10-31 Wockhardt Limited Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions
WO2003050107A1 (en) * 2001-12-13 2003-06-19 Wockhardt Limited New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6608078B2 (en) 2000-05-08 2003-08-19 Wockhardt Limited Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
WO2003099815A1 (en) * 2002-05-28 2003-12-04 Wockhardt Limited Crystalline fluoroquinolone arginine salt form
GB2403653A (en) * 2003-07-10 2005-01-12 Secr Defence Use of fluoroquinone antibiotics for the treatment of plague
WO2005023805A1 (en) * 2003-09-04 2005-03-17 Wockhardt Limited Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
WO2005026145A2 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
US6878713B2 (en) 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
WO2005070941A1 (en) * 2004-01-13 2005-08-04 Cumbre Pharmaceuticals Inc. Rifamycin imino derivatives effective against drug-resistant microbes
WO2005089738A2 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
WO2005070940A3 (en) * 2004-01-13 2005-09-29 Cumbre Inc Rifamycin derivatives effective against drug-resistant microbes
US7098219B2 (en) 2000-08-01 2006-08-29 Wockhart Limited Inhibitors of cellular efflux pumps of microbes
WO2007106537A3 (en) * 2006-03-13 2007-11-29 Activx Biosciences Inc Aminoquinolones as gsk-3 inhibitors
WO2008019292A2 (en) * 2006-08-04 2008-02-14 Trustees Of Boston University Compositions and methods for potentiating antibiotic activity
WO2007102061A3 (en) * 2006-03-07 2009-04-23 Wockhardt Ltd Prodrugs of benzoquinolizine-2-carboxylic acid
US7569563B2 (en) 2005-06-30 2009-08-04 Aicuris Gmbh & Co. Hk Substituted quinolones II
EP1918289A3 (en) * 2002-05-28 2009-08-19 Wockhardt Limited Crystalline nadifloxacin arginine salt form
US7829543B2 (en) 2003-01-07 2010-11-09 Paratek Pharmaceuticals, Inc. Substituted polyamines as inhibitors of bacterial efflux pumps
US7867992B2 (en) 2004-07-21 2011-01-11 Aicuris Gmbh & Co. Kg Substituted quinolones
US7902227B2 (en) 2007-07-27 2011-03-08 Janssen Pharmaceutica Nv. C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents
US7977349B2 (en) 2006-02-09 2011-07-12 Aicuris Gmbh & Co. Kg Substituted quinolones III
US7994225B2 (en) 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
WO2011101710A1 (en) * 2010-02-16 2011-08-25 Wockhardt Research Centre Efflux pump inhibitors
US8071591B2 (en) 2009-03-11 2011-12-06 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as GSK-3 inhibitors
CN102351880A (en) * 2007-09-11 2012-02-15 杏林制药株式会社 Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
US8476261B2 (en) 2007-09-12 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
CN103183684A (en) * 2011-12-29 2013-07-03 杭州师范大学 Quinolone lactone compound, and preparation method and application thereof
EP2751083A4 (en) * 2011-08-31 2015-06-10 Otsuka Pharma Co Ltd Quinolone compound
US9155792B2 (en) 2006-02-13 2015-10-13 Trustees Of Boston University RecA inhibitors with antibiotic activity, compositions and methods of use
CN109486739A (en) * 2018-11-23 2019-03-19 上海海洋大学 A method of induction vibrio parahemolyticus generates levofloxacin resistance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300735A1 (en) * 1987-07-20 1989-01-25 CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. Antimicrobial pharmaceutical composition
WO1997024128A1 (en) * 1995-12-27 1997-07-10 Bayer Corporation Otic microbial combinations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300735A1 (en) * 1987-07-20 1989-01-25 CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. Antimicrobial pharmaceutical composition
WO1997024128A1 (en) * 1995-12-27 1997-07-10 Bayer Corporation Otic microbial combinations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A.M.DHOPLE, M.A.IBANEZ: "In vivo susceptibility of mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin" ARZNEIMITTEL-FORSCHUNG, vol. 44, no. 4, 1994, pages 563-565, XP001108849 *
E.M.MATEU-DE-ANTONIO, M.MARTIN: "In vitro efficacy of several antimicrobial combinations against Brucella canis and Brucella melitensis strains isolated from dogs" VETERINARY MICROBIOLOGY, vol. 45, no. 1, 1995, pages 1-10, XP001112917 *
H.C.NEU, N.X.CHIN: "In vitro activity of fleroxacin in combination with other antimicrobial agents" AMERICAN JOURNAL OF MEDICINE, vol. 94, no. 3A, 1993, pages 9S-16S, XP008008698 *
N.X.CHIN, H.C.NEU: "Combination of ofloxacin and other antimicrobial agents" JOURNAL OF CHEMOTHERAPY (FLORENCE), vol. 2, no. 6, 1990, pages 343-347, XP008008692 *
P.VAN DER AUWERA E.A.: "Comparative in vitro activity of CI934, a new fluoroquinolone, alone and in combination with coumermycin, against gram-positive bacteria" DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, vol. 13, no. 3, 1987, pages 125-132, XP008008697 *

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608078B2 (en) 2000-05-08 2003-08-19 Wockhardt Limited Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
US7098219B2 (en) 2000-08-01 2006-08-29 Wockhart Limited Inhibitors of cellular efflux pumps of microbes
US6878713B2 (en) 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US7626032B2 (en) 2001-04-25 2009-12-01 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
WO2002085886A3 (en) * 2001-04-25 2003-05-22 Souza Noel J De Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions
WO2002085886A2 (en) * 2001-04-25 2002-10-31 Wockhardt Limited Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions
US7393957B2 (en) 2001-04-25 2008-07-01 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
WO2003050107A1 (en) * 2001-12-13 2003-06-19 Wockhardt Limited New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
WO2003099815A1 (en) * 2002-05-28 2003-12-04 Wockhardt Limited Crystalline fluoroquinolone arginine salt form
US6664267B1 (en) 2002-05-28 2003-12-16 Wockhardt Limited Crystalline fluoroquinolone arginine salt form
EP1918289A3 (en) * 2002-05-28 2009-08-19 Wockhardt Limited Crystalline nadifloxacin arginine salt form
US7132541B2 (en) 2002-05-28 2006-11-07 Wockhardt Limited Crystalline fluoroquinolone arginine salt form
US7829543B2 (en) 2003-01-07 2010-11-09 Paratek Pharmaceuticals, Inc. Substituted polyamines as inhibitors of bacterial efflux pumps
GB2403653A (en) * 2003-07-10 2005-01-12 Secr Defence Use of fluoroquinone antibiotics for the treatment of plague
WO2005023805A1 (en) * 2003-09-04 2005-03-17 Wockhardt Limited Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
US7164023B2 (en) 2003-09-04 2007-01-16 Wockhardt Limited Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
HRP20060079B1 (en) * 2003-09-04 2008-05-31 Wockhardt Limited Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
WO2005026145A2 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
WO2005026145A3 (en) * 2003-09-12 2005-06-16 Warner Lambert Co Quinolone antibacterial agents
WO2005070941A1 (en) * 2004-01-13 2005-08-04 Cumbre Pharmaceuticals Inc. Rifamycin imino derivatives effective against drug-resistant microbes
US7238694B2 (en) 2004-01-13 2007-07-03 Cumbre Pharmaceuticals, Inc. Rifamycin imino derivatives effective against drug-resistant microbes
US7247634B2 (en) 2004-01-13 2007-07-24 Cumbre Pharmaceuticals Inc. Rifamycin derivatives effective against drug-resistant microbes
WO2005070940A3 (en) * 2004-01-13 2005-09-29 Cumbre Inc Rifamycin derivatives effective against drug-resistant microbes
US7947741B2 (en) 2004-03-17 2011-05-24 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
WO2005089738A2 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
US7994225B2 (en) 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
WO2005089738A3 (en) * 2004-03-17 2007-08-23 Mpex Pharmaceuticals Inc Use and administration of bacterial efflux pump inhibitors
US7867992B2 (en) 2004-07-21 2011-01-11 Aicuris Gmbh & Co. Kg Substituted quinolones
US7569563B2 (en) 2005-06-30 2009-08-04 Aicuris Gmbh & Co. Hk Substituted quinolones II
US7977349B2 (en) 2006-02-09 2011-07-12 Aicuris Gmbh & Co. Kg Substituted quinolones III
US9155792B2 (en) 2006-02-13 2015-10-13 Trustees Of Boston University RecA inhibitors with antibiotic activity, compositions and methods of use
WO2007102061A3 (en) * 2006-03-07 2009-04-23 Wockhardt Ltd Prodrugs of benzoquinolizine-2-carboxylic acid
US7868173B2 (en) 2006-03-07 2011-01-11 Wockhardt Limited Prodrugs of benzoquinolizine-2-carboxylic acid
KR101364900B1 (en) * 2006-03-07 2014-02-19 욱크하트 리미티드 Prodrugs of benzoquinolizine-2-carboxylic acid
AU2007225088B2 (en) * 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
JP2009530292A (en) * 2006-03-13 2009-08-27 アクティヴィックス バイオサイエンシーズ インコーポレイテッド Aminoquinolones as GSK-3 inhibitors
WO2007106537A3 (en) * 2006-03-13 2007-11-29 Activx Biosciences Inc Aminoquinolones as gsk-3 inhibitors
US8063221B2 (en) 2006-03-13 2011-11-22 Kyorin Pharmaceutical Co., Ltd. Aminoquinolones as GSK-3 inhibitors
WO2008019292A3 (en) * 2006-08-04 2008-08-14 Univ Boston Compositions and methods for potentiating antibiotic activity
WO2008019292A2 (en) * 2006-08-04 2008-02-14 Trustees Of Boston University Compositions and methods for potentiating antibiotic activity
US7902227B2 (en) 2007-07-27 2011-03-08 Janssen Pharmaceutica Nv. C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents
US8389514B2 (en) 2007-09-11 2013-03-05 Kyorin Pharmaceutical Co., Ltd. Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
CN102351880A (en) * 2007-09-11 2012-02-15 杏林制药株式会社 Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
CN102351880B (en) * 2007-09-11 2014-11-12 杏林制药株式会社 Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
US8901112B2 (en) 2007-09-12 2014-12-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
US8476261B2 (en) 2007-09-12 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
US8071591B2 (en) 2009-03-11 2011-12-06 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as GSK-3 inhibitors
WO2011101710A1 (en) * 2010-02-16 2011-08-25 Wockhardt Research Centre Efflux pump inhibitors
EP2751083A4 (en) * 2011-08-31 2015-06-10 Otsuka Pharma Co Ltd Quinolone compound
US9067887B2 (en) 2011-08-31 2015-06-30 Otsuka Pharmaceutical Co., Ltd Quinolone compound
US9440951B2 (en) 2011-08-31 2016-09-13 Otsuka Pharmaceutical Co., Ltd Quinolone compound
JP2017039733A (en) * 2011-08-31 2017-02-23 大塚製薬株式会社 Quinolone compound
CN103183684A (en) * 2011-12-29 2013-07-03 杭州师范大学 Quinolone lactone compound, and preparation method and application thereof
CN103183684B (en) * 2011-12-29 2015-11-18 杭州师范大学 A kind of quinlone lactone compound and its preparation method and application
CN109486739A (en) * 2018-11-23 2019-03-19 上海海洋大学 A method of induction vibrio parahemolyticus generates levofloxacin resistance
CN109486739B (en) * 2018-11-23 2022-02-01 上海海洋大学 Method for inducing vibrio parahaemolyticus to generate levofloxacin drug resistance

Also Published As

Publication number Publication date
EP1305048A2 (en) 2003-05-02
WO2002009758A3 (en) 2002-12-27
AU2001280091A1 (en) 2002-02-13
CA2417799A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
WO2002009758A2 (en) Inhibitors of cellular efflux pumps of microbes
US7626032B2 (en) Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US5137892A (en) Quinoline, naphthyridine and pyridobenzoxazine derivatives
ES2558685T3 (en) Use of pyrroloquinoline compounds to eliminate clinically latent microorganisms
US7247634B2 (en) Rifamycin derivatives effective against drug-resistant microbes
US7229996B2 (en) Rifamycin derivatives
US7820823B2 (en) Dual action antibiotics
KR101307717B1 (en) Tri- or tetra-substituted-3-aminopyrrolidine derivatives
US6964966B2 (en) Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
JP2012522807A (en) Hydroxythienoquinolones and related compounds as antiinfectives
NZ783605A (en) Macrocyclic broad spectrum antibiotics
JP2005511743A (en) A new generation of triple-targeted chiral broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, methods for their preparation, compositions, and pharmaceutical use
HU221952B1 (en) 5-amino-8-methyl-7-pyrrolidinyl-quinoline-3-carboxylic acid derivatives and pharmaceutical compositions containing them
US7098219B2 (en) Inhibitors of cellular efflux pumps of microbes
KR20180094042A (en) Compound containing 7-oxo-6- (sulfooxy) -1,6-diazabicyclo [3.2.1] octane-2-carboxamide and its use for the treatment of bacterial infections
RU2248970C2 (en) Cycloalkyl-substituted derivatives of aminomethylpyrrolidine and antibacterial agent based on thereof
EP0429304A2 (en) Pyridone-carboxylic acid derivatives and their use as veterinary medicines
US20120058989A1 (en) Antibacterial fluoroquinolone analogs
EP0302371B1 (en) 7-(2-Methyl-4-aminopyrrolidinyl)naphthyridine and quinoline compounds
JPH05132479A (en) Amino acid azetidinyl substituted pyridone derivative, preparation thereof and medicinal application thereof
Petersen Quinolone antibiotics: the development of moxifloxacin
Miyauchi et al. Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl) pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria
JP2021504489A (en) Antibacterial heterocyclic compounds and their synthesis
RU2029771C1 (en) Optically active pyridobenzoxazine derivatives or salts thereof
PT682030E (en) 8-AMINO-10- (AZABICYLIC-ALKYL) -PYRIDY-1,2,3-D, E-1,3,4-BENZOXADIAZINE DERIVATIVES FOR THEIR PREPARATION AND ANTIBACTERIAL AGENTS CONTAINING THESE COMPOUNDS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2417799

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001958373

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001958373

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001958373

Country of ref document: EP